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Abstract 
 
 
Abstract 
 
The cardiovascular system (CVS) has emerged as an important target of 
corticosteroid hormones. Mineralocorticoid receptor antagonists provide 
cardiovascular protection and are now routinely used in disorders such as primary 
hyperaldosteronism, resistant hypertension and congestive heart failure (CHF) but 
the underlying molecular mechanisms of corticosteroid hormone action remain 
unclear. 
We have characterised corticosteroid hormone action and metabolism by 11β-
hydroxysteroid-dehydrogenases (11β-HSDs) in isolated adult rat cardiomyocytes 
(CM) and cardiac fibroblasts (cFb). We have detected 11β-HSD1 expression and 
activity in CM and cFb where it facilitates glucocorticoid hormone action, whereas 
11β-HSD2 was absent. We have shown differential gene regulation by aldosterone 
(Aldo) and corticosterone in CM and identified novel Aldo target genes which may 
provide insights into the molecular mechanisms of Aldo action. 
We have also studied the role of corticosteroids in essential hypertension and the 
effect of spironolactone (Spiro) upon their secretion and metabolism in patients with 
chronic kidney disease. We have shown that mineralocorticoids but not 
glucocorticoids are involved in elevated blood pressure in essential hypertension and 
that Spiro treatment results in compensatory activation of the renin-angiotensin-
aldosterone system (RAAS), whereas glucocorticoid secretion and metabolism 
remain unchanged. 
In summary, these data provide novel molecular and clinical insights into 
corticosteroid hormone action in the CVS. 
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1.1 The clinical problem 
Heart disease is a broad term describing a wide spectrum of diseases of different 
aetiologies affecting the heart such as ischaemic and hypertensive heart disease, 
cardiomyopathies, inflammatory and valvuar heart disease. All these conditions affect 
the performance of the heart and can ultimately result in CHF which is defined by the 
inability of the heart to supply sufficient blood flow to meet the body's needs. 
CHF is a common, costly, disabling and deadly condition (McMurray & Pfeffer, 2005). 
It has been estimated that around 2% of adults in developing countries suffer from 
heart failure. However, over the age of 65 the prevalence increases to 6 - 10% 
(Dickstein et al., 2008; McMurray & Pfeffer, 2005). Heart failure is the reason for at 
least 20% of all hospital admissions among persons older than 65 years and 
moreover, the rate of hospitalisations for heart failure has increased by 159% over 
the past decade. Associated costs have been estimated to amount for 2% of the total 
budget of the National Health Service (NHS) in the United Kingdom (Stewart et al., 
2002), and more than $35 billion in the United States (Lloyd-Jones et al., 2009). 
Furthermore, quality of life is impaired in heart failure patients and deteriorates with 
progression of the condition (Juenger et al., 2002). CHF usually worsens with time 
unless the underlying cause is reversible. Although some patients survive many 
years, progressive disease is associated with an overall annual mortality rate of 10% 
(Neubauer, 2007). 
Over the years, many studies have explored the underlying pathophysiological 
mechanisms of heart failure and consequently drugs that interfere or modulate these 
processes have been proven to be effective treatments in slowing down disease 
progression and thereby reducing morbidity and mortality. Two landmark clinical 
trials, the Randomised ALdactone Evaluation Study (RALES) and the Eplerenone 
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Post-acute myocardial infarction Heart failure Efficacy and Survival Study 
(EPHESUS), have highlighted the adverse effects of corticosteroids in CHF and the 
incremental clinical benefit of mineralocorticoid receptor antagonists (MRA) in 
patients with heart failure (Pitt et al., 2003b; Pitt et al., 1999) (Figure 1-1). However, 
despite these important clinical insights and therapeutical advances, very little is 
known about the underlying cellular and molecular mechanisms. 
 
Figure 1-1 Kaplan-Mayer curves showing survival of patients with 
advanced congestive heart failure according to treatment group 
(placebo vs spironolactone) in the RALES study (Pitt et al., 1999). 
1.2 The adrenal gland 
The adrenal glands are located in the retroperitoneum on top of the kidneys. Both 
anatomically and functionally the adrenal gland can be divided into an outer layer, the 
adrenal cortex, and a central core, the adrenal medulla. The medulla can be 
considered as specialised ganglia of the sympathetic nervous system which releases 
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catecholamines (adrenaline, noradrenaline) into the circulation. By contrast, the 
adrenal cortex secretes steroid hormones and consists of three histologically distinct 
layers (zones) which produce three distinct classes of steroid hormones. The outer 
layer (zona glomerulosa) is located beneath the capsule (Figure 1-2) and is the main 
site of mineralocorticoid hormone production, namely aldosterone (Aldo). Adjacent to 
the zona glomerulosa lies the zona fasciculata which is the main site of glucocorticoid 
hormone production (cortisol in humans, corticosterone in rodents). The most inner 
zone of the adrenal cortex is the zona reticularis which predominantly produces the 
sex steroid precursor hormone dehydroepiandrosterone (DHEA) and its sulfated 
ester DHEAS. However, only humans and higher primates exhibit this zone and are 
capable of producing adrenal sex steroids whereas all other vertebrates only produce 
glucocorticoids and mineralocorticoids in the adrenal. 
 
Figure 1-2 Histological section through the cortex of the human 
adrenal gland. Mineralocorticoids are synthesised in the zona 
glomerulosa (ZG), glucocorticoids in the zona fasciculate (ZF) and sex 
steroids the zona reticularis (ZR). 
Chapter 1  General Introduction 
  5 
1.3 Adrenal steroidogenesis 
1.3.1 Biosynthesis and uptake of cholesterol 
Cholesterol is the common precursor of all steroid hormones and therefore adrenal 
cells require a constant supply of cholesterol. Three mechanisms contribute to the 
cholesterol pool within the adrenal gland. Firstly, cholesterol can be synthesised de 
novo from acetyl coenzyme A. The key and rate limiting enzyme involved in this 
process is hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase which converts 
β-hydroxy-β-methylglutaryl-CoA to mevalonic acid. HMG-CoA reductase is 
expressed in the adrenal and is up-regulated by the adrenocorticotropic hormone 
(ACTH) (Mason & Rainey, 1987). Secondly, cholesterol-esters can be taken up from 
circulating low density lipoproteins (LDL) through receptor mediated endocytosis 
involving apolipoprotein B and E or LDL receptors and are subsequently hydrolysed 
by cholesterol ester hydrolase to yield cholesterol. Finally, a high density lipoprotein 
receptor, scavenger receptor class B type 1 (SR-B1), has been identified on 
adrenocortical cells (Acton et al., 1996). In contrast to LDL-mediated delivery of 
cholesterol, HDL apolipoproteins are not internalised but binding of apolipoprotein A1 
(apoA1) to SR-B1 leads to formation of channels by which cholesterol esters can 
enter the cell. In rodents this mechanism may account for up to 90% of adrenal 
cholesterol supply (Kraemer, 2007). 
1.3.2 Biosynthesis of steroid hormones 
The structure of steroid hormones is depicted in Figure 1-3. The first step of 
steroidogenesis is catalysed by the side chain cleavage enzyme (P450scc) which is 
responsible for the scission of the cholesterol side chain between carbon atoms C20 
and C22 resulting in the formation of pregnenolone (Figure 1-3). P450scc is located 
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in the inner mitochondrial membrane and requires the steroid acute regulatory protein 
(StAR) which is embedded in the outer mitochondrial membrane in order to facilitate 
cholesterol translocation across the mitochondrial membranes. The exact mechanism 
underlying mitochondrial cholesterol transport remains unresolved but other proteins 
such as the translocator protein have been shown to bind cholesterol and directly 
interact with StAR (Rone et al., 2009). In keeping with the pivotal role of StAR in 
adrenal steroidogenesis, mutations in its gene result in an almost complete inability 
for steroid hormone synthesis which presents clinically as congenital lipoid adrenal 
hyperplasia (Stocco, 2002). 
 
Figure 1-3 Schematic view of the steroid backbone with its classical 
nomenclature. Letters A-D identify rings, numbers the carbon atoms. 
Pregnenolone serves as a substrate for all subsequent downstream steroids. Its 
fate is determined by the spatial expression of steroidogenic enzymes which are 
distinct in each zone (Figure 1-4). 
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Figure 1-4 Pathways of adrenal mineralocorticoid, glucocorticoid 
and sex steroid synthesis. P450scc: side chain cleavage enzyme; 3β-
HSD: 3β-hydroxysteroid dehydrogenase; P450c17: 17α-
hydroxylase/17-20 lyase, P450c21: 21-hydroxylase; P450c11: 11-
hydroxylase; P450c11/AS: aldosterone synthase. 
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1.3.2.1 Cortisol synthesis 
In humans, the zona fasciculata expresses the enzyme 3β-HSD2, 17α-hydroxlase 
(P450c17), 21-hydroxylase (P450c21) and 11β-hydroxylase (P450c11) which results 
in synthesis of the glucocorticoid cortisol (Figure 1-5). Following side chain scission 
of cholesterol by P450scc in the mitochondria, pregnenolone is released from the 
mitochondria into the cytoplasm where it serves as a substrate for the enzyme 3β-
hydroxysteroid dehydrogenase 2 (3β-HSD2) resulting in dehydrogenation of the 3-
hydroxyl group and isomerisation of the double bond at C5 to form progesterone. 
Progesterone is subsequently hydroxylated at the position C17 by the enzyme 17α-
hydroxlase (P450c17) located in the endoplasmic reticulum to form 17-
hydroxyprogesterone. The final two modifications resulting in cortisol production 
occur in the mitochondria. First 17-hydroxyprogesterone is hydroxylated at the C21 
position by the enzyme P450c21 to form 11-deoxycortisol which is then hydroxylated 
at the C11 position by the enzyme P450c11 resulting in cortisol (Arlt & Stewart, 
2005). In contrast to humans and higher primates, rodents do not express the 
enzyme P450c17 in the adrenal gland and therefore corticosterone is the principal 
glucocorticoid secreted by the zona fasciculata. 
1.3.2.2 Aldosterone synthesis 
Aldo production occurs in the zona glomerulosa which expresses the steroidogenic 
enzymes 3β-HSD2, 11β-hydroxylase (P450c11), 21-hydroxylase (P40c21) and 
aldosterone synthase (P450c11AS) but not P450c17. Similar to the synthesis of 
cortisol pregnenolone is firstly converted to progesterone in the endoplasmic 
reticulum. All further biochemical modifications occur in the mitochondria where 
progesterone is hydroxylated at the C21 position to form 11-deoxycorticosterone 
(DOC). The final reactions in Aldo synthesis are carried out by aldosterone synthase, 
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which hydroxylates 11-deoxycorticosterone at C11 to corticosterone then at the C18 
position to form 18-hydroxycorticosterone followed by dehydrogenation at C18 to 
form Aldo which is the principal mineralocorticoid. 
1.3.2.3 Adrenal androgen synthesis 
Adrenal androgen production only occurs in humans and higher primates through the 
expression of P450c17 in the zona reticularis of the adrenal gland. Following 
pregnenolone synthesis form cholesterol in the mitochondria, pregnenolone serves 
as a substrate for P450c17 located in the endoplasmic reticulum. P450c17 harbors 
two distinct enzymatic activities, namely 17α-hydroxylase and 17, 20 lyase. Both 
enzymatic steps rely on the presence of P450 oxidoreductase (POR) which serves as 
an electron donor whereas the lyase reaction in addition also relies on the presence 
of cytochrome b5 as a co-factor. Cytochrome b5 is only expressed in the zona 
reticularis but not the zona fasciculata and thus, the lyase reaction is restricted to the 
zona reticularis. These two P450c17 reactions result in the production of the sex 
steroid hormone precursor DHEA.  
1.4 Steroid hormone action 
1.4.1 Steroid hormone receptors 
Nuclear hormone receptors such as the glucocorticoid (GR) and mineralocorticoid 
(MR) receptor are ligand activated transcription factors and belong to the nuclear 
receptor superfamily. The GR and the MR derive from a gene duplication of an 
ancestral corticoid receptor deep in the vertebrate lineage (Bridgham et al., 2006). 
Both receptors are composed of different domains with different functions (Figure 
1-5). At the N-terminus of steroid hormone receptors (A/B region) resides the 
activation function (AF1)/tau1 domain which plays a critical role in the regulation of 
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target gene transcription (Figure 1-5). The DNA binding domain (DBD) (C region) has 
the most conserved amino acid sequence among members of the steroid hormone 
receptor family, and consists of two zinc-finger motifs, each containing four highly 
conserved cysteine molecules which coordinate binding of a zinc atom. This results 
in the formation of a tertiary structure containing helices that interact with specific 
DNA sequences, so called hormone response elements (HRE). The ligand binding 
domain (LBD) (E region) participates in several activities including hormone binding, 
homo- and/or heterodimerisation, formation of the heat-shock protein (HSP) complex 
and transcriptional activation and repression. Between the DBD and LBD lies the 
hinge region (D region) which is important for conformational changes upon ligand 
binding. 
 
Figure 1-5 Schematic diagram of the steroid hormone receptor 
structure. The 1d model shows the different functional domains. The 3d 
model shows the interaction of the DNA binding domain with DNA and 
the interaction of the ligand binding domain (LBD) with a steroid ligand. 
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The hinge region allows the DBD and LBD to adopt different conformations without 
creating a steric hindrance. The hinge region also harbors a nuclear localisation 
signal or elements of a functional nuclear localisation signal. 
1.4.2 Co-regulators of steroid hormone receptors 
Following ligand binding, steroid hormone receptors undergo a conformational 
change which increases their affinity for co-regulator proteins. Co-regulators function 
as adaptors in a signaling pathway that transmits transcriptional responses from the 
DNA bound ligand-receptor complex to the basal transcriptional machinery.  
Numerous co-regulator proteins have been identified that interact with steroid 
hormone receptors such as the glucocorticoid (GR) and mineralocorticoid receptor 
(MR) to regulate transcription of target genes (Lonard & O'Malley, 2006). Depending 
on their effect on target gene transcription, co-regulators are divided in two different 
classes, co-activators and co-repressors. Co-activator proteins such as members of 
the p160 steroid receptor co-activators (SRCs) possess intrinsic histone 
acetyltransferase activity (HAT) and contain distinct regions and motifs for the 
recruitment of other proteins with enzymatic activities, including CREB-binding 
protein CBP/p300 and co-activator associated arginine methyltransferase 1 (CARM-
1) (Stallcup et al., 2003; Xu & Li, 2003). Histone acetylation is important in 
maintaining an open chromatin structure, which facilitates the access of the ligand-
activated steroid hormone receptor to the proximal promoter of a target gene. By 
contrast, co-repressors such as nuclear co-repressor (N-CoR) and silencing mediator 
of the retinoid and thyroid hormone receptor (SMRT) proteins have intrinsic histone 
deacetyltransferase activity that catalyse chromatin deacetylation and thereby form 
surfaces for the recruitment of additional components of co-repressor complexes, 
resulting in reduced transcriptional activity of target genes (Deroo & Archer, 2001). 
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1.4.3 Gene regulation by steroid hormones 
Steroids are lipophilic hormones and can diffuse through plasma membranes. 
Classically steroid hormones exert their effects by binding to their cognate nuclear 
hormone receptor which in their unbound form reside in the cytoplasm where they 
form a multimeric protein complex (Figure 1-6). Chaperones such as HSPs are an 
integral part of this protein complex and ensure that the steroid hormone receptor 
remains in a high affinity conformation. Upon binding of the steroid to the LBD, HSPs 
dissociate from the receptor-ligand complex. Classically, the activated receptor then 
forms a homodimer and translocates to the nucleus where the steroid-nuclear 
receptor complex binds the HRE via its DBD. Following DNA binding, co-regulator 
proteins are recruited and interact with the transcriptional machinery to modulate 
target gene expression (described in section 1.4.2). 
Besides their role in regulating transcription of target genes which typically occurs 
within minutes to hours, steroids can also exert more rapid effects which occur within 
seconds. To distinguish this alternative mode of steroid hormone action from 
classical transcriptional events, it is referred to as non-genomic or non-genotropic 
effects (Losel et al., 2004; Wehling et al., 2006). These rapid effects of steroid 
hormones were first observed by Hans Selye more than 60 years ago when he 
noticed that steroid infusions within a few minutes led to anaesthesia of laboratory 
animals (Selye, 1941). Since then these rapid effects have been studied on a cellular 
level and various classes of steroids including glucocorticoids, mineralocorticoids, 
estrogens and progestins have been shown to exert rapid effects in the cytoplasm 
resulting in activation of signal transduction pathways including the mitogen activated 
protein kinase (MAPK) / extracellular activated kinase (ERK), protein kinase A (PKA) 
and protein kinase C (PKC) pathway (Boldyreff & Wehling, 2003; Marino et al., 2006). 
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Not all of these rapid effects can be blocked by classical steroid hormone receptor 
antagonists suggesting that nuclear hormone receptors may not always be involved 
in mediating these effects. 
 
Figure 1-6 Schematic illustration of steroid hormone action. Steroid 
hormones bind to their cognate nuclear receptor (NR) which results in 
release of heat shock proteins (HSP). Two receptor monomers form a 
homodimer and translocate to the nucleus to bind to hormone 
responsive elements (HRE) and recruit co-activators and co-repressors 
to modulate target gene transcription. 
1.5 Glucocorticoids 
1.5.1 Regulation of glucocorticoid production 
Adrenal glucocorticoid secretion is regulated by the hypothalamo-pituitary-adrenal 
(HPA) axis (Figure 1-7). The hypothalamus links the nervous and the endocrine 
system and in response to various stimuli releases corticotrophin releasing hormone 
(CRH) into the hypothalamo-hypophyseal portal vein. CRH then travels to the 
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pituitary gland to stimulate the release of the adrenocorticotropic hormen (ACTH) 
from the corticotroph cells located in the anterior lobe of the pituitary gland. In 
addition, ACTH release can be augmented by hypothalamic release of arginine 
vasopressin (AVP). By binding to the melanocortin 2 receptor (MC2R) ACTH 
stimulates adrenal zona fasciculata cells to release cortisol which exert a negative 
feedback upon CRH release in the hypothalamus and ACTH release in the pituitary 
gland (Figure 1-7). 
HPA drive is tightly regulated by a variety of stimuli. Under physiological conditions 
HPA activity and consequently cortisol levels follow a circadian rhythm with highest 
levels in the morning reaching a nadir around midnight. Circadian regulation of 
hypothalamic CRH release is complex but the suprachiasmatic nucleus (SCN) of the 
hypothalamus appears to play a pivotal role as destruction of the SCN in rats results 
in the loss of corticosteroid periodicity (Moore & Eichler, 1972). Besides circadian 
rhythm, HPA drive is determined by a variety of factors such as food intake, mood, 
nutritional status, physical and psychological stress, and circulating cytokines. The 
dynamic range of the HPA axis is exemplified by the wide range of 24h cortisol 
secretion rates. Normal daily cortisol production adds up to approximately 8-12mg 
(Esteban et al., 1991) whereas under situations of severe stress, such as trauma or 
systemic infections, production rates can increase by up to 5 fold (Salem et al., 
1994). 
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Figure 1-7 The hypothalamo-pituitary-adrenal (HPA) axis (taken 
from http://www.cns.med.ucla.edu). 
1.5.2 Glucocorticoid hormone action 
Virtually all cells in the body express the glucocorticoid receptor (GR) and are 
therefore glucocorticoid targets. Two splice variants of the GR exist, GRα and GRβ, 
but GRβ has a low affinity for glucocorticoids and may therefore function as a 
dominant negative regulator of GRα activation (Oakley et al., 1999). Following 
binding of cortisol (corticosterone in rodents) to the GR, the steroid-receptor complex 
forms a homodimer, translocates to the nucleus and binds to HREs which are 
organised as inverted repeats of the hexanucleotide motif TGTTCT with a spacer of 3 
base pairs (ie AGAACAnnnTGTTCT). Following DNA binding, co-activators and co-
repressors are recruited to activate or repress gene transcription (described in 
section 1.4.2) 
Chapter 1  General Introduction 
  16 
Besides binding to HREs as a dimer, the GR can also directly interact with other 
transcription factors as a monomer and thereby modulate gene expression of target 
genes. These transcription factors include the nuclear factor κB (NF-κB), activating 
protein 1 (AP-1), interferon regulatory factor 3 (IRF-3), nuclear factor of activated T-
cells (NFAT) and cyclic adenosine monophosphate (cAMP) response element-
binding protein (CREB) and are typically involved in activation of inflammatory genes 
(De Bosscher et al., 2008). Direct interaction of monomeric GR with these 
transcription factors, however, represses expression of these inflammatory genes. It 
is therefore believed that the classical mode of action of GR by binding as a dimer to 
HREs is predominantly responsible for transactivation of target genes whereas 
monomeric interaction with other transcription factors is the main mode for 
transrepression (Reichardt et al., 2001). 
1.5.2.1 Metabolic effects 
Glucocorticoids play a pivotal role in carbohydrate, lipid and amino acid metabolism. 
In the liver, glucocorticoids increase gluconeogenesis and facilitate glucose release 
(Rooney et al., 1993). In muscle tissue, they induce protein catabolism resulting in 
release of amino acids. In adipose tissue, glucocorticoids induce both hormone-
sensitive lipase and lipoprotein lipase activity which causes release of free fatty acids 
and glycerol into the circulation (Arner, 2005). Glucocorticoids impair insulin mediated 
glucose uptake which results in insulin resistance of peripheral tissues including the 
liver, muscle and adipose tissue (van Raalte et al., 2009). 
In the skin, glucocorticoids reduce collagen synthesis which causes loss of 
connective tissue and as a result thinning and vulnerability, whereas in bone 
glucocorticoids suppress osteoblast function and thereby favour bone catabolism 
over bone formation. 
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1.5.2.2 Immune modulatory effects 
Glucocorticoids have inhibitory effects on a broad range of specific immune 
responses mediated by T cells and B cells as well as potent suppressive effects on 
the effector functions of monocytes and neutrophils. Not only do glucocorticoids 
reduce the number of circulating lymphocytes and monocytes, they also suppress the 
activity of B cells and proliferation of cytotoxic T cells by interacting with 
macrophages and helper T cells. For example, glucocorticoids decrease the 
synthesis of interleukin 1 (IL-1) by macrophages (MacDermott & Stacey, 1981) and 
the synthesis of interleukin 2 (IL-2) by T helper cells (Gillis et al., 1979). These 
cytokines increase the activity of B cells and cytotoxic T cells, as well as those of 
other leukocytes including macrophages and helper T cells. 
1.5.3 Glucocorticoid excess 
Glucocorticoid excess most commonly results from pharmacological treatment with 
synthetic glucocorticoids whereas endogenous glucocorticoid excess (Cushing’s 
syndrome) is a rare condition of excessive cortisol production. The phenotypic 
pattern of glucocorticoid excess can be predicted from the physiological effects of 
cortisol. One of the most striking features associated with glucocorticoid excess is 
weight gain which is caused by accumulation of adipose tissue in defined regions 
including visceral, dorsal and facial fat depots resulting in the clinical appearance of 
an “apple shape” body composition, a “buffalo hump” and the appearance of a “moon 
face”, respectively (Figure 1-8). In contrast, glucocorticoid excess leads to muscle 
atrophy resulting in sarcopenia and proximal myopathy. In the skin, glucocorticoid 
excess results in thinning, easy bruising and development of purple striae on the 
abdominal skin. Glucocorticoid excess results in a reduction of bone mineral density 
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and development of osteoporosis. In addition, patients have high blood pressure and 
show insulin resistance which may manifest as type II diabetes mellitus. 
 
Figure 1-8 Depiction of the clinical signs of Cushing’s syndrome. 
This picture shows the progression of classical clinical signs of overt 
cortisol excess (Cushing’s syndrome) including “moon face”, “buffalo 
hump”, central obesity, abdominal stretch marks, proximal myopathy, 
loss of height due to osteoporotic fractures. 
In order to prevent these detrimental consequences of glucocorticoid excess, 
exogenous glucocorticoid treatment should be at the lowest acceptable dose and for 
as short duration as possible. Whereas in patients with Cushing’s syndrome the 
underlying condition (i.e. pituitary adenoma, ectopic ACTH producing tumour or 
adrenal adenoma/carcinoma) requires surgically removal. 
1.5.4 Glucocorticoid metabolism 
Plasma cortisol is bound with high affinity to corticosteroid-binding globulin (CBG), 
which protects it from degradation. The normal plasma half-life of cortisol is 
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approximately 80-100 minutes (Brien, 1981). Increased metabolism of cortisol results 
in a shortened half life. In order to prevent a fall in circulating cortisol, HPA drive and 
consequently adrenal cortisol production increases, compensating for increased 
cortisol clearance. Historically the liver has been regarded as the predominant site of 
cortisol metabolism but a wide variety of extra hepatic tissues express enzymes 
involved in cortisol metabolism. The major enzymatic reactions contributing to cortisol 
metabolism are depicted in Figure 1-9. Cortisol can be converted to cortisone by the 
enzyme 11β-HSD2 which is predominantly found in the kidney. The opposite 
reaction, namely the reactivation of cortisol from cortisone, is catalysed by 11β-HSD1 
which is predominantly expressed in the liver and adipose tissue. Global activities of 
both isozymes determine the ratio of cortisol to cortisone in the circulation and 
consequently, alterations of enzymatic activities results in an altered equilibrium. 
Cortisol and cortisone can be metabolised by reduction of the double bond of the A 
ring by the action of 5α- and 5β-reductases resulting in the respective 5α- and 5β-
dihydro steroids. These are subsequently dehydrogenated by 3α-hydroxysteroid 
dehydrogenases (3α-HSDs) leading to the generation of tetrahydro-cortisone (THE), 
5β-tetrahydro-cortisol (5β-THF) and 5α-tetrahydro-cortisol (5α-THF). In normal 
human physiology global 5β-reductase activity is twice as high as that of 5α-
reductase resulting in a 5β-THF / 5α-THF ratio of approximately 2. To a lesser extent 
cortisol and cortisone are also metabolised by hydroxylation at positions C6, C20 
(Shackleton et al., 1985). 
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Figure 1-9 Depiction of the main enzymatic steps involved in cortisol 
metabolism (3α-, 11β-, 20α/β-hydroxysteroid dehydrogneases (HSDs), 
5α-, 5β-reductases). 
1.6 Mineralocorticoids 
1.6.1 Regulation of mineralocorticoid production 
Aldo, the principal mineralocorticoid hormone, plays a pivotal role in the regulation of 
electrolyte and fluid homeostasis by regulating sodium reabsorption and potassium 
excretion in mineralocorticoid target tissues such as the kidney, salivary glands and 
colon. Aldo secretion from the zona glomerulosa of the adrenal gland is regulated by 
distinct mechanisms, the most important being the RAAS (Figure 1-10). Sodium 
depletion, low blood pressure and/or hypovolaemia are key stimuli, sensed by cells of 
the macula densa of the juxtaglomerular apparatus in the kidney, to release renin 
which is a protease that converts angiotensinogen into Ang I. Ang I then undergoes a 
second proteolytic step catalysed by the angiotensin converting enzyme (ACE) 
resulting in angiotensin II (Ang II). In the zona glomerulosa of the adrenal gland, Ang 
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II by binding to angiotensin II type 1 receptors stimulates Aldo production and 
release. In mineralocorticoid target cells Aldo binds to its cognate receptor, the MR, 
resulting in target gene regulation which ultimately leads to increased urinary sodium 
reuptake, potassium excretion and water retention. Fluid and sodium retention in turn 
results in expansion of the extracellular space and as a consequence blood pressure 
increases. By contrast, high blood pressure and/or fluid overload inhibits renin 
secretion and as a consequence Ang II and Aldo levels decrease. 
 
Figure 1-10 Schematic illustration of the renin-angiotensin-
aldosterone system (RAAS). 
Beside the RAAS, Aldo synthesis and secretion is also directly stimulated by high 
potassium levels (hyperkalaemia) and by ACTH. Consequently, Aldo levels similarly 
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to cortisol also exhibit a circadian rhythm with highest levels in the morning and 
lowest levels before midnight. 
1.6.2 Mineralocorticoid action 
Classical mineralocorticoid responsive cells which are characterised by the 
concomitant expression of the MR and the enzyme 11β-HSD2 (described in section 
1.7.2.2), encompass epithelial cells of the distal nephron (distal tubule and collecting 
duct) of the kidney, ductal cells of sweat glands and enterocytes of the distal colon. 
After entering the cytoplasm, Aldo binds to the MR which homodimerises and 
translocates into the nucleus where it binds to HREs, which have an identical DNA 
sequence to HREs bound by the GR. Target genes for the MR in the kidney include 
the serum and glucocorticoid induced kinase 1 (SgK1), glucocorticoid-induced 
leucine zipper (GILZ), the α subunit of the epithelial sodium channel (α-ENaC), the 
renal outer medullary potassium channel (ROMK), and the sodium/potassium 
adenosine triphosphatase (ATPase) (Bens et al., 2006). 
ENaC is expressed at the apical membrane and constitutes the rate-limiting step in 
transepithelial Na+ transport. The abundance of functional ENaC is dynamically 
regulated both at the level of ENaC production and integration into the cell 
membrane, as well as ENaC endocytosis and degradation (Figure 1-11). The 
ubiquitin ligase neural precursor expressed, developmentally down-regulated protein 
4-2 (Nedd4-2), is associated with ENaC at the cell surface and facilitates degradation 
and endocytosis by ubiquitination of N-terminal lysines of the α and γ subunit of 
ENaC (Kamynina & Staub, 2002; Snyder, 2005). 
MR mediated Aldo action increases ENaC abundance and thereby transepithelial 
Na+ transport by two separate mechanisms. Firstly, Aldo directly stimulates 
expression of α-ENaC, which in turn facilitates ENaC release from the endoplasmic 
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reticulum resulting in the formation of new ENaC complexes. Secondly, it also up-
regulates the serine/threonine kinase SgK-1 which phosphorylates Nedd4-2 resulting 
in reduced degradation of ENaC. 
Other direct target genes of Aldo action include that of the renal outer medullary 
potassium (ROMK) channel, which is expressed at the apical membrane and 
facilitates potassium excretion, and the Na+/K+ ATPase which is expressed at the 
basolateral membrane to exchange intracellular sodium and potassium. 
 
Figure 1-11 Schematic illustration of aldosterone action in cells of the 
distal nephron of the kidney. ENaC: epithelial sodium channel; ROMK: 
renal outer medullary potassium channel; SgK-1: serum and 
glucocorticoid induced kinase 1; Nedd4-2: neural precursor expressed, 
developmentally down-regulated protein 4-2 (Kiryluk & Isom, 2007). 
1.6.3 Primary hyperaldosteronism 
Primary hyperaldosteronism (PHA) is now considered the most frequent cause of 
secondary hypertension accounting for 5-10% of all hypertensives. Primary 
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hyperaldosteronism is either caused by an Aldo producing adenoma (APA) (about 
1/3 of all patients) or by excessive bilateral Aldo production from hyperplastic 
adrenals and is then referred to as idiopathic hyperaldosteronism (IHA). Aldo excess 
invariably leads to increased salt and fluid retention, reflected by suppressed renin 
levels and high blood pressure but hypokalaemia develops only in 50% of APA and 
20% of IHA patients (Rossi et al., 2006). Patients with APAs may be amenable for 
surgery, whereas all other patients are treated medically with the overriding goal to 
normalise blood pressure to prevent co-morbidities secondary to high blood pressure 
levels (Young, 2007). 
Familial hyperaldosteronism (FH) is a rare heritable form of primary 
hyperaldosteronism and two types have been described.  FH type I, or glucocorticoid-
remediable aldosteronism (GRA), is autosomal dominant in inheritance and caused 
by a fusion of the promoter region of the gene for CYP11B1 and the coding 
sequences of CYP11B2, resulting in ACTH-dependent activation of the aldosterone 
synthase gene in the zona glomerulosa. Suppression of ACTH drive by exogenous 
glucocorticoids results in down-regulation of aldosterone synthase activity and 
ameliorates Aldo excess in FH type I. FH type II refers to the familial occurrence of 
APA or IHA or both but so far the underlying cause has not been identified (So et al., 
2005). 
1.6.4 Secondary hyperaldosteronism 
Secondary hyperaldosteronism is characterised by the hypersecretion of Aldo as a 
consequence of increased activation of the RAAS and can be divided into two 
categories depending on the presence of hypertension. In the absence of 
hypertension RAAS activation is a result of homeostatic attempts to maintain sodium 
or circulatory volume which occurs in diarrhea, excessive sweating, low cardiac 
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output states, and hypoalbuminemia due to liver or renal disease. Renovascular 
hypertension is the most common cause of secondary hyperaldosteronism 
associated with high blood pressure. It is caused by ischemia of the renal 
parenchyma secondary to atherosclerotic renal artery stenosis or fibromuscular 
dysplasia. By contrast, renin secreting juxtaglomerular cell tumours of the kidney and 
Wilms tumours are rare forms of elevated renin and Aldo levels in the presence of 
hypertension. 
1.6.5  Mineralocorticoid receptor antagonists 
MR antagonists are steroid based compounds (Figure 1-12) that competitively inhibit 
the binding of Aldo to the MR and thereby prevent Aldo induced MR activation. Given 
the classical role of Aldo in blood pressure regulation, both Spiro and EPL are 
licensed as anti-hypertensive drugs and exhibit a particularly good blood pressure 
lowering effect in patients with so called “resistant hypertension” (Chapman et al., 
2007) and patients with primary hyperaldosteronism (Karagiannis et al., 2008). In 
addition, Spiro has also been used for a long time in patients with chronic liver 
disease (Moore et al., 2003) and heart failure (Weber & Villarreal, 1993), conditions 
characterised by avid salt and fluid retention as a result of RAAS activation. More 
recently, the RALES and EPHESUS study have shown beneficial effects of MR 
antagonists in patients with chronic and acute post-MI heart failure as low doses of 
Spiro and EPL, respectively, dramatically improved survival in these patients (Pitt et 
al., 2003b; Pitt et al., 1999). The use of these drugs, however, may be limited in 
some patients given their side effects. Spiro is an unselective MR antagonist as it 
exhibits also anti-androgenic and progestional effects which can result in 
gynecomastia and erectile dysfunction in men and irregular menstrual bleeding in 
females. By contrast, EPL does not interfere with the androgen or progesterone 
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receptor and is therefore considered a selective Aldo receptor antagonist (SARA). 
Both drugs, however, even when used at low doses have the risk to cause 
hyperkalaemia, particularly in patients who are already treated with an angiotensin 
converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) and 
patients with chronic renal impairment. Therefore in these patients potassium levels 
need to be monitored regularly. 
 
Figure 1-12 Structures of aldosterone and its antagonists eplerenone 
and spironolactone. 
1.6.6 Mineralocorticoid metabolism 
The half life of Aldo in the circulation is approximately 30 minutes (Coppage et al., 
1962). The liver is the main site of Aldo metabolism. Only small amounts of Aldo 
appear in the urine whereas the majority is excreted as biologically inactive, water-
soluble Aldo metabolites. The main urinary Aldo metabolite is 3α,5β-tetrahydro-
aldosterone (TH-Aldo) which results from A ring reduction by 5β-reductase and 
subsequent dehydrogenation by 3α-HSDs (Figure 1-13). Other Aldo metabolites 
include 3α-hydroxy-5β-pregnane-(11β-18),(18-20)-dioxide and aldosterone-18-
glucuronide. By contrast, only trace amounts of Aldo appear as 5α-reduced 
metabolites in the urine. 
Eplerenone SpironolactoneAldosterone
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Figure 1-13 Metabolism of aldosterone. 
1.7 11β hydroxysteroid dehydrogenases 
The interconversion of active glucocorticoids cortisol (Kendall’s compound F) in man 
and corticosterone (Kendall’s compound B) in rodents into their biologically inactive 
metabolites (cortisone in man, 11-dehydrocorticosterone in rodents (Kendall’s 
compounds E and A, respectively)) is catalysed by two 11β-HSD isoenzymes (Figure 
1-14). 11β-HSD type 1 was initially purified from rat liver microsomes and showed 
only dehydrogenase activity in tissue homogenates (conversion of cortisol to 
cortisone) (Lakshmi & Monder, 1988). This was a surprising finding because in vivo 
the liver showed oxoreductase activity (conversion of cortisone to cortisol) suggesting 
the existence of a second isoform (Monder et al., 1989). Later on it became clear that 
11β-HSD1 indeed possesses both oxoreductase and dehydrogenase activities in 
vitro but in vivo and in intact cells it predominantly functions as an oxoreductase. 
Evidence for an additional isoenzyme that was active in mineralocorticoid target 
tissues was initially obtained from histochemical studies on kidney sections. A few 
years after purification and cloning of 11β-HSD1, this isoenzyme was identified by 
expression cloning and named 11β-HSD2 (Albiston et al., 1994). The two 
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isoenzymes are products of two separate genes, possess only 14% identity, exhibit 
different enzymatic kinetics and have different expression patterns. 
 
Figure 1-14 Interconversion of cortisol and cortisone by 11β-
hydroxysteroid dehydrogenases (11β-HSDs) (Hammer & Stewart, 
2006). 
1.7.1 11β-hydroxysteroid dehydrogenase type 1 
1.7.1.1 Characterisation of 11β-HSD1 
The human 11β-HSD1 enzyme is encoded by the HSD11B1 gene located on 
chromosome 1q32.2-41 spanning 30 kbp. The gene consists of 6 exons encoding a 
messenger ribonucleic acid (mRNA) of approximately 1400 nucleotides which is 
translated into a protein of 292 amino acid with a molecular weight of 30 kDa 
(Tomlinson et al., 2004). The enzyme belongs to the family of the short-chain 
dehydrogenases/reductases and predominantly utilises NADPH/NADP+ as a co-
factor. 
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Enzymatic studies of purified homogenous enzyme revealed Michaelis-Menten (Km) 
constants of 1.83 - 0.06 µM for cortisol and 17.3 - 2.24 µM for corticosterone. 
Although first-order rate constants are one order of magnitude lower for cortisol than 
corticosterone, maximal velocities are similar (Lakshmi & Monder, 1988). 
1.7.1.2 Function and expression 
Initially, kinetic assessment of 11β-HSD1 revealed only dehydrogenase activity in 
tissue homogenates but subsequent studies in intact tissues (Duperrex et al., 1993) 
as well as whole cells (Low et al., 1994) showed oxoreductase activity. It is now well 
accepted that although 11β-HSD1 is a bidirectional enzyme, capable of catalysing 
both oxoreductase as well as dehydrogenase reactions, in vivo almost exclusively 
behaves as an oxoreductase. The enzyme is attached to the membrane of the 
endoplasmic reticulum (Monder & Lakshmi, 1988) with its catalytic domain facing the 
lumen of the endoplasmic reticulum (Odermatt et al., 1999; Ozols, 1995). Although 
the endoplasmic reticulum as a whole is regarded an oxidative environment, it 
harbors the enzyme hexose-6-phosphate dehydrogenase (H6PDH) which 
regenerates NAPDH from NADP+ by converting glucose-6-phosphate into 6-
phospho-gluconolactone (Figure 1-15). It has recently been demonstrated that 
NADPH production by H6PDH is indispensable for 11β-HSD1 oxoreductase activity 
as mice which with a disruption of the H6PDH gene show a complete loss of 
oxoreductase activity and reversal of its enzymatic activity from an oxoreductase to a 
dehydrogenase (Lavery et al., 2006). 
11β-HSD1 facilitates tissue specific GR-mediated hormone action and is widely 
expressed in both man (Ricketts et al., 1998) and rodents (Gomez-Sanchez et al., 
2008) with highest expression levels and activity in liver and adipose tissue as well as 
gonads and the brain (Tomlinson et al., 2004). 
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Figure 1-15 Schematic illustration of 11β-HSD1 function in the 
endolasmic reticulum. 11β-HSD1 faces the lumen of the endoplasmic 
reticulum where it reduces inactive into active glucocorticoids (GC) at 
the expense of NADPH which is oxidised to NADP+. NADPH supplies 
are regenerated from NADP+ by the microsomal enzyme hexose-6-
phosphate-dehydrogenase (H6PDH) which converts glucose-6-
phosphate (G6P) to 6-phospho-gluconolactone (6PG). G6P enters the 
endoplasmic reticulum via G6P translocase (G6PT). 
1.7.1.3 Cortisone reductase deficiency 
Cortisone reductase deficiency (CRD) is characterised by a failure to regenerate 
cortisol from cortisone via 11β-HSD1. To date only heterozygote mutations resulting 
in 11β-HSD1 haploinsufficiency have been described in humans. A putative 
phenotype may be predicted from genetically engineered mice with a disruption of 
the gene encoding for 11β-HSD1. These mice are unable to convert inert 11-
dehydrocorticosterone to corticosterone resulting in a reduced half life of 
corticosterone (Kotelevtsev et al., 1997). This is compensated for by an increased 
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HPA drive with increased adrenal corticosterone production reflected by hyperplastic 
adrenal glands. Phenotypically, these mice exhibit mainly metabolic changes. On 
starvation they show attenuated activation of the key hepatic gluconeogenic enzymes 
glucose-6-phosphatase and phosphoenolpyruvate carboxykinase and are resistant to 
hyperglycemia provoked by obesity or stress. Thus, attenuation of hepatic 11β-HSD-
1 may provide a novel approach to modulate hepatic gluconeogenesis and thereby 
improve glucose homeostasis. 
In man, mutations in the gene encoding for H6PDH have been described which result 
in a functional loss of 11β-HSD1 oxoreductase activity (Draper et al., 2003; Lavery et 
al., 2008). Biochemically these patients show very low ratios of urinary cortisol 
(THF+5α-THF) to cortisone (THE) metabolites of 0.05 or lower (reference range, 0.7–
1.2) which are in agreement with loss of 11β-HSD1 oxoreductase and gain of 
dehydrogenase activity. Clinically, female patients show a mild phenotype of 
androgen excess which is a result of increased HPA drive resembling that of 
polycystic ovarian syndrome (PCOS). The male phenotype is precocious puberty 
which presumably reflects increased adrenal androgen production (Lavery et al., 
2008). 
1.7.1.4 11β-HSD1 and the metabolic syndrome 
The metabolic syndrome describes an aggregation of cardiovascular risk factors and 
according to the World Health Organisation (WHO) is defined by the presence of 
diabetes mellitus, impaired glucose tolerance, impaired fasting glucose or insulin 
resistance and presence of two of the following criteria: elevated blood pressure (≥ 
140/90 mmHg), dyslipidaemia (triglycerides: ≥ 1.695 mmol/L and high-density 
lipoprotein cholesterol (HDL-C) ≤ 0.9 mmol/L (male), ≤ 1.0 mmol/L (female)), central 
obesity (waist : hip ratio > 0.90 (male); > 0.85 (female), or body mass index > 30 
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kg/m2) and microalbuminuria (urinary albumin excretion ratio ≥ 20 µg/min or albumin 
creatinine ratio (ACR) ≥ 30 mg/g). 
Although patients with the metabolic syndrome and Cushing’s syndrome share many 
clinical features, circulating cortisol levels in patients with the metabolic syndrome are 
normal whereas in Cushing’s syndrome they are elevated. The enzyme 11β-HSD1 
plays a pivotal role in determining tissue specific glucocorticoid concentrations by 
regenerating active from inactive glucocorticoids, and thus, it has been hypothesised 
that increased 11β-HSD1 activity may be involved in the pathogenesis of the 
metabolic syndrome. To further explore this theory, transgenic mice strains have 
been created which overexpress 11β-HSD1 in adipose tissue (Masuzaki et al., 2001; 
Masuzaki et al., 2003) and the liver (Paterson et al., 2004). Mice overexpressing 11β-
HSD1 in adipocytes exhibit visceral obesity, insulin-resistant diabetes, 
hyperlipidaemia and hyperphagia (Masuzaki et al., 2001) and develop salt-sensitive 
hypertension (Masuzaki et al., 2003). By contrast, mice with liver specific 
overexpression of 11β-HSD1 remain lean but exhibit fatty liver, insulin-resistance and 
also develop hypertension as a result of liver glucocorticoid excess (Paterson et al., 
2004). Taken together, increased 11β-HSD1 activity in these mouse models strikingly 
recapitulates many features of the metabolic syndrome suggesting that increased 
11β-HSD1 activity may be a critical contributory factor in the development and 
pathogenesis of the metabolic syndrome. 
1.7.1.5 Pharmacological inhibition of 11β-HSD1 
11β-HSD1 activity is inhibited by the liquorice derivatives, glycyrrhizic acid, its 
hydrolytic product glycyrrhetinic acid (GE), and the hemisuccinate derivative 
carbenoxolone (CBX). Glycyrrhetinic acid is a potent competitive inhibitor of 11β-
HSD1 (Monder et al., 1989; Whorwood et al., 1993), but it is not selective to 11β-
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HSD1 as it also inhibits 11β-HSD2 with an inhibition constant (Ki) of 5–10 nM 
(Albiston et al., 1994; Stewart et al., 1994). 
1.7.2 11β-hydroxysteroid dehydrogenase type 2 
1.7.2.1 Characterisation of 11β-HSD2 
The human 11β-HSD2 enzyme is encoded by the HSD11B2 gene located on 
chromosome 16q22 spanning 6.2 kbp (Agarwal et al., 1995). The gene consists of 5 
exons encoding for a mRNA of approximately 1800 nucleotides which is translated 
into a protein of 405 amino acid with a molecular weight of approximately 40 kDa 
(Brown et al., 1996a). 11β-HSD2 belongs to the family of short-chain alcohol 
dehydrogenases. Sequence alignment shows highest similarity (37%) with placental 
17β-hydroxysteroid dehydrogenase type 2 (Wu et al., 1993), whereas it is only 21% 
identical to the predicted sequence of human 11β-HSD1 (Tannin et al., 1991). 
Similar to the 11β-HSD1 isoenzyme, 11β-HSD2 is bound to the membrane of the 
endoplasmic reticulum, but in contrast, its catalytical domain faces the cytoplasm 
(Odermatt et al., 1999; Ozols, 1995). Hydropathicity analysis suggests that 11β-
HSD2 has three successive hydrophobic segments of approximately 20 amino acids 
each in the N-terminal region (Agarwal et al., 1994) which may function as 
transmembrane segments anchoring the enzyme to the membrane of the 
endoplasmic reticulum. 
Kinetic studies of 11β-HSD2 show that in contrast to 11β-HSD1, it functions solely as 
a dehydrogenase (converting cortisol to cortisone) and has a high affinity for cortisol 
and corticosterone with an apparent Km of 47 and 5.1 nM, respectively, and relies on 
the presence of NADH/NAD+ as a co-factor (Albiston et al., 1994; Brown et al., 1993; 
Stewart et al., 1994). Mutations (1.7.2.3) or pharmacological inhibition of 11β-HSD2 
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(1.7.2.4) results in reduced cortisol metabolism and as a consequence cortisol half 
life is prolonged. 
1.7.2.2 Localisation and function – MR specificity 
Expression of 11β-HSD2 has been examined by RNA blot hybridisation in various 
species including humans, sheep and rodents. In all species, this isoenzyme is highly 
expressed in the placenta and mineralocorticoid target tissues, particularly the 
kidney, sweat glands and the colon, whereas it is not detected in the liver, heart, or 
adult testis (Agarwal et al., 1994; Albiston et al., 1994; Cole, 1995; Zhou et al., 1995). 
11β-HSD2 is also expressed in vascular smooth muscle cells (Hatakeyama et al., 
1999) and the brain where its expression is restricted to cells in the commissural 
portion of the nucleus tractus solitarius, subcommissural organ, and ventrolateral and 
ventromedial hypothalamus (Roland et al., 1995). 
The distinct tissue expression pattern of 11β-HSD2 in classical mineralocorticoid 
target tissues is closely related to its function. Circulating concentrations of cortisol 
and corticosterone are 100 to 1000-fold higher than those of Aldo but, paradoxically, 
the MR has similar affinities for both Aldo and cortisol in vitro (Edwards et al., 1988; 
Funder et al., 1988). Therefore, MR selectivity for Aldo in mineralocorticoid target 
tissues relies on efficient pre-receptor inactivation of cortisol to cortisone by 11β-
HSD2 (Figure 1-16). In contrast to cortisol, Aldo cannot be metabolised by 11β-HSD2 
because it forms a C11-C18 hemi-ketal group in aqueous solution.  
Besides classical mineralocorticoid target tissues, 11β-HSD2 is also highly 
expressed in the placenta where it protects the embryo from maternal spill over of 
active glucocorticoids. Insufficient placental metabolism of active glucocorticoids 
results in intrauterine growth restriction (IUGR) (Shams et al., 1998). Furthermore, 
excess intrauterine glucocorticoid exposure leads to fetal programming of adult 
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disease including increased blood pressure in adulthood, glucose levels, HPA axis 
activity and anxiety-related behaviors (Seckl & Holmes, 2007). 
 
Figure 1-16 Schematic illustration of aldosterone action in the kidney. 
The mineralocorticoid receptor (MR) has equal affinities for cortisol and 
aldosterone. Binding of aldosterone (Aldo) in the kidney is ensured by 
11β-HSD2 which converts cortisol (F) into inactive cortisone (E). 
Activation of the MR by Aldo results in target gene expression including 
the epithelial sodium channel (ENaC) (Hammer & Stewart, 2006). 
1.7.2.3 Apparent Mineralocorticoid Excess 
Apparent mineralocorticoid excess (AME) is an extremely rare form of hypertension; 
so far fewer than 100 cases have been described worldwide (Funder et al., 1988; 
Wilson et al., 2001). AME is inherited in an autosomal recessive fashion and more 
than 60 kindreds with affected siblings have been reported. Presentation is usually 
during neonatal life or childhood with low birth weight, failure to thrive, short stature, 
severe hypertension and hypokalaemic metabolic alkalosis. In addition, renal cysts 
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and nephrocalcinosis have been reported and may lead to renal insufficiency. 
Biochemical abnormalities comprise hypokalaemia, suppressed renin and 
undetectable Aldo levels, hence the term ‘apparent mineralocorticoid excess’. The 
molecular basis for this condition was only elucidated after cloning the HSD11B2 
gene. All identified patients harbor bi-allelic HSD11B2 mutations resulting in a 
functionally defective enzyme (Figure 1-17). Lack of functional 11β-HSD2 leaves the 
MR unprotected from cortisol binding and activation. These findings in humans are 
reflected in mice with a genetically engineered disruption of the HSD11B2 gene 
which show a similar phenotype as AME patients (Kotelevtsev et al., 1999). At 
present, over 30 different mutations have been identified within the HSD11B2 gene 
to cause AME. Missense mutations have emerged as the most frequent genetic 
alteration in AME but frame shift and splice site mutations have also been described 
(Hammer & Stewart, 2006). 
 
Figure 1-17 Schematic illustration of the HSD11B2 gene structure 
and all mutations that have been identified to cause AME (Hammer & 
Stewart, 2006). 
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1.7.2.4 Pharmacological inhibition of 11β-HSD2 
Liquorice extract (Glycyrrhiza glabra) has been used for hundreds of years as a 
sweetener in confectionery and as a herbal remedy. Isolation of the active 
component, glycyrrhetinic acid and the observation that liquorice promotes healing of 
peptic ulcers led to the development of carbenoxolone, an 18β-hemisuccinate 
derivative of GA, which subsequently was used as a drug in the treatment of both 
duodenal and gastric ulcerations. However, both liquorice and carbenoxolone induce 
undesirable mineralocorticoid-like side effects including oedema, hypertension and 
hypokalaemia in up to 50% of patients (Card et al., 1953) which are explained by 
their potent ability to inhibit 11β-HSD2 with a Ki in the low nanomolar range. 
Therefore, liquorice intoxication is now well accepted as the acquired counterpart to 
the inherited syndrome of AME. 
1.7.2.5 11β-HSD2 in essential hypertension 
Although patients with essential hypertension do not exhibit overt signs of 
mineralocorticoid excess, blood pressure levels have been positively correlated with 
plasma sodium and negatively correlated with plasma potassium levels, suggesting 
that adrenal corticosteroids may play a role in the pathogenesis of essential 
hypertension (Beretta-Piccoli et al., 1983). Furthermore, in analogy to milder forms of 
AME, a proportion but not all patients with essential hypertension exhibit an 
increased cortisol half-life (Walker et al., 1993) and an elevated urinary free cortisol / 
cortisone (UFF/UFE) ratio suggesting that subtle changes in 11β-HSD2 activity may 
be involved in the pathogenesis of essential hypertension (Mariniello et al., 2005). A 
contributory role of 11β-HSD2 is further underlined by genetic studies which have 
reported associations of a polymorphism in the first intron of the HSD11B2 gene with 
reduced 11β-HSD2 activity and high blood pressure in patients with salt-sensitive 
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hypertension compared to controls (Agarwal et al., 2000; Carvajal et al., 2005). 
Additionally, in a recent report 4 polymorphisms in the promoter region of the 
HSD11B2 gene have been linked to the presence of salt-sensitive essential 
hypertension and reduced expression levels of the HSD11B2 gene in vitro which for 
the first time provides a mechanistic explanation for impaired 11β-HSD2 activity 
caused by polymorphisms in patients with salt-sensitive essential hypertension 
(Alikhani-Koupaei et al., 2007). 
1.8 Heart disease 
Heart disease is a broad term for a variety of disorders affecting the heart including 
ischaemic heart disease, hypertensive heart disease, cardiomyopathies and CHF. 
Heart disease remains the leading cause of death in England and Wales followed by 
cerebrovascular disease and cancer (News report 2006, UK National statistics) and 
the United States (National Vital Statistics Report 2007, Centers for disease control 
and prevention). 
1.8.1 Ischaemic heart disease 
Ischaemic heart disease is characterised by reduced blood supply to the heart 
muscle and is caused by atherosclerosis of the coronary arteries and is the most 
common cause of death in most Western countries, and a major cause of hospital 
admissions. Known risk factors include age, smoking, hypercholesterolaemia, 
diabetes mellitus, hypertension, male gender and a positive family history for 
ischaemic heart disease. 
Atherosclerosis initially leads to narrowing of the coronary arteries, compromising 
blood supply to the heart, particularly during physical activity to cause shortness of 
breath and chest pain (angina) on exertion. Cession of blood supply caused by 
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complete blockage of coronary blood flow invariably results in myocardial infarction 
(MI). Following MI, the heart undergoes reorganisation of its architecture with scar 
formation of the infarcted area and changes to non-infarcted areas such as 
compensatory hypertrophy of myocardial tissue and cardiac fibrosis (Figure 1-18). 
These changes are referred to as ‘cardiac remodelling’ and may lead to the 
development of heart failure (1.8.3). 
 
Figure 1-18 Schematic illustration of post infarct remodelling. The 
grey area depicts infarcted myocardium, the black area represents 
viable myocardium which undergoes remodelling post myocardial 
infarction (Opie et al., 2006). 
1.8.2 Hypertensive heart disease 
Hypertensive heart disease describes the changes inflicted by chronic elevated blood 
pressure levels. Besides the contributory effects of high blood pressure on the 
development and progression of ischaemic heart disease, long standing 
hypertension also directly affects the myocardium both structurally and functionally. 
High blood pressure causes compensatory left ventricular hypertrophy (LVH) (Figure 
1-19) which eventually results in heart failure. In contrast to patients with ischaemic 
or idiopathic heart failure who usually have an enlarged and dilated left ventricle, 
patients with hypertensive heart disease initially develop a hypertrophied but normal-
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sized left ventricular chamber characterised by myocyte hypertrophy (with increased 
width relative to length) and ventricular wall thickening without chamber dilatation, a 
response that may be a compensatory mechanism to normalise wall stress. LVH is 
accompanied by pathologic features including CM death, fibrosis and scarring. 
Cardiac fibrosis seems to be more widespread in hypertensive heart disease than in 
other causes of heart failure which contributes to myocardial stiffness, especially 
during diastole. Characteristically systolic function in these patients is preserved but 
myocardial hypertrophy impairs relaxation and filling of the left ventricle resulting in 
smaller stroke volumes which is referred to as diastolic heart failure (or heart failure 
with preserved ejection fraction) (Berk et al., 2007). 
 
Figure 1-19 Schematic illustration of concentric left ventricular 
hypertrophy. Chronic pressure overload results in thickening of 
cardiomyocytes and the left-ventricular wall (Opie et al., 2006). 
1.8.3 Heart failure 
Besides idiopathic cardiomyopathy and valvular heart disease, ischaemic and 
hypertensive heart disease are the most frequent underlying conditions leading to 
CHF (Jessup & Brozena, 2003). CHF may be secondary to either systolic or diastolic 
dysfunction or a combination of both. To date, no gold standard has been agreed on 
but different criteria which are predominantly or exclusively based on signs and 
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symptoms have been proposed (Framingham, Boston or Duke criteria). Clinical signs 
of CHF include reduced exercise tolerance, shortness of breath, peripheral and/or 
pulmonary oedema and cyanosis. Severity of CHF has been classified by the New 
York Heart Association (NYHA) into four classes (I-IV) according to clinical signs and 
symptoms and more recently by the American Colleague of Cardiology (ACC) / 
American Heart Association (AHA) into four stages (A-D). 
1.8.4 Cardiac remodelling and fibrosis 
1.8.4.1 Cardiac remodelling 
Cardiac remodelling describes the changes that occur in response to disorders such 
as MI, pressure or volume overload, inflammatory heart muscle disease and 
idiopathic dilated cardiomyopathy (Cohn et al., 2000). Histopathologically, the 
remodelling process is characterised by structural rearrangement of components of 
the normal chamber wall that involves CM disarray and hypertrophy, cardiac 
fibroblast proliferation and accelerated and aberrant accumulation of extracellular 
matrix (ECM), referred to as cardiac fibrosis (Massie & Shah, 1996; Sun & Weber, 
2000; Swynghedauw, 1999). These alterations at the cellular level eventually lead to 
changes in heart shape, size and most importantly function. Although these 
remodelling processes initially play an important role in wound healing and augment 
performance, over the longer term they often develop to a maladaptive response and 
progressively impair cardiac function resulting in heart failure. Maladaptive 
remodelling has been associated with an impaired prognosis in patients after MI and 
patients with CHF and therefore represents an important therapeutic target for 
medical therapy (Cohn et al., 2000). Neurohormonal activation including that of the 
RAAS and the sympathetic nervous system is an important driver of cardiac 
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remodelling. Consequently drugs interfering with these pathways such as ACEi, 
angiotensin receptor blockers (ARBs) and MR antagonists ameliorate the remodelling 
process and thereby slow down disease progression, and improve symptoms, co-
morbidities and mortality (1997; Garg & Yusuf, 1995; Packer et al., 1996; Pitt et al., 
1999). 
1.8.4.2 Cardiac fibrosis 
Cardiac fibrosis is an integral feature of cardiac remodelling and is characterised by 
disproportionate accumulation of ECM. The ECM forms a three dimensional scaffold 
around individual and bundles of CM to generate a stress-tolerant network. Collagen 
type I and III are the major stress-bearing elements within the ECM in the heart 
accounting for approximately 80% and 10%, respectively, of total cardiac collagen 
content (Jugdutt, 2003). Cardiac fibrosis results from a disproportionate increase in 
the synthesis and/or inhibition of degradation of ECM proteins and has important 
functional consequences for the heart. Firstly, collagen accumulation leads to 
ventricular stiffening, which initially impairs ventricular relaxation resulting in 
predominantly diastolic dysfunction but if severe can compromise cardiac contraction 
and result in systolic dysfunction. Secondly, cardiac fibrosis disrupts 
electrophysiological connections between cardiac myocytes and provides an 
electrical substrate for arrhythmogenesis. Thirdly, capillary density is reduced by 
fibrosis and thereby oxygen diffusion distance increases leading to CM hypoxia 
(Sabbah et al., 1995). Cardiac fibrosis is not uniform and displays characteristic 
differences depending on the underlying aetiology. While reparative (replacement) 
fibrosis takes place at sites of myocyte death to replace areas of dead myocytes by a 
structural scar, reactive fibrosis is characterised by interstitial (collagen appears in 
the intermuscular space) and/or perivascular (collagen accumulates around coronary 
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arteries and arterioles) collagen deposition and is not directly associated with CM 
death (Weber et al., 1989). 
CFb are the predominant secretory cells of ECM proteins in the heart and are thus 
key in normal and pathological cardiac remodeling. Following cardiac injury, 
fibroblasts undergo a phenotypic transformation into myofibroblasts (MyoFb) which 
are characterised by their ability to contract and actively secret ECM proteins and 
thereby facilitate wound closure (Sun & Weber, 2000). MyoFb are characterised by 
the expression of the pro-contractile protein α smooth muscle actin (α-SMA) and are 
exclusively found at sites of remodelling but not in the normal heart (with the 
exception of valve leaflets). Following activation, MyoFb become particularly 
responsive to pro-inflammatory cytokines such as tumour necrosis factor alpha 
(TNFα), interleukin-1 (IL-1), interleukin-6 (IL-6), transforming growth factor-beta 
(TGF-β) and vasoactive peptides (including Ang II, endothelin-1) (Porter & Turner, 
2009). These stimuli in turn lead to alterations in the proliferative and migratory 
properties of MyoFb, modulate ECM turnover and regulate the secretion of cytokines 
and growth factors including TNFα, Il-6 and Il-1β (Porter & Turner, 2009). While 
apoptosis of the MyoFb has been shown to be associated with the advancement of 
granulomatous tissue to become a mature scar, persistence of MyoFb has been 
suggested to be an important driver of maladaptive cardiac fibrosis. 
Cardiac ECM homeostasis is a continuous process and is determined by the balance 
between formation and degradation (Brown et al., 2005; Camelliti et al., 2005). While 
the aforementioned formation of ECM is directly related to the transcriptional activity 
of genes encoding for collagens, degradation of collagens requires the expression 
and activity of matrix metalloproteinases (MMPs). MMPs constitute a proteolytic 
enzyme family with more than 20 members capable of digesting ECM proteins (Visse 
& Nagase, 2003). MMP activity is regulated through transcriptional regulation, 
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activation of latent pro-enzymes and by tissue inhibitors of metalloproteinases 
(TIMPs), which are naturally-occurring inhibitors of MMP activity (Nagase & 
Woessner, 1999). MMPs are not exclusively expressed by fibroblasts, but also by 
CM, endothelial and inflammatory cells and in addition to ECM degradation are also 
involved in regulating of cell growth and migration, cell survival/death and 
angiogenesis. 
1.9 Corticosteroids and the heart 
1.9.1 Clinical studies 
1.9.1.1 Corticosteroids and cardiovascular risk 
1.9.1.1.1 Aldosterone and cardiovascular risk 
Besides its classical physiological role and function in regulating salt and fluid 
homeostasis, Aldo has emerged as a cardiovascular risk factor in patients with 
underlying heart disease. The first evidence came from early ACE inhibitor trials such 
as the cooperative north scandinavian enalapril survival (CONSENSUS) study, which 
showed a positive relationship between plasma Aldo levels and mortality in patients 
with CHF (Swedberg et al., 1990), whereas the survival and ventricular enlargement 
(SAVE) study showed that Aldo levels in patients post MI predict development of 
heart failure (Vantrimpont et al., 1998). More recent studies confirmed these initial 
findings and showed that Aldo levels in patients with MI predicted mortality (Beygui et 
al., 2006; Palmer et al., 2008). Similar findings have been observed in patients with 
CHF in which high Aldo levels were associated with increased mortality (Guder et al., 
2007). 
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More recent evidence for a direct, blood pressure independent effect of Aldo on the 
CV system comes from studies in patients with primary hyperaldosteronism 
(described in section 1.6.3). Echocardiographic studies in these patients have 
demonstrated that in comparison to patients with essential hypertension matched for 
blood pressure, cardiac hypertrophy is augmented (Matsumura et al., 2006; Muiesan 
et al., 2008; Rossi et al., 1996) and cardiac texture suggests increased collagen 
deposition (Rossi et al., 2002). In addition, primary hyperaldosteronism patients also 
have a significantly increased risk for MI, stroke and atrial fibrillation in comparison to 
blood pressure matched patients with essential hypertension (odds ratio: 4.2, 6.5 and 
12.1, respectively) (Milliez et al., 2005), again, suggesting a direct detrimental effect 
of Aldo on the CVS. Similar, blood pressure independent effects of Aldo on the heart 
have also been described in patients with essential hypertension in whom Aldo levels 
were positively correlated with left ventricular hypertrophy even after adjusting for 
mean 24 blood pressure (Duprez et al., 1993). Finally, in normotensive subjects 
higher Aldo levels predispose to the development of hypertension in the future 
(Vasan et al., 2004). 
1.9.1.1.2 Glucocorticoids and cardiovascular risk 
Long term treatment of patients with pharmacological doses of glucocorticoids or 
chronic endogenous cortisol excess (Cushing’s syndrome) causes central obesity, 
hypertension, insulin resistance and dyslipidaemia, all of which comprise risk factors 
for cardiovascular disease. As a consequence, mortality due to cardiovascular 
complications (including early atherosclerosis, coronary artery disease, heart failure 
and stroke) is 4 times higher in patients with Cushing’s syndrome than in the normal 
population (matched for sex and age) (Etxabe & Vazquez, 1994) resulting in a 5 year 
all cause mortality of 50% (Plotz et al., 1952). Furthermore, pharmacological 
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glucocorticoid treatment has been shown to be associated with an increased risk of 
heart failure (Souverein et al., 2004) and cardiovascular disease (Wei et al., 2004). 
Cortisol excess in Cushing’s syndrome causes hypertension in more than 90% of 
patients through a number of different mechanisms. In the kidney, excessive cortisol 
levels swamp the enzyme 11β-HSD2 which in turn is no longer able to protect the 
MR from illicit cortisol binding. This results in a glucocorticoid induced form of 
mineralocorticoid hypertension similar to apparent mineralocorticoid excess (AME) 
(described in section 1.7.2.3). In the vasculature, cortisol increases peripheral 
resistance by increasing vascular reactivity to vasconstricting stimuli including Ang II, 
and catecholamines, and by inhibiting mediators of vasodilation including nitric oxide 
and prostacyclin. In the liver, cortisol excess increases synthesis of angiotensinogen 
which results in increased levels of Ang II (Arnaldi et al., 2004). Besides its effects on 
blood pressure, cortisol excess induces adverse metabolic changes including central 
obesity, insulin resistance and dyslipidaemia which are all well established 
cardiovascular risk factors associated with macrovascular morbidity and mortality. 
Clinical studies in patients with Cushing’s syndrome suggest a high prevalence of 
cardiac hypertrophy and impaired cardiac function suggesting direct detrimental 
effects of glucocorticoids on the heart (Baykan et al., 2008; Muiesan et al., 2003). 
Interestingly, high normal cortisol levels have recently also been associated with 
adverse outcome in patients with CHF but otherwise normal HPA function suggesting 
that cortisol levels even when within the normal reference range may constitute a 
novel risk factor in CHF (Guder et al., 2007). 
1.9.1.2 Mineralocorticoid receptor antagonists 
The significance of these observational studies has subsequently been underpinned 
by randomised double blind placebo controlled intervention studies in which low 
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doses of MR receptor antagonists were added to standard treatment regimes in heart 
failure patients. In the randomised aldactone evaluation study (RALES) low doses of 
Spiro showed a substantial (30%) improvement in cardiovascular morbidity and 
mortality in patients with CHF compared with those given placebo (Pitt et al., 1999). 
Similar results were found in the Eplerenone Post-Acute Myocardial Infarction Heart 
Failure Efficacy and Survival Study (EPHESUS). In this study, patients with acute left 
ventricular failure post MI treated with the selective aldosterone antagonist 
eplerenone (EPL) showed a 15% reduction in mortality in comparison to placebo (Pitt 
et al., 2003b). Animal models of extensive MI resulting in acute LV dysfunction 
underpin these results as they show that double RAAS blockade with EPL and an 
ACEi or ARB is more effective than EPL alone in improving remodelling (Fraccarollo 
et al., 2003; Fraccarollo et al., 2005).  
In the 4E (Eplerenone, Enalapril and Eplerenone/Enalapril) study, patients with 
essential hypertension and left ventricular hypertrophy were assigned to treatment 
with enalapril, EPL or a combination of both. Both drugs by themselves proved to be 
equally effective in reducing blood pressure and LVH, whereas the combination of 
both drugs was more effective than EPL alone (Pitt et al., 2003a). Another study 
assessed cardiac function in hypertensive patients with suspected diastolic 
dysfunction and found that addition Spiro treatment resulted in echocardiographic 
improvement in cardiac function in comparison to placebo irrespective of blood 
pressure (Mottram et al., 2004). Surprisingly however, addition of EPL in 
asymptomatic patients with moderate to severe aortic stenosis, did not slow down the 
onset of LV dysfunction, decrease LV mass or reduce progression of valve stenosis 
compared to placebo (Stewart et al., 2008). The lack of clinical benefit of EPL in this 
clinical trial contrasts results from a mouse model of aortic stenosis inflicted by aortic 
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banding in which the administration of EPL slowed down disease progression and 
improved survival (Kuster et al., 2005). 
Treatment with Spiro in patients with CHF has been shown to reduce natriuretic 
peptides, collagen markers and improve vascular function (endothelial function, 
vascular ACE activity) which reflect the favourable effects of Spiro in CHF patients 
(Macdonald et al., 2004; Rousseau et al., 2002). However, the underlying molecular 
mechanisms accounting for the improvements in remodelling and beneficial 
outcomes remain largely unknown. 
1.9.1.3 Aldosterone escape 
Aldo escape or Aldo breakthrough describes a phenomenon in which despite an 
acute fall in Aldo levels in response to administration of an ACEi, Aldo levels 
subsequently start to rise, and in some patients return back to baseline levels. 
Insufficiently suppressed Aldo levels following ACEi treatment have been described 
in different patient cohorts including hypertensive patients with LVH (Sato & Saruta, 
2001), post MI (Borghi et al., 1993) and CHF patients (MacFadyen et al., 1999; 
Swedberg et al., 1990). 
The mechanism by which Aldo levels during ACEi treatment after an initial fall rise 
again despite ongoing treatment is unclear. Although Ang II levels during ACEi 
therapy exhibit a similar course (MacFadyen et al., 1999; Roig et al., 2000), however 
dissociation of Ang II and Aldo has been described (Lee et al., 1999) suggesting an 
Ang II independent mechanism. This is consistent with findings from the Randomised 
Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study in 
which mean Aldo levels after 43 weeks of treatment with maximum doses of enalapril 
and candesartan had returned back to baseline (McKelvie et al., 1999). 
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Given the strong association of Aldo levels with poor outcome in patients with heart 
disease, the phenomenon of Aldo escape may in part explain the beneficial effects 
observed in the RALES and EPHESUS study, where addition of an MR antagonist on 
top of standard ACEi or ARB treatment regime dramatically improved morbidity and 
mortality compared to placebo. 
1.9.2 Animal studies 
Animal studies have been instrumental in elucidating the functional, cellular and 
molecular consequences of corticosteroid hormone action, particularly that of Aldo, 
on the CVS. Insights have been gained from several animal paradigms as well as 
genetically engineered mice. 
1.9.2.1 Experimental studies of corticosteroid hormone action  
One of the first reports on the detrimental effects of Aldo on the CVS came from a 
study by Brilla and Weber (Brilla et al., 1990). In this study an animal paradigm of 
aortic banding, which induces high blood pressure proximal to the site of banding, 
was explored. The key observation from this study was that only suprarenal aortic 
banding lead to activation of the RAAS secondary to renal hypoperfusion and 
resulted in the development of severe cardiac fibrosis whereas infrarenal banding in 
which renal perfusion was not compromised and RAAS not activated, did not. Similar 
changes including high blood pressure levels, cardiac hypertrophy and fibrosis were 
also observed in uninephrectomised animals treated with Aldo and given high salt 
solutions to drink. In these animals Aldo levels are high but Ang II levels are 
suppressed, suggesting that the detrimental fibrotic changes are a direct effect of 
Aldo and not Ang II (Brilla & Weber, 1992). Importantly, the detrimental 
cardiovascular effects elicited in this paradigm critically relied on concomitant high 
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salt intake in addition to treatment with Aldo, as Aldo excess in the presence of a low 
salt diet is insufficient for the development of hypertension, cardiac hypertrophy and 
fibrosis. Moreover, it was noted that cardiac fibrosis in this animal model developed 
similarly in both the right and left ventricle, strongly suggesting that fibrosis was a 
humoral rather than a haemodynamic consequence of Aldo. Several subsequent 
studies have now established that the detrimental cardiac effects of Aldo or that of its 
precursor 11-deoxycorticosterone acetate (DOC) which is also a mineralocorticoid 
but less potent than Aldo, are blood pressure independent. Administration of low 
doses of MR antagonists have been shown to prevent or ameliorate cardiac fibrosis 
without affecting blood pressure (Brilla et al., 1993). Furthermore, infusion of Aldo 
peripherally or centrally (at 1/100 the dose) results in similar increases in blood 
pressure but hypertrophy only develops in animals infused peripherally, suggesting a 
direct blood pressure independent effect (Gomez Sanchez, 1995). Moreover, 
concomitant intracerebroventricular application of the MR antagonist RU28318 in 
animals infused with Aldo blunts increases in blood pressure yet does not affect 
cardiac hypertrophy (Young et al., 1995). Lastly, in Ang II infused rats adrenalectomy 
(Rocha et al., 2000) as well as treatment with low doses of EPL (Rocha et al., 2002a) 
prevents cardiac fibrosis without affecting blood pressure. 
In sharp contrast to the MR which plays a central role in mediating mineralocorticoid 
effects, the GR appears to be inert in the pathophysiology of cardiac inflammation 
and fibrosis in these models as administration of the GR antagonist RU486 does not 
appear to impact on fibrosis (Rickard et al., 2006; Rickard et al., 2007). 
Based on the potent effects of MR antagonist in preventing cardiac inflammation and 
fibrosis in mineralocorticoid/salt excess, MR antagonists have been studied in other 
animal paradigms of heart disease which in general are characterised by 
neurohormonal activation including elevated Aldo levels. In an animal model of aortic 
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stenosis, administration of EPL has been shown to reduce myocardial fibrosis, 
myocyte apoptosis, oxidative stress, macrophage infiltration resulting in improved 
cardiac function and survival (Kuster et al., 2005). Furthermore, in an animal model of 
MI, administration of EPL 10 days post MI has been shown to improve LV 
remodelling (Fraccarollo et al., 2005). Addition of an ACEi substantially potentiated 
this effect by complementary prevention of LV fibrosis and cardiac hypertrophy. The 
optimal time point to start treatment with MR antagonists after MI is not clear, but a 
recent report showed that selective MR blockade immediately after MI accelerated 
macrophage infiltration and transiently increased the expression of healing promoting 
cytokines and factor XIIIa resulting in enhanced neovascularisation and reduced 
early LV dilation and dysfunction (Fraccarollo et al., 2008). 
MR antagonists have recently been shown to elicit similar beneficial effects even 
when Aldo levels are low. Dahl salt sensitive rats when fed a high salt diet develop 
hypertension and cardiac hypertrophy but consistent with this salt excess state the 
RAAS is suppressed. Nevertheless, Nagata and colleagues have shown that 
administration of sub-pressor doses of the MR antagonist EPL reduced oxidative 
stress and vascular inflammation resulting in attenuated hypertrophy and heart failure 
independent of blood pressure (Nagata et al., 2006). Beneficial cardiac effects of MR 
antagonists have also been described in a rat model of chronic renal failure, in which 
administration of sub-pressor doses of EPL attenuated cardiac hypertrophy and 
cardiac oxidative despite absence of increased Aldo levels compared to control 
animals (Michea et al., 2008). 
Collectively, these animal studies show that a) inappropriate Aldo for salt status leads 
to cardiac inflammation and fibrosis independent of blood pressure, b) administration 
of MR antagonists attenuates cardiac sequelae c) cardiac hypertrophy at least 
Chapter 1  General Introduction 
  52 
partially results from direct Aldo actions independent of blood pressure, and lastly d) 
MR antagonists are beneficial even when Aldo levels are not elevated. 
1.9.2.2 Genetically engineered mice 
Further important insights into the pathophysiological role of corticosteroid hormones 
have been gained from studies with genetically engineered mice. Given the pivotal 
role of nuclear steroid hormone receptors in mediating steroid hormone action, global 
MR and GR knock out mice have been created. However, GR null mice die a few 
hours after delivery from respiratory failure due to a lack of lung maturation (Cole et 
al., 1995), whereas global MR null mice die around post natal day 10 from severe salt 
wasting and dehydration (Berger et al., 1998). To date, no results for cardiac specific 
MR or GR knock out mice have been published. 
Nevertheless, the consequences of reduced levels of both receptors have been 
studied in knock down models in which antisense RNA to the respective mRNA of the 
GR or MR is overexpressed in CM leading to formation of double stranded RNA 
which no longer can be translated into protein and subsequently is degraded. The 
results from these studies have been puzzling. MR knock down mice show a 50% 
reduction in cardiac MR mRNA levels and as a consequence surprisingly develop 
severe cardiomegaly, heart failure and cardiac fibrosis at 3 months (Beggah et al., 
2002). In this model, reduced expression levels of the MR could be reverted to 
normal levels by turning off antisense RNA expression, which resulted in complete 
reversal of the phenotype. 
Using a similar model, the same group also studied consequences of CM specific 
overexpression of the MR (Ouvrard-Pascaud et al., 2005). These mice show 
increased mortality as a result of severe ventricular arrhythmias which could be 
prevented by the administration of Spiro. However, no structural abnormalities of the 
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heart were reported in this model. The consequences of CM specific GR 
overexpression have also been addressed (Sainte-Marie et al., 2007). These mice 
exhibit electrocardiogram (ECG) abnormalities including a prolonged PQ interval, 
increased QRS and QTc duration as well as chronic atrio-ventricular block, in the 
absence of any structural cardiac abnormalities such as hypertrophy or fibrosis. 
In addition to these studies focusing on the consequences of altered steroid hormone 
receptor levels, the effects of changes in cardiac steroid hormone levels have been 
addressed by creating transgenic which overexpress enzymes involved in steroid 
synthesis and metabolism in CM. Given that 11β-HSD2 is not expressed, both 
glucocorticoids and mineralocorticoids must be considered as physiological MR 
ligands in the heart. As the concentration of glucocorticoids in the circulation exceeds 
those of Aldo by at least by 100 fold, glucocorticoid binding may protect the MR from 
Aldo through tonic inhibition of the receptor. This theory is supported by an animal 
model in which overexpression of 11β-HSD2 in CM resulted in inactivation of 
corticosterone to its inert compound 11-dehydrocorticosterone. These mice develop 
severe cardiac hypertrophy, CHF and cardiac fibrosis and die prematurely by the age 
of 4-6 months (Qin et al., 2003). Consistent with an MR mediated effect, 
administration of the MR antagonist EPL in this model ameliorated the phenotype. 
Garnier et al assessed the consequences of overexpression of aldosterone synthase, 
the terminal enzyme involved in Aldo synthesis (1.3.2.2) (Garnier et al., 2004). These 
mice merely exhibit coronary dysfunction but otherwise have no alterations in cardiac 
structure or function despite 1.7 fold elevated cardiac Aldo levels compared to WT 
mice. 
The downstream effects of steroid hormone action in the heart are not well 
understood. However, animal models with deletions of genes involved in steroid 
hormone signalling and action have shed light on some of the underlying 
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mechanisms. SgK1 is an important target of Aldo action in epithelial cells of the distal 
nephron in the kidney, and elevated SgK1 levels have been reported in a range of 
inflammatory/fibrotic diseases (Lang et al., 2000; Waerntges et al., 2002). Compared 
to WT mice, DOCA/salt treated SgK1 knock out mice are protected from cardiac 
fibrosis despite similar blood pressure levels (Vallon et al., 2006), suggesting a 
pivotal role for SgK1 in mediating the fibrotic response in this model. One of the 
molecular effects of Aldo action in vitro is induction of reactive oxygen species (ROS) 
by activation of the NADPH dependent oxidase (NOX) (Rude et al., 2005). These 
findings are supported by mice harboring a deletion of the NOX2 gene which 
encodes for a subunit of the multimeric NADPH dependent oxidase complex. 
Compared to WT mice, NOX2 knock out mice treated with Aldo in the presence of 
high salt in the drinking water are protected from cardiac fibrosis (Johar et al., 2006), 
consistent with a pivotal role of ROS in mediating cardiac fibrosis. 
Although some of these animal models show unexpected and unexplained 
phenotypes which might be partly caused by technical issues related to the 
transgene expression, they do provide important insights into the pathophysiological 
function of corticosteroid hormone action in the heart. 
1.9.3 Mechanisms of corticosteroid hormone action in the heart 
The heart consists of four main cell types: cFb, CM, endothelial cells (ECs) and, 
vascular smooth muscle cells (VSMCs) (Figure 1-20). Corticosteroid hormone action 
in the heart is determined by several factors. First of all, action of steroid hormones 
critically relies on the presence of steroid hormone receptors and thus, only cells 
which express these receptors can be considered as steroid target cells. The 
magnitude of steroid effects is directly related to their concentration. With regard to 
steroid hormones that are exclusively produced in endocrine glands, circulating levels 
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are decisive for the effects in peripheral tissues. However, steroids may also be 
synthesised locally in the heart, either de novo from cholesterol or from other pre-
cursor steroids such as DOC. Steroid hormones may also be modulated by steroid 
modifying enzymes within target cells. Through this mechanism, also referred to as 
pre-receptor modulation, steroids may be activated or inactivated within target cells 
prior to exhibiting their effects via their cognate receptors. 
 
Figure 1-20 Schematic illustration of cellular architecture in the heart 
(Weber, 2001). 
1.9.3.1 Steroid hormone receptor expression 
The GR is ubiquitously expressed, and thus, virtually all cells are considered as 
potential glucocorticoid target cells. Presence of the GR in the heart has been 
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detected by various techniques such as binding studies (Turner & Moses, 1986), 
northern blot analysis (Kalinyak et al., 1987) and by Western blotting (Pujols et al., 
2001). The predominant isoform expressed in the human heart is GRα whereas GRβ 
expression levels are much lower (Pujols et al., 2001). In contrast to GRα, GRβ is 
unable to bind glucocorticoids. It functions as a dominant negative isoform of GRα-
induced transactivation of GRE-containing, glucocorticoid-responsive promoters and 
therefore is a natural inhibitor of glucocorticoid actions. 
Expression levels of the GR are regulated by circulating glucocorticoids by negative 
feedback inhibition as adrenalectomy results in up-regulation, and conversely, 
treatment with pharmacological doses of dexamethasone (DEX) causes down-
regulation of the GR in the heart as well as in other tissues (Kalinyak et al., 1987; 
Turner & Moses, 1986). 
In contrast to the GR, expression of the MR is much more restricted. More than 20 
years ago high affinity binding sites for Aldo (so called type I receptors, which are 
now referred to as MR) were described in the heart. (Barnett & Pritchett, 1988; 
Pearce & Funder, 1987). Moreover, expression of the MR in the heart has been 
confirmed in several species by various techniques including Northern blot analysis 
(Arriza et al., 1987), in situ hybridisation (Brown et al., 1996b; Lombes et al., 1995) 
and immunohistochemistry (Lombes et al., 1995; Lombes et al., 1992). From these 
studies, expression of the MR appears to be restricted to CM and ECs whereas 
expression in cFb is undetectable. These findings are underlined by RNAse 
protection assays in isolated cells from neonatal rat hearts, which show expression of 
the MR only in CM but not in cFb (Sheppard & Autelitano, 2002). 
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1.9.3.2 Cardiac steroidogenesis 
Glucocorticoids and mineralocorticoids are synthesised in the cortex of the adrenal 
gland (1.3.2). However, given their effects in modulating cardiovascular disease, a 
number of studies have addressed whether the heart is capable of synthesising 
corticosteroids which may then directly impact on the development and progression 
of cardiac disease. A pre-requisite for de novo synthesis of corticosteroids is the 
presence of steroidogenic enzymes such as P450scc, 3β-HSD, P450c21, P450c11 
and P450c11AS whereas Aldo synthesis from precursor steroids such as  DOC from 
the circulation only requires the presence of aldosterone synthase. 
Slivestre and colleagues assessed steroidogenic enzymes in isolated rat hearts and 
were able to detect both expression and enzymatic activity of P450c11 and 
P450c11AS. Moreover, enzymatic activities in the heart were further induced by 
ACTH and Ang II treatment (Silvestre et al., 1998). In addition, following MI, 
expression of aldosterone synthase was increased in rat hearts whereas expression 
in the adrenal glands remained unchanged, suggesting that locally synthesised Aldo 
might play a modulatory role post MI (Silvestre et al., 1999). These results are 
underlined by a study from Takeda and colleagues who report increased P450c11AS 
expression and activity in spontaneously hypertensive rats (SHRSP) compared to 
Wistar-Kyoto rats, which suggests a role for locally produced Aldo in cardiac 
hypertrophy (Takeda et al., 2000). However, expression levels were found to be 1000 
fold lower compared to the adrenal gland raising the question of the biological 
significance of these findings. A subsequent study has questioned these findings as 
cardiac levels of Aldo following adrenalectomy (ADX) were either undetectable or 
present only at extremely low concentrations suggesting that cardiac Aldo levels only 
reflect those in the circulation (Gomez-Sanchez et al., 2004). Recently, cardiac 
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glucocorticoid production was assessed in two animal models of cardiac hypertrophy. 
In both Dahl salt sensitive (DS) rats on a high salt diet and mice subjected to 
transthoracic aortic banding (TAC) there was increased tissue concentrations of 
corticosterone compared to control animals (Ohtani et al., 2009). Moreover, 
expression levels of P450scc, P450c11 and StAR but not those of P450c11AS were 
found to be significantly up-regulated compared to control animals, suggesting that 
cardiac glucocorticoid synthesis may contribute to the development of cardiac 
hypertrophy. 
Expression of steroidogenic enzymes has also been studied in human heart tissue. In 
both healthy and failing hearts, P450scc, 3β-HSD and P450c21 mRNA have been 
found to be expressed by reverse transcriptase polymerase chain reaction (RT-PCR), 
albeit at very low levels, whereas P450c11 and P450c11AS could not be detected 
suggesting that human hearts are incapable of de novo glucocorticoid and 
mineralocorticoid synthesis (Kayes-Wandover & White, 2000; Young et al., 2001). 
However by contrast, Satoh and colleagues found P450c11AS to be expressed in 
biopsies of patients with CHF (Satoh et al., 2002). Expression levels were higher in 
patients with more severe heart failure defined by an ejection fraction of less than 
30% and were positively correlated with collagen content. In agreement with these 
findings, P450c11AS expression levels were increased in hearts of deceased CHF 
patients compared to patients without cardiovascular disease (Yoshimura et al., 
2002). Cardiac steroidogenic activity has also been assessed in vivo by subtracting 
steroid hormone concentrations in arterial blood from that of the coronary sinus, 
which drains blood from the heart. The difference between these two concentrations 
is thought to reflect locally produced steroids. Using this method, Aldo concentrations 
were found to be increased in patients with systolic and diastolic left ventricular 
dysfunction (Mizuno et al., 2001) as well as in hypertensive patients (Yamamoto et 
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al., 2002) compared to healthy controls suggesting that Aldo is synthesised in the 
heart in patients with heart failure or left ventricular hypertrophy, respectively. 
In conclusion, these studies suggest that the heart expresses some but not all 
steroidogenic enzymes necessary for de novo steroid synthesis, albeit at very low 
levels. In patients with heart failure and hypertension Aldo appears to be produced by 
the heart but it is likely that its synthesis relies on adrenal precursor steroids such as 
DOC. However, the biological significance of these findings in the development and 
progression of heart disease is likely to be minor. 
1.9.3.3 11β-HSD1 and the cardiovascular system 
11β-HSD1 facilitates GR mediated action by converting cortisone (11-dehydro-
corticosterone in rodents) to cortisol (corticosterone in rodents). A few studies have 
addressed expression levels, cellular localisation and activity of 11β-HSD type1 in 
the heart. Compared to liver, where 11β-HSD1 is highly expressed, both enzymatic 
activity and expression levels of 11β-HSD1 were much lower in the heart (Brereton et 
al., 2001; Walker et al., 1991). Moreover, expression of 11β-HSD1 within the heart 
appeard to be restricted to interstitial fibroblasts of the endocardium and isolated cells 
surrounding cardiac vessels and could not be detected in CM (Brereton et al., 2001). 
Consistent with this restricted pattern of expression, enzymatic activity observed in 
cardiac homogenates were found to be low (Walker et al., 1991). However by 
contrast, high levels of 11β-HSD1 oxoreductase activity and expression have been 
reported in isolated CM as well as fibroblasts from neonatal rat hearts (Sheppard & 
Autelitano, 2002). 
Regulation of 11β-HSD1 has been studied in hearts from Dahl salt sensitive (DS) and 
Dahl salt resistant (DR) rats which were either fed a low or high salt diet. Both activity 
and expression levels of 11β-HSD1 were higher in DR compared to DS rats. 
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However, no differences in 11β-HSD1 expression and activity were observed in DS 
on a high compared to low salt diet despite markedly increased blood pressure levels 
and cardiac hypertrophy (Mazancova et al., 2005). 
To date, the biological role of 11β-HSD1 in the heart remains unclear. Mice with a 
deletion of the 11β-HSD1 gene (11β-HSD1-/-) do not seem to exhibit an obvious 
cardiac phenotype at rest (Kotelevtsev et al., 1997). However, in a mouse model of 
MI 11β-HSD1-/- compared to WT mice exhibited increased cardiac angiogenesis and 
improved  cardiac function suggesting that 11β-HSD1 by modulating local 
glucocorticoid levels plays a role in post MI remodelling (McSweeney et al.; Small et 
al., 2005). 
1.9.3.4 11β-HSD2 and the cardiovascular system 
In the kidney, 11β-HSD2 plays a pivotal role in protecting the MR from glucocorticoid 
binding and thereby ensuring Aldo specificity. Hence, there has been great interest in 
the presence and function of 11β-HSD2 in the heart as Aldo has emerged as a CV 
risk factor and pharmacological blockade of the MR in heart failure patients has been 
shown to greatly reduce mortality. 
At the time 11β-HSD2 was cloned, no expression was reported in human heart tissue 
(Albiston et al., 1994; Funder et al., 1988). However, in subsequent studies an NAD+ 
dependent enzyme with a high affinity for corticosterone was detected in heart tissue 
from human transplant donors, suggesting presence of 11β-HSD2 which was 
confirmed by RT-PCR analysis (Slight et al., 1996). In contrast, in rat hearts, NAD+ 
dependent enzymatic activity was absent (Walker et al., 1992) and, using in situ 
hybridisation, expression could not be detected (Roland & Funder, 1996). During 
early embryological development, high expression levels of 11β-HSD2 have been 
detected in the murine heart by in situ hybridisation (Brown et al., 1996b). However, 
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beyond embryonic day 13, 11β-HSD2 expression ceases and is not detectable in 
adult life. The phenotype of mice with deletion of the 11β-HSD2 gene (11β-HSD2-/-) 
resembles that of humans with inactivating mutations in HSD11B2 (Kotelevtsev et al., 
1999). 11β-HSD2-/- mice develop high blood pressure and exhibit an increased heart 
/ body weight ratio which develops as a consequence of hypertension but otherwise 
no cardiac abnormalities have been reported. 
In conclusion, expression of 11β-HSD2 in the heart remains controversial. If 
detectable, levels of 11β-HSD2 appear to be extremely low, and thus, its biological 
relevance in the heart is more than questionable. Therefore, unlike classical Aldo 
target cells, the MR in the heart is considered not to be protected by 11β-HSD2 and 
therefore is a target for both glucocorticoids and mineralocorticoids. 
1.9.3.5 Molecular mechanisms of steroid hormone action in the heart 
1.9.3.5.1 Corticosteroid effects on cardiac fibroblasts 
Given that Aldo excess results in severe interstitial and perivascular fibrosis while MR 
blockade protects the heart from these fibrotic changes, cFb were believed to be the 
primary target of Aldo action. Initial studies showed that Aldo and Ang II were indeed 
capable of inducing collagen production in isolated rat cFb in vitro, determined by 3H-
proline incorporation (Brilla et al., 1994). These effects could be blocked by co-
incubation with the MR antagonist Spiro and the AT2-receptor antagonist PD12377, 
respectively. A subsequent report by the same group confirmed these results and, in 
addition, showed that Aldo and Ang II were capable of inducing expression of type I 
collagen mRNA expression (Zhou et al., 1996). However, in contrast, a different 
group employing the same technique was unable to detect a direct effect of Aldo on 
collagen production in isolated neonatal and adult cFb from various rat strains 
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(Sprague-Dawley, WKY, SHR), suggesting that Aldo does not directly affect collagen 
production in cFb (Fullerton & Funder, 1994). 
Stockand and Meszaros found that near-physiological concentrations of Aldo (10 
nmol/l) promote proliferation of cFb via activation of the k-Ras and MAPK 1/2 
signalling pathways. These effects could be blocked by Spiro but not the GR 
antagonist RU486, confirming that Aldo was acting through the MR (Stockand & 
Meszaros, 2003). Although these studies suggest that Aldo has direct effects on cFb, 
the significance of these findings in vivo, particularly with regard to the direct 
induction of collagen synthesis by Aldo, remains unclear. 
1.9.3.5.2 Direct effects of aldosterone on cardiomyocytes 
In order to better understand mechanisms of Aldo action in the heart, a number of 
studies have addressed direct effects of Aldo on cell viability, hypertrophy and gene 
expression in isolated CM in vitro.  
Administration of Aldo to rats resulted in increased apoptosis of cardiomyocoytes and 
skeletal myocytes after 48h in vivo (Burniston et al., 2005). Both CM and skeletal 
myocyte apoptosis in this model could largely be prevented by prior application of the 
MR antagonist Spiro, confirming that apoptosis following Aldo administration was an 
MR mediated effect. Subsequent in vitro studies in isolated neonatal rat 
cardiomyocytes (nrCM) by Mano and colleagues confirmed these findings. Treatment 
with high doses of Aldo (1-10 µM) resulted in a rapid calcium influx in nrCM via an 
Aldo membrane receptor which accelerates the mitochondrial apoptotic pathway 
through calcineurin activation and dephosphorylation of the pro-apoptotic factor Bad 
(Mano et al., 2004). 
The increased mortality in patients with CHF is in part due to an increased incidence 
of ventricular arrhythmias and treatment of CHF patients with Spiro drastically 
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reduced arrhythmic events suggesting that MR signalling contributes to 
arrythmogenicity (Pitt et al., 1999). A number of electrophysiological studies have 
investigated Aldo effects on myocyte ionic homeostasis. Aldo has been shown to 
increase L-type Ca2+ current and decrease transient outward K+ current (Ito) in rat 
CM (Benitah et al., 2001; Benitah & Vassort, 1999). Moreover, Aldo increases the 
fast Na+ current in adult mouse ventricular myocytes (Boixel et al., 2006) and has 
been shown to induce expression of the Na+/K+-ATPase in nrCM (Ikeda et al., 1991). 
Lalevee and colleagues reported that Aldo increases the beating frequency of nrCM 
by enhanced T-type and L-type Ca2+ currents following stimulation of gene 
expression (Lalevee et al., 2005). Increased spontaneous beating in response to 
Aldo was also reported in nrCM which was found to be mediated by increased If 
currents resulting from increased expression of the If channels HCN2 and HCN4 
(Muto et al., 2007). These electrophysiological studies demonstrate that Aldo exhibits 
complex electrophysiological effects on Na+, K+ and Ca2+ currents in CM which are 
likely to be involved in the increased risk of ventricular arrhythmias in patients with 
CHF and cardiac hypertrophy. 
Clinical studies also suggest that Aldo is directly involved in cardiac hypertrophy 
independent of blood pressure levels (Rossi et al., 1996). In vitro studies have 
underpinned these findings, as Aldo treatment augmented protein incorporation and 
increased myocyte surface in nrCM which are surrogate markers of CM hypertrophy 
(Okoshi et al., 2004). Aldo treatment has also been shown to lead to cell enlargement 
of murine atrial HL-1 cells via induction of corticotrophin-1 (CT-1) as this effect could 
be blocked by co-administration of antibodies against CT-1 or its receptors (Lopez-
Andres et al., 2008). CT-1 induction in this study could be blunted by both MR and 
GR antagonists suggesting that both receptors are involved in CT-1 up-regulation by 
Aldo. In vivo studies underpin these findings as only WT but not CT-1 knock out mice 
Chapter 1  General Introduction 
  64 
exhibited increased expression of cardiac markers of hypertrophy in response to 
Aldo. (Lopez-Andres et al., 2008). 
Besides its apoptotic and hypertrophic effects, Aldo has been shown to directly 
regulate gene expression in CM. In the circulation Ang I is converted to Ang II by 
ACE. However, the ACE gene is also expressed in the heart where it is believed to 
facilitate local Ang II production. In failing human hearts ACE expression is 
increased, suggesting a contributory role in cardiac remodelling and progression of 
heart failure (Studer et al., 1994). In vitro studies show that Aldo by acting through 
the MR directly induces ACE expression in nrCM and by this mechanism may 
contribute to cardiac Ang II production (Harada et al., 2001). More recently, an ACE 
isoenzyme (ACE2) has been identified which converts Ang I to a shorter fragment 
which is biologically inactive. In nrCM Aldo represses expression levels of the ACE2 
gene through an MR dependant mechanism and thereby further facilitates local Ang 
II production by inhibiting Ang I inactivation (Yamamuro et al., 2008). In summary, 
Aldo appears to regulate cardiac Ang II production by simultaneous up-regulation of 
the ACE1 and down-regulation of the ACE2 gene. 
Cardiac remodelling is characterised by an inflammatory reaction and increased 
myocardial expression of pro-inflammatory markers including osteopontin (OPN), 
cyclooxygenase-2 (COX-2), plasminogen activator inhibitor (PAI-1), interleukin-6 (Il-
6) and macrophage chemo attractant protein-2 (MCP-1) (Rocha et al., 2002b). Aldo 
plays an important role in inducing and mediating these inflammatory responses 
suggesting that Aldo may directly regulated these genes (Rocha et al., 2002a; Rocha 
et al., 2002b). Following MI cardiac expression levels of the pro-inflammatory 
markers COX-2 and Il-6 are increased. Administration of the MR antagonist RU28318 
completely prevents COX-2 induction and partially blocks that of Il-6 suggesting that 
Aldo via  MR is implicated in the regulation of these genes. In vitro studies have 
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confirmed that Aldo is capable of inducing COX-2 and Il-6 expression in nrCM but not 
in cFb  (Rebsamen et al., 2004). 
Connective tissue growth factor (CTGF) promotes fibrosis by inducing collagen type I 
and fibronectin expression. CTGF expression is up-regulated in ischaemic hearts in 
CM and mesenchymal cells adjacent to the infarct zone suggesting that CTGF might 
be regulated by Aldo. Indeed, subsequent in vitro studies show that Aldo induces 
CTGF expression via the p38 MAPK pathway in embryonic ventricular CM (Lee et al., 
2004). Interleukin-18 (Il-18) is another pro-inflammatory cytokine that belongs to the 
Il-1 family. It plays a critical role in myocardial inflammation and CM hypertrophy and 
is up-regulated on a transcriptional level by Aldo in nrCM (Doi et al., 2008). However, 
this effect appears to be indirect as it is dependent on endothelin-1 and Ang II. 
In addition to these transcriptional effects, Aldo also exhibits posttranslational effects 
on CM independent of transcription. In one report Aldo diminished nitric oxide 
production by directly inhibiting inducible nitric oxide synthase (iNOS) activity (Chun 
et al., 2003) whereas another study reported activation of MMP-2 and MMP-9 by 
Aldo which was mediated via production of NADPH-oxidase dependent reactive 
oxygen species (Rude et al., 2005). 
Collectively, these studies provide important mechanistic insights into the role of Aldo 
as a regulator of genes involved in cardiac remodelling and fibrosis. However, the 
pathophysiological relevance of these studies is hampered by two facts. Firstly, 
significant effects of Aldo in these studies are by and large only observed at 
supraphysiological Aldo concentrations, equal to or greater than 10nM. Secondly, 
given that the MR has equal affinities for glucocorticoids and Aldo and that in the 
absence of 11β-HSD2 both steroids must be considered as MR ligands, the 
specificity for Aldo in mediating these effects is questionable as glucocorticoids 
through the MR or possibly even the GR may exhibit similar effects on the 
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transcriptional regulation of these genes. For this reason, identification of genes that 
are regulated exclusively by Aldo but not glucocorticoids might be key for our 
understanding of Aldo pathophysiology. 
1.10 Hypothesis and aims 
1.10.1 Characterisation of steroid hormone action in the heart 
It is now clear that Aldo and glucocorticoids have detrimental effects on the CVS 
(described in detail in section 1.9). However, so far it has not been clarified which cell 
type in the heart constitutes the primary target of steroid hormone action. So far, 
expression levels of key components involved in corticosteroid hormone signalling 
including the GR, MR, 11β-HSD1 and 2 have only been studied in nrCM. 
In chapter 3 we will characterise expression of key components involved in steroid 
hormone signalling in primary cultures of adult rat CM and cFb in an attempt to better 
understand corticosteroid hormone action in the adult heart. Furthermore, we will 
investigate glucocorticoid hormone modulation by 11β-HSDs and the effects on gene 
regulation in primary cultures of rat CM and cFb. 
1.10.2 Differential gene regulation by corticosteroids in cardiomyocytes 
There is a large body of evidence from animal and clinical studies suggesting that 
Aldo has detrimental effects on the CVS and that blockade of the MR is 
cardioprotective. However, on a molecular basis this phenomenon remains less well 
defined. The MR has equal affinities for corticosterone and Aldo. In the kidney 
specificity for Aldo is achieved by the enzyme 11β-HSD2 which inactivates 
corticosterone to 11-dehydrocorticosterone which is no longer able to bind and 
activate the MR. In non-epithelial cells such as CM, 11β-HSD2 does not seem to be 
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expressed leaving the MR accessible for both gluco- and mineralocorticoids which 
raises the question of ligand specific effects. 
In chapter 4 we will therefore aim to identify genes differentially regulated by 
corticosteroid hormones in CM employing microarray technology. We hypothesise 
that the adrenal steroids Aldo and corticosterone induce a differential transcriptome 
via their cognate steroid hormone receptors. These differentially regulated genes 
may give important mechanistic insights in our understanding of the detrimental 
effects of Aldo on the CVS in the absence of 11β-HSD2. 
1.10.3 Steroid hormones in essential hypertension 
Blood pressure is influenced by steroid hormones. This is exemplified in conditions of 
glucocorticoid and mineralocorticoid excess such as Cushing’s syndrome and 
primary hyperaldosteronism, respectively, which invariably result in high blood 
pressure. However, the role of steroids on blood pressure in the absence of overt 
excess states is less clear. Some but not all studies have suggested that 
polymorphisms in the HSD11B2 gene encoding for 11β-HSD 2 and the CYP11B2 
gene encoding for aldosterone synthase are associated with hypertension. 
In chapter 5 we set out to characterise corticosteroid hormone secretion and 
metabolism in essential hypertension employing urinary steroid hormone metabolite 
analysis by gas chromatography / mass spectrometry. 
1.10.4 Effects of spironolactone on corticosteroid hormone secretion 
and metabolism in chronic kidney disease 
MR antagonists such as Spiro and EPL are now widely used in patients with primary 
hyperaldosteronism, resistant hypertension and heart failure. By reducing blood 
pressure and improving cardiac remodelling, respectively, the aim is to lower 
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cardiovascular morbidity and mortality. It is unknown if MR inhibition may also alter 
corticosteroid hormone secretion and metabolism which may further contribute to the 
protective effects of MR antagonists. We hypothesise two different mechanisms by 
which Spiro may impact on glucocorticoid hormone secretion. Firstly, that MR in the 
central nervous system are involved in the regulation of HPA drive and secondly that 
there is direct inhibition of the 11β-hydroxylase enzyme by Spiro or one of its 
metabolites. 
In chapter 6 we will characterise the effects of Spiro on steroid hormone secretion 
and metabolism in patients with mild to moderate chronic kidney disease. We 
hypothesise that MR blockade results in altered steroid hormone secretion and 
metabolism. 
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2.1 In vitro techniques 
Unless otherwise stated, reagents were purchased from Sigma (Sigma, UK). The 
following reagents were purchased from VWR: NaCl, KCl, MgSO4, NaHCO3, CaCl2, 
Pyruvate, D-Glucose, KH2PO4, H20 (VWR International, Pool, UK)). Cell culture 
plastic ware was purchased from Corning (Artington, Surrey, UK). 
2.1.1 Cell culture 
2.1.1.1 Isolation of rat cardiomyocytes and cardiac fibroblasts 
2.1.1.1.1 Principle 
CM are firmly connected to one other by intercalated discs consisting of tight 
junctions and gap junctions and so are difficult to cleave without damaging the cells. 
In order to obtain and isolate intact rod-shaped CM, freshly isolated hearts need to 
be applied to a Langendorff apparatus by cannulation of the ascending aorta (Figure 
2-1). This then allows retrograde perfusion of the heart through the coronary arteries. 
In order to keep the heart at a physiological temperature during the isolation 
procedure, the cannulated heart is placed into the inner chamber of an organ bath 
which is perfused through an outer chamber with water at 37ºC. First the heart is 
perfused via the aortic cannula with a solution with a low concentration of calcium 
ions. Subsequently the low calcium solution is switched to solution containing 
collagenase to digest and break up the ECM freeing individual cells. Following 
digestion, CM can be separated from all other cardiac cell types including fibroblasts 
and endothelial cells by gravity centrifugation. CFb are then separated from 
endothelial cells by making use of their ability to quickly adhere to non-coated culture 
dishes within a few hours whereas endothelial cells remain in the supernatant. 
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Figure 2-1 Photograph of a cannulated heart in a Langendorff 
apparatus (http://www.fmigmbh.de). 
2.1.1.1.2 Methods 
CM from adult rats were isolated by digestion of intact perfused ventricle as 
previously described (Lewis et al., 2004). Male Sprague–Dawley (300-340 g) rats 
were killed by cervical dislocation and the heart was rapidly excised and placed into 
an ice-cold low calcium solution (CaCl2 10µM, NaCl 120mM, KCl 5.4mM, MgSO4 
5mM, pyruvate 5mM, glucose 20mM, taurine 20mM, HEPES 10mM, nitrilotriacetic 
acid (NTA)). The aorta was cannulated and the heart was retrogradely perfused for 8 
minutes with low calcium solution using a Langendorff apparatus at a constant flow of 
5ml/min. Thereafter the heart was perfused for 20 minutes with enzyme solution 
(CaCl2 200µM, NaCl 120mM, KCl 5.4mM, MgSO4 5mM, pyruvate 5mM, glucose 
20mM, taurine 20mM, HEPES 10mM, pH 7.4) supplemented with, collagenase 
(1mg/ml) (Worthington, Lakewood, USA) and hyaluronidase (0.6mg/ml) (Sigma, 
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York, UK) equilibrated with 100% O2. Following perfusion, the atria were separated 
from the ventricles and the pre-digested heart was chopped into small pieces which 
were incubated for another 30 minutes at 37°C in a shaking water bath. Single CM 
and cFb were separated from undigested tissue by filtering the cell suspension 
through a gauze of mesh (300µm) (Cadisch, London, UK). CM were pelleted for 3 
min at 400xg and the supernatant containing cFb and endothelial cells was 
transferred to a 50ml Falcon tube. The CM pellet was resuspended in 50ml enzyme 
solution (without any enzymes added) and allowed to settle by gravity for 15 minutes. 
CM were then washed twice with media M199 (Invitrogen Ltd, Paisley, UK) and the 
supernatant containing cFb was transferred to 50ml Falcon tubes. 
2.1.1.1.3 Culturing of primary cardiomyocytes 
CM were resuspended in CM culture media and viability and purity of CM was 
assessed by light microsopy. Healthy and viable CM have a rod shape appearance 
and spontaneously contract in culture (Figure 2-2). During preparation and isolation 
of CM a proportion of CM die as a result of membrane disruption through mechanical 
force or from calcium influx through gap junctions. Non viable cells have a round 
shape appearance and following staining with trypan blue take up dye and stain blue 
(described in section 2.1.2). The percentage of dead cells varied from preparation to 
preparation from 10% to 40% (Figure 2-3). CM were counted in a haemocytometer 
and approximately 200,000 rod shaped CM were incubated in CM culture media 
(M199 media (Invitrogen, UK), 1% penicillin/streptomycin, 0.1mM ascorbic acid, 5mM 
creatine monohydrate, 2mM carnitine, 5mM taurine) in the presence of 10% fetal calf 
serum (FCS) for 1h to allow CM to attach and adhere to the culture plate. Non-
adherent CM were aspirated and the adherent CM were washed once with M199 
media and subsequently incubated in CM culture media. 
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Figure 2-2 Isolated and purified rat cardiomyocytes in culture. 
 
Figure 2-3 Trypan blue staining of isolated cardiomyocytes in 
culture. Dead cells have a round shape appearance from spontaneous 
contracture resulting from calcium influx and take up trypan blue stain. 
2.1.1.1.4 Culturing of cardiac fibroblasts 
Falcon tubes containing cFb in suspension were centrifuged for 10min at 250 x g. 
The cell pellet was resuspended in cardiac fibroblast media (DMEM (PAA, UK), 
containing 10% FCS and 1% penicillin/streptomycin) and incubated in a 75cm2 
culture flask for 2h to let cFb adhere to the flask. Non attached cells were removed 
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and cFb were washed three times with cFb culture media. After 3-4 days cFb had 
grown to approximately 80% confluence and were used for further experiments. 
 
Figure 2-4 Isolated cardiac fibroblasts (cFb) in culture. 
2.1.2 Trypan blue staining 
2.1.2.1 Principle 
Trypan blue is a diazo dye and used to selectively colour dead cells blue. Viable cells 
with intact cell membranes are not coloured, whereas in a viable cell trypan blue is 
not absorbed and cells are excluded from staining. 
2.1.2.2 Method 
100 µl Trypan blue 0.4% is added and gently mixed with 100 µl cell suspension and 
incubated at room temperature for 5 minutes. Subsequently, the percentage of dead 
cells is determined by counting of stained (dead) and unstained (viable) cells using a 
hemocytometer. 
100µm
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2.1.3 Proliferation assay 
2.1.3.1 Principle 
The effect of cytokines, hormones and drugs on cellular proliferation can be 
assessed by measuring the incorporation of 3H-thymidine into newly synthesised 
DNA. The amount of radioactivity as measured by liquid scintillation counting as a 
marker of DNA synthesis and reflects cellular proliferation. 
2.1.3.2 Method 
Primary cFb were split and seeded at a density of 12,500 cells per well in 6 well 
plates in the presence of culture media (DMEM supplemented with 10% FCS and 
Penicillin/Streptomycin (1x)). The following day, cells were treated with steroids and 
incubated for 24h. Subsequently, 10µl 3H-thymidine (1:50) (Perkin Elmer, Bucks, UK) 
was added to the cell culture media and cells were incubated for 4h. Media was 
removed and cells were washed with PBS and ice cold 5% trichloroacetic acid was 
added for 30 min to precipitate DNA. Subsequently, trichloroacetic acid was 
removed, cells washed with PBS and detached from the culture dish by adding 300µl 
100mM NaOH. Cells were scraped off the culture dish using a rubber policeman and 
100µl cell suspension was added to scintillation vials containing 5ml of scintillation 
fluid. Radioactivity was measured on a liquid scintillation counter (Model 2500 TR, 
Packard Instruments) for 5 minutes per sample. 
2.1.4 RNA extraction using TriReagent 
2.1.4.1 Principle 
For isolation of total RNA from cultured primary rat CM and from human left 
ventricular biopsies, Tri Reagent® (Ambion, Huntingdon, UK) was used. The 
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principle of this extraction is based in the one-step acid guanidinium method first 
described by Chomczynski and Sacchi (1987) (Chomczynski & Sacchi, 1987). 
2.1.4.2 Method 
Total RNA was extracted from heart biopsies and monolayer cells using TriReagent. 
For monolayer cells, 1ml of TriReagent was added to cells and the cell lysate was 
transferred to an Eppendorf tube. Heart biopsies were homogenised in 1ml 
TriReagent in round bottom silicate tubes using a homogeniser and minced tissue 
was transferred to an Eppendorf tube.  
Per 1ml of TriReagent® containing the cell/tissue lysate 0.2ml of Chloroform was 
added, mixed and incubated at RT for 15 min. The solution was then centrifuged at 
12,000xg for 15 min at 4ºC to separate the RNA containing aqueous phase from the 
protein containing organic phase. The aqueous phase was carefully transferred to a 
new Eppendorf tube and 0.5 ml of isopropanol was added to precipitate the RNA. For 
small amounts of RNA, 1µl GlycoBlue® (Ambion, Huntingdon, UK) was added for 
RNA precipitation and to stain the RNA pellet with a blue color which is easily visible. 
The RNA was precipitated by centrifugation at 12,000xg for 15 min at 4ºC. 
Subsequently, the supernatant was aspirated, the pellet washed with 75% ethanol 
and centrifuged for at 8,000xg for 5 min at 4ºC. The supernatant was removed and 
the pellet air dried for 5 min and subsequently resuspended in an appropriate volume 
of nuclease free water and stored at -80ºC. 
The concentration and purity of the extracted RNA was checked by a Nanodrop (ND-
1000) spectrophotometer (Thermo Scientific, Cheshire, UK). Protein contamination of 
RNA was assessed by the OD260/280 with a ratio of 1.85-2.1 indicating minimal 
contamination. RNA concentration was quantified by OD260 with one unit being 
equivalent to 40µg of RNA. The integrity of the RNA was checked on 1% agarose gel 
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containing 0.05 µl/ml ethidium bromide and visualised under ultra violet light. Intact, 
non degraded RNA exhibits a clear 28s and 18s rRNA bands of which the 28s band 
is about twice as intense as the 18s band. 
2.1.5 RNA extraction using RNeasy® spin columns 
2.1.5.1 Principle 
For microarray studies (Chapter 2.1.13) RNA was extracted using the Qiagen 
RNeasy mini kit (Qiagen, West Sussex, UK) according to the manufacturer’s 
protocol. This method is based on an affinity column which contains a matrix that 
selectively binds RNA yielding pure RNA free of genomic DNA. 
2.1.5.2 Method 
CM were homogenised in 350µl RLT buffer (provided by Qiagen) by gentle pipetting 
and transferred to an Eppendorf tube. After addition of 350µl 70% ethanol 
homogenates were transferred to a Qiagen RNA column and centrifuged for 30 
seconds at 13,000 rpm in order to bind the RNA to the matrix of the column. The 
RNA was then washed twice with 500µl RPE buffer (provided by Qiagen) and eluted 
with 15µl ddH20 by centrifugation at 13,000 rpm for 1min. 
2.1.6 Reverse transcription and polymerase chain reaction 
2.1.6.1 Principles 
2.1.6.1.1 RT-PCR 
Reverse transcription (RT) is a technique by which RNA is converted into single 
stranded complementary DNA (cDNA). After extraction, total RNA is incubated with 
random hexamers, deoxy-nucleotides, reverse transcriptase in the presence of 
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RNAse inhibitor for cDNA synthesis. Following the RT reaction, single stranded DNA 
can be used for amplification by means of polymerase chain reaction. 
2.1.6.1.2 Polymerase chain reaction 
Polymerase chain reaction (PCR) is a technique which allows amplification of DNA 
by using oligonucleotides which are complementary to the 5’ and 3’ ends of the DNA 
region to be amplified. After annealing of the oligonucleotides to the corresponding 
DNA strand, they are extended by Taq polymerase which elongates the new DNA 
strand by incorporation of nucleotides. The newly synthesised DNA strands then 
serve as templates for subsequent cycles resulting in exponential DNA amplification 
until production plateaus due to limitation of nucleotides and/or polymerase. 
2.1.6.1.3 Agarose gel electrophoresis 
Agarose gel electrophoresis separates a mixed population of DNA and RNA 
fragments by length. Nucleic acid molecules are separated by applying an electric 
field to move the negatively charged molecules through an agarose matrix. As 
shorter molecules migrate more easily through the pores of the gel they move faster 
and migrate farther than longer molecules. Size was assessed using ladders 
consisting of nucleic acid standards of defined sizes. 
2.1.6.2 Methods 
2.1.6.2.1 Reverse transcription polymerase chain reaction 
For reverse transcription polymerase chain reaction (RT-PCR) a high capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, Warrington, UK) was used according 
to the manufacturer’s manual.  
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Up to 1 µg of total RNA was used in a 20µl reaction: reaction buffer (1x), dNTP (1x), 
random primers (1x), RT buffer (1x), RNAse inhibitor (1x) and MuLV reverse 
transcriptase (1x). In a thermal cycler, samples were incubated at 26º for 10min, 37º 
for 2h followed by a 5 min incubation at 95º to inactivate the reverse transcriptase. 
cDNA was then diluted to a final concentration of 1.25-5 ng cDNA / µl using nuclease 
free water. cDNA was stored at -20ºC until further use. Efficiency of the RT reaction 
was assessed by amplification of the housekeeping gene 18s. 
2.1.6.2.2 PCR 
PCR was carried out in 20 µl reactions containing the following components (final 
concentration 1x): reaction buffer (1x), MgCl2 2mM, dNTPs (200 µM), Taq 
polymerase (0.05 U/µl) (Bioline, London, UK), forward and reverse primer (0.4 µM) 
and 5-10ng of cDNA. Samples were incubated in a thermal cycler with an initial DNA 
denaturing step of 95ºC for 5 min followed by 32-34 cycles of 95ºC (30 sec), 60ºC 
(30sec), 72ºC (1min) and for final extension samples were incubated at 72ºC for 7 
min. 
2.1.6.2.3 Agarose gel electrophoresis 
PCR products were analysed by agarose gel electrophoresis. 5µl of the PCR reaction 
was mixed with 1µl of loading dye (Bioline, London, UK), loaded onto a 2% agarose 
gel containing 0.05µl of ethidium bromide and electrophoresed at 100V in Tris borate 
EDTA buffer (TBE) buffer (89mM Tris, 89mM boric acid, 2mM EDTA) for 20 minutes. 
DNA was visualised under ultra violet light. Size of PCR products was assessed 
using HyperLadder IV (Bioline, London, UK). 
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2.1.7 Relative quantitative (real-time) polymerase chain reaction 
2.1.7.1 Principle 
Quantitative real-time PCR (qPCR) is a technique based on the polymerase chain 
reaction, which enables quantification of the amplified DNA product in real time. The 
set up of the reaction is similar to conventional PCR, but is carried out in a real-time 
thermal cycler that allows measurement of fluorescence of the samples. Similar to 
conventional PCR a 5’ and 3’ oligonucleotide primers flanking the DNA region that is 
to be amplified are used but in addition, in TaqMan real-time PCR a probe is added 
to the reaction which consists of a single-stranded oligonucleotide complementary to 
a segment of 20-60 nucleotides within the DNA template located between the two 
primers and contains a fluorescent reporter (fluorophore) and a quencher (Figure 
2-5). The proximity of the quencher dye inhibits the fluorescence emitted by the 
reporter through fluorescence resonance energy transfer (FRET). During 
polymerisation, the probe gets degraded by the 5’ exonuclease activity of the 
polymerase and the fluorophore gets released and breaks the close proximity to the 
quencher, allowing fluorescence of the fluorophore. Therefore fluorescence detected 
in the real-time PCR thermal cycler is directly proportional to the fluorophore released 
and the amount of DNA template present in the PCR. The exponential increase of the 
fluorescent signal is used to determine the threshold cycle (CT) which refers to the 
PCR cycle number at which a significant exponential increase in fluorescence is 
detected, and which is directly correlated with the number of copies of DNA template 
present in the reaction. The higher the copy number of the target DNA in the sample 
the lower the cycle at which fluorescence is detected and, hence, the lower the Ct 
value. In order to determine relative expression levels, the Ct values of the target 
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gene is subtracted from the Ct value of a housekeeping gene (ie the 18s ribosomal 
RNA subunit) of which expression levels are constant. 
 
Figure 2-5 Schematic depiction of the TaqMan real time PCR 
principle. R: reporter; Q: quencher. 
2.1.7.2 Methods 
Quantitative PCR (qPCR) was carried out employing reagents and expression 
assays from Applied Biosystems (Applied Biosystems, Qarrington, UK). Reactions for 
genes of interest and the housekeeping gene 18s were always carried out in 
duplicated and either as singleplex (i.e. separate reactions for gene of interest and 
18s) or multiplex (i.e. amplification of gene of interest and 18s in the same reaction) 
reactions. The fluorophore for probes of genes of interest was TAMRA whereas 18s 
probes were labeled with VIC (a pre-requisite for multiplexing). For multiplexing 
reactions, independent amplification of the housekeeping gene 18s and the gene of 
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interest was ensured through a dilution series to rule out amplification and/or 
detection interference of the two probes. The total reaction volume was 10µl 
consisting of 5µl (2x) master mix, 4µl (1.25-5ng) of cDNA and for amplification and 
detection of target genes 0.5 µl (20x) expression assay (containing primers and 
probes) or for amplification of the housekeeping gene 18s 0.3 µl of 18s expression 
assay and water. For multiplexing reactions both primers and probes of genes of 
interest and 18s were added to the same reaction. Amplification and detection was 
carried out on an ABI 7500 real time PCR machine. ∆Ct values were calculated by 
subtracting Ct values for 18s from Ct values for the gene of interest. Data were 
expressed as arbitrary units which were calculated from ∆Ct values employing the 
formula: expression = 1000 *2-∆Ct.  
2.1.8 In-house production of 3H-11-dehydrocorticosterone 
In contrast to tritiated corticosterone (B), 11-dehydrocorticosterone (A) is not 
commercially available. Therefore a protocol was developed to convert 3H-B into 3H-
A. 20µl of 3H-B (Perkin Elmer, Bucks, UK) was converted into 3H-A in the presence of 
250 µl of homogenised human placenta, NAD+ (500µM) in a total volume of 500 µl of 
0.1 M phosphate buffer, pH 7.4. The mixture was incubated for 3h in a shaking water 
bath at 37ºC. Steroids were extracted by adding 7ml of dichloromethane and 
vigorous shaking and vortexing for 1 min. The organic phase containing the steroids 
was separated from the aqueous phase by centrifugation at 80xg for 15 min. 
Subsequently the top aqueous phase was aspirated and the organic phase was 
evaporated at 55ºC und constant air flow using a sample concentrator (Techne, UK). 
Steroids were then resuspended in 100µl of dichloromethane and spotted on a silica 
plate (Fluka, Sigma-Aldrich, UK) and separated using a thin layer chromatography 
(TLC) chamber with chloroform:ethanol (92:8) as a mobile phase for 2 h. Dried silica 
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plates were scanned using an imaging scanner (Bioscan 200, Lablogic, Sheffield, 
UK) to localise tritiated steroids. Following detection of tritiated A, the corresponding 
spot of the silica plate was cut out, silica was scraped off into a glass tube and the 
3H-A was eluted overnight in 500µl ethanol. The next day the silica ethanol 
suspension was centrifuged for 15 min at 100xg and the ethanol was transferred to a 
new glass tube. Purity and activity of the extracted 3H-A was assessed by running 
one microliter on a TLC plate as described above. 3H-A was considered pure and 
suitable for further experiments if a single peak was detected representing the 3H-A 
with an activity of 1000 counts per minute. In case the activity was lower, the 3H-A 
stock was concentrated until the desired activity was achieved. The 3H-A was stored 
-20ºC until use. 
2.1.9 11β-hydroxysteroid dehydrogenase enzyme assays 
2.1.9.1 Principle 
The activity of the 11β hydroxysteroid dehydrogenase (11β-HSD) enzyme was 
analysed by measuring the interconversion of corticosterone and 11-
dehydrocorticosterone. A known concentration of substrate (A for oxoreductase 
activity (conversion of A to B), B for the dehydrogenase activity (conversion of B to 
A)) and a trace amount of radioactively labeled steroid was added to either isolated 
cells or tissue and the reaction mixture was incubated at 37 ºC for a previously 
optimised period. Steroids were then extracted with organic solvent and steroids 
separated by TLC (Figure 2-6). Fractional conversion was calculated as pmols of 
product per mg protein (for cells grown in a monolayer), 1 Mio cells (CM grown in 
suspension) or g wet tissue (for explanted heart tissue). 
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Figure 2-6 Typical Bioscan trace reflecting tritiated steroids 
separated by thin layer chromatography. Peaks show corticosterone 
and 11-dehydrocorticosterone. 
2.1.9.2 Solutions 
Stock solutions of corticosterone and 11-dehydrocorticosterone were prepared as 
follows: 3.464mg B / 3.444mg A were diluted in 1ml of absolute ethanol and stored at 
-20 ºC for up to 6 months. On the day of experiment, steroids were diluted to the 
desired concentration in cell culture media, resulting in a final ethanol concentration 
of 0.1% 
3H-B working solution was prepared from 3H-B stock (1mCi/ml, Perkin Elmer, Bucks, 
UK) diluted with ethanol 1:10, 3H-A working solution was prepared from 3H-B as 
described in section 2.1.8. 
2.1.9.3 Protocol 
CM and cFb were isolated, purified and cultured as described in section 2.1.1.1. For 
murine heart explants, ventricles were separated from the atria and cut in 
11-deydrocorticosteronecorticosterone
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approximately 20-30 tissue pieces. 11β-HSD dehydrogenase and oxoreductase 
assays were either carried out by incubating cultured CM, cFb or murine heart 
explants in the presence of 100 nM cold substrate and a trace amount of tritiated 
steroid substrate at 37 ºC degrees in air/5%CO2 for a suitable time period which was 
established in preliminary experiments. The reaction was stopped by transferring 
culture media to 10ml glass tubes and addition of 7ml of dichloromethane. Steroids 
were extracted by vigorous shaking and vortexing for 10 seconds and the aqueous 
phase was separated from the steroid containing organic phase by centrifugation for 
10 min at 1000xg at RT. The aqueous phase and interphase were aspirated and the 
organic phase was evaporated at 55ºC under constant air flow. Steroids were then 
resuspended in 60 µl dichloromethane and spotted onto a TLC silica plate together 
with 1 µl of a standard containing a mixture of A and B (102 M). Steroids were 
separated using 200ml of a mobile phase consisting of chloroform:ethanol (92:8). 
Cold standards were visualised under ultra violet light to determine steroid migration. 
Subsequently, TLC plates were scanned on a Bioscan System 200 and fractional 
enzymatic activity was determined by calculating the percentage conversion 
(countsproduct/(countssubstrate + countsproduct)) per mg protein (monolayer cells), 100,000 
CM (suspension cells) or per g wet tissue (cardiac explants) per h and expressed as 
pmol/106 cells/h (pmol/g wet tissue/h). 
2.1.9.4 11β-hydroxysteroid kinetics 
2.1.9.5 Principle 
In order to characterise the properties of any enzyme, the maximum velocity (Vmax) 
and the Michaelis-Menten constant (Km) for each substrate needs to be determined 
experimentally (Figure 2-7). Determination of Vmax and Km is useful for various 
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biochemical purposes such as estimation of reaction rates, isoform comparison and 
definition of the potency of inhibitors. 
2.1.9.6 Methods 
To determine kinetic properties of 11β-HSD oxoreductase activity, CM were isolated 
and 100,000 rod-shaped cells were cultured as described in section 2.1.1.1 in 6 well 
plates. Cells were then incubated in the presence of increasing concentrations of 11-
dehydrocorticosterone and traces of radioactively labeled 3H-11-
dehydrocorticosterone. Following a 2h incubation period, steroids were extracted 
using dichloromethane, spotted onto TLC silica plates and separated by TLC 
(described in section 2.1.9.3). Subsequently, TLC plates were scanned and fractional 
enzymatic activity was determined by calculating the percentage conversion. 
Concentration dependant enzymatic activities were calculated and expressed as 
pmol/mg protein/hour or pmol/106 cells/h. Following Lineweaver-Burk transformation, 
the Michaelis-Menten constant (Km) and Vmax was calculated for 11β-HSD 
oxoreductase activity in CM. 
 
Figure 2-7 Illustration of the reaction rate (velocity) of an enzyme in 
relation to substrate concentration. Km denotes the substrate 
concentration at half of the maximum velocity. 
Km
Vmax
½ Vmax
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2.1.10 Protein extraction 
2.1.10.1  Principle 
Monolayer cells are lysed in a buffer containing detergent to break open cell 
membranes. In addition, cells are freeze thawed once to further disrupt cell 
membranes 
2.1.10.2  Methods 
Culture media was removed from cells grown in monolayer and cells were briefly 
rinsed with PBS. RIPA buffer (50mM Tris pH 7.4, 1% NP40, 0.25% SDS, 150mM 
NaCl, 1mM EDTA pH 8) (if cell lysate were used for Western blot analysis, protease 
inhibitors were added to the RIPA buffer in addition) was added to the cells (50 
µl/well (12 well plate), 200 µl/well (6 well plate)) and cells were frozen at -80ºC until 
further use. After thawing, cells were scraped with a rubber policeman and 
transferred to an Eppendorf tube and centrifuged at 12,000xg for 15 min at -4ºC to 
spin down insoluble cell debris. The supernatant was transferred to a new Eppendorf 
tube and stored at -80ºC until further use. 
2.1.11 Protein quantification 
2.1.11.1 Principle 
Protein concentrations of cell extracts were measured using the BioRad RC DC 
protein assay (BioRad, Hemle Hempstead, Herts). This is a colourimetric assay for 
protein concentration following detergent solubilisation. The assay is based on the 
Lowry method and the reaction of protein with an alkaline copper tartrate solution and 
then reduction of Folin reagent. Folin reagent is reduced by the loss of 1, 2 or 3 
oxygen atoms, primarily due to the amino acids tyrosine, tryptophan and to a lesser 
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extent, cystine, cysteine and histidine. The reduction of Folin reagent can produce 
several reduced species which have a characteristic blue colour, with a maximum 
absorbance at 750nm and a minimum absorbance at 405nm. The protein 
concentration of a sample was determined employing a standard curve which was 
generated from a dilution series of a sample with a known protein concentration 
(Figure 2-8). 
2.1.11.2 Methods 
Protein assays were carried out in 96 well plates according to the manufacturer’s 
protocol. Per well, 5µl of protein standard (range 0, 0.5, 1, 2, 4, 6, 8 mg/ml BSA) or 
sample was added. Subsequently, 25µl of solution A (alkaline copper tartrate 
solution) was added followed by addition of 200µl of solution B (Folin reagent). The 
plate was incubated for 10 and then read at 690nm on a Victor3 1420 multilabel 
counter (PerkinElmer, Bucks, UK). 
 
Figure 2-8 Representative protein standard curve from protein 
standards containing 0, 0.5, 1, 2, 4, 8 mg of protein/ml. 
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2.1.12 Western Blotting 
2.1.12.1 Principle 
Western blotting allows detection and measurement of relative amounts of a specific 
protein in a mixed protein sample (Towbin et al., 1992). The proteins are separated 
by size by SDS-PAGE and subsequently transferred to a membrane, usually 
nitrocellulose or polyvinylidene difloride (PVDF). The membrane is blocked with a 
generic protein, such as cow milk proteins or BSA, to prevent unspecific binding of 
antibodies to the membrane. Thereafter, the membrane is incubated with the primary 
antibody that binds specifically to the protein of interest. The membrane is then 
incubated with an enzyme conjugated secondary antibody that is directed against the 
primary antibody. The secondary antibody is typically conjugated to horseradish 
peroxidise (HRP) which catalyses the oxidation of a chemiluminescent substrate 
producing light. The reaction is captured onto photographic film.  
2.1.12.2 Method 
SDS-PAGE and protein transfer were performed in a BioRad mini protein 3 
apparatus using a modified protocol provided with the kit. Between 10-40µg of 
protein was mixed with the appropriate amount of 4 X loading buffer and boiled for 5 
mins. Samples were loaded on an 8-12% SDS-PAGE gel and run at 200V for 1hr to 1 
hr 30 min. Proteins were transferred onto nitrocellulose membrane at 140V for 1-1.5 
hr depending on the molecular weight of the protein to detect. To check for efficient 
transfer of proteins, membranes were incubated in Ponceau staininig solution with 
slight agitation for 30 sec, and then rinsed with water until protein bands appeared. 
Bands should be distinct and well spread out. Membranes were then blocked in 
10mL of blocking buffer for 1hr with constant agitation, rinsed twice with washing 
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buffer, incubated in primary antibody overnight at 4ºC with constant agitation. 
Membranes were then washed 3 times for 15 min in washing buffer (PBS, Tween 
0.1%). Secondary antibody incubation was for 1 hr at room temperature followed by 
washing 3 times for 15 min in 50mL of washing buffer. Chemiluminesence was used 
for antibody detection; substrate A and B were mixed in equal quantities (0.5 mL 
each per membrane) and allowed to equilibrate for 5 min. 1mL of substrate was put 
on each membrane and incubated for 2 min. Membranes were placed between two 
sheets of clear plastic and in the dark exposed to photographic film for 2 sec to 1 hr. 
Photographic film was developed on Compact X4 (Xograph Imaging Systems, 
Gloustershire, UK) 
2.1.13 Microarray studies 
2.1.13.1 Principle 
Whole genome DNA microarrays are used to measure changes in expression levels 
of multiple genes. Whole genome microarrays cover all genes of a particular genome 
and allow the study of expression levels at baseline as well as changes in response 
to a treatment. 
A microarray consists of a series of thousands microscopic spots, so called features, 
which contain picomoles of single stranded DNA oligonucleotides that are 
immobilised on a solid surface such as glass or silicone. Each spot represents one 
gene as the DNA sequence of the oligonucleotides is complimentary to that of the 
messenger RNA of the corresponding gene. In order, to assess gene expression 
levels, the mRNA is labeled with a fluorochrome and hybridised to the immobilised 
complementary oligonucleotides on the array at a high stringency. The intensity of 
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fluorescence of each spot directly reflects expression levels of the corresponding 
gene (Figure 2-9). 
 
Figure 2-9 Illustration of a scanned microarray slide. One slide contains 
four individual microarrays containing 43,380 features representing 
genes. Following hybridisation of the labeled cRNA probe, the 
microarray slides are scanned. The intensity of each spot reflects the 
expression level (the brighter the spot the higher the level of 
expression) of the corresponding gene. 
2.1.13.2 Method 
Figure 2-10 gives an overview of the multistep protocol involved in the generation of 
labelled cRNA probes. In brief, extracted RNA is reversely transcribed into 1st and 2nd 
strand cDNA by reverse transcriptase from the moloney mouse leukemia virus 
(MMLV RT). The 2nd strand cDNA subsequently serves as a template for the T7 RNA 
polymerase to finally synthesis labelled complementary RNA (cRNA) by incorporating 
Cytosins which are linked to the fluorophore Cy3. For details see materials and 
methods in Chapter 4. 
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Figure 2-10 Schematic illustration of RNA labeling. RNA is reversely 
transcribed into cDNA which then serves as a template for the synthesis 
of complementary RNA (cRNA) in which Cy3-labeled Cytosine is 
incorporated. 
2.1.13.3 Bioinformatic analysis 
Assessment and analysis of microarray data was carried out using the software “R: A 
language and environment for statistical computing” (http://www.r-project.org/) using 
packages from Bioconductor, open source software for bioinformatics. 
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(http://www.bioconductor.org/). In order to compare microarray results, raw 
microarray data was normalised using quantile normalisation. Following quality 
assurance employing the principal component analysis (PCA) and correspondence 
analysis (CA), the linear models for microarray analysis (limma) package was used to 
determine differentially expressed genes. For details see materials and methods in 
Chapter 4. 
2.2 Clinical studies 
Several clinical studies are reported in this thesis. All patients were recruited from the 
University Hospital Birmingham NHS trust. All studies had ethical approval of the 
Local Research Ethics Committee and all patients gave their informed written 
consent to participate. Studies were conducted at the Wellcome Trust Clinical 
Research Facility, Queen Elizabeth Hospital, Birmingham. Study protocols are 
described in the individual chapters. 
2.2.1 Biochemical analysis 
2.2.1.1 Gas chromatography/mass spectrometry for urinary steroid 
hormone metabolites 
2.2.1.1.1 Method 
The gas chromatography/mass spectrometry (GC/MS) method used is based on the 
method described by Palermo and Shackelton (Palermo et al., 1996). Steroid 
extraction was carried out by Seppak C19 cartridges. To this extract, 200ng of 
sigmasterol and cholesteryl-butyrate were added as external standard and 
methyloxime-trimethylsilyl ether were prepared according to established procedures. 
Following derivatisation, the excess reagent was removed by Lipidex 
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chromatography; the samples were automatically introduced in a Hewlett Packard 
5970 mass spectrometer with a 15m DB1 capillary column. Quantification was 
achieved by monitoring selected ions for the analytes (fragment 531 for cortisone and 
605 for cortisol) and internal standards (m/Z 534 and 609, respectively). Relative 
peak areas were determined and reported as µg/24 h of the individual compound. 
Validation of the method was performed by comparing the curve of increasing 
amounts of the analyte to the ratio between the areas of different amounts of the 
analyte and fixed concentrations of the internal standard (r=0.998 for cortisol and 
0.999 for cortisone). Intra and inter-assay coefficients of variation were <10% for both 
cortisol and cortisone. 
2.2.1.1.2 Urinary steroid metabolites and their ratios 
The sum of total cortisol metabolites (THF, THE, 5α-THF, α-cortolone, cortisone, 
cortisol, cortisol, β-cortolone, β-cortol, and α-cortol) provides a reflection of the 
cortisol secretion rate. The ratio of tetrahydro-metabolites of cortisol (THF + 5α-THF) 
to those of cortisone (THE) provides a reflection of 11β-HSD1 activity when 
considered with the ratio of urinary free cortisol (UFF) to cortisone (UFE), which more 
accurately reflects renal 11β-HSD2 activity (Palermo et al., 1996). The ratios of 
cortols to cortolones and of 11β-hydroxy-etiocholanolone and 11β-hydroxy-
androsterone combined to 11oxo-etiocholanolone also reflect 11β-HSD1 activity 
(Walker et al., 2007). The activities of 5α- and 5β-reductases can be inferred from 
measuring the ratio of 5α-THF to THF and androsterone to etiocholanolone. TH-Aldo 
is the main urinary Aldo metabolite and reflects 24h Aldo production. The activity of 
11β-hydroxylase can be inferred from measuring the ratio of total cortisol metabolites 
(see above) to tetrahydro-11-desoxycortisol (THS) (Freel et al., 2007). 
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2.2.1.2 Plasma measurements 
Urea, creatinine and electrolytes were measured using standard laboratory methods 
at the Department of Biochemistry, University Hospital of Birmingham NHS trust.  
2.2.1.2.1 Steroid secretion and metabolism in essential hypertension 
Plasma renin activity (PRA) and Aldo were kindly measured by Dr C Webster, Dept 
of Clinical Biochemistry, Birmingham Heartlands Hospital, Birmingham, UK. PRA was 
measured using the Biodata Renin MAIA assay (Serono Diagnostics, Woking, 
Surrey, UK) and plasma Aldo using a solid phase (coated tube) radioimmunoassay 
technique, DPC Coat-a-Count assay (DPC, Llanberis, Caernarfon, Gwynedd, UK). 
The intra-assay correlation coefficients of these measurements were all below 10%. 
The reference range in the supine position ranged from 0.51 - 2.64 ng/ml/h for PRA 
and 28 - 445 pmol/l for Aldo. 
2.2.1.2.2 Spironolactone in chronic kidney disease patients 
PRA, Ang II and Aldo in the circulation were kindly measured by Dr J Morton, 
Department of Cardiology, Western Infirmary, Glasgow, Scotland, United Kingdom. 
PRA was measured by an in-house antibody trapping technique in the presence of 
added excess renin substrate (Millar et al., 1980). The coefficient of variation was 
3.4%. An in-house radioimmunoassay was used for plasma Ang II as previously 
described (Morton & Webb, 1985). Ang II was pre-extracted from plasma before 
assay. The coefficient of variation was 10%. Aldo was measured with a solid-phase 
(coated tube) radioimmunoassay kit supplied by Diagnostic Products (UK) Ltd. The 
coefficient of variation was <8.3%. 
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2.3 Collection of human left ventricular cardiac biopsies 
During cardiac surgery full-thickness free wall LV biopsy samples were obtained 
using Tru-Cut Biopsy Needles (Allegiance Healthcare Corp, McGaw Park, Ill) 
immediately before AXC placement (pre-ischemia). Biopsies were immediately snap 
frozen in liquid nitrogen and stored at -80ºC until further use. 
2.4 Blood pressure measurements 
Office brachial blood pressure was recorded with the subject lying supine in the non-
dominant arm using a validated oscillometric sphygmomanometer (Dinamap® 
Procare, GE). 24 hour ambulatory blood pressure (24h ABP) measurement was 
performed using a Meditech® ABPM-04 (Budapest, Hungary). 
2.5 Statistical analysis 
2.5.1 General statistics 
All statistics were performed using SPSS 16.0 software (SPSS inc., Chicago, USA). 
Parametric data are described as mean ± standard deviation (SD), non-parametric 
data are described as Mean (interquartile range). Where applicable non-parametric 
data was log transformed. For comparisons between two groups student’s t-test for 
parametric data, Mann-Whitney U test for non-parametric data and the chi-square 
test for categorical data was used. When more than two groups were compared, 
analysis of variation (ANOVA) was used. Correlation coefficients (Pearson for 
parametric, Spearman for non-parametric data) were obtained when the strength of a 
relationship between two variables was examined.  
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3.1 Introduction 
The CVS has emerged as an important target of corticosteroid hormone action. The 
GR and the MR are both expressed in the heart (described in section 1.9.3.1) and a 
growing body of evidence from both experimental and clinical studies has established 
an important role for steroid hormones in the development and modulation of 
cardiovascular disease (described in section 1.9). 
Most experimental studies have focused on the modulatory effects of Aldo in heart 
disease, considerably less is known about the effects of glucocorticoids although 
chronic glucocorticoid excess similar to Aldo excess has adverse effects on the CVS. 
This is exemplified in patients with Cushing’s syndrome, characterised by excessive 
endogenous cortisol production, who have a high prevalence of left ventricular 
hypertrophy (Muiesan et al., 2003; Muiesan et al., 2008). In keeping with these 
findings, cardiovascular risk in these patients is increased 4 times compared to the 
normal population (Etxabe & Vazquez, 1994). Glucocorticoid treatment is associated 
with an increased risk of heart failure (Souverein et al., 2004) as well as 
cardiovascular disease (Wei et al., 2004). Moreover, high-normal cortisol levels have 
recently been associated with increased mortality in patients with CHF (Guder et al., 
2007). 
Glucocorticoid action in target tissues is not exclusively dependent on circulating 
levels but also determined by the inter-conversion of active and inactive forms of the 
steroid within target cells. This pre-receptor metabolism is catalysed by two isozymes 
of 11β-HSDs (described in section 1.7). 11β-HSD2 is expressed mainly in classic 
Aldo target tissues such as the kidney, colon and salivary glands where it functions 
as a dehydrogenase converting cortisol to cortisone (in rodents: corticosterone to 11-
dehydrocorticosterone). By this mechanism MR specificity for Aldo is maintained as 
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the MR has equal affinities for glucocorticoids and mineralocorticoids in vitro (Funder 
et al., 1988). In the heart, 11β-HSD2 appears to be expressed only at very low levels 
(Kayes-Wandover & White, 2000; Slight et al., 1996) or is undetectable (Walker et al., 
1992) and thus, is unlikely to sufficiently protect the MR from glucocorticoids 
(described in section 1.9.3.4). Experimental evidence from a mouse model 
overexpressing 11β-HSD2 in CM suggests that in fact glucocorticoids may be 
beneficial by tonically occupying the MR and thereby protecting it from Aldo binding 
and action (Qin et al., 2003). 
In contrast to the type 2 isozyme, 11β-HSD type 1 (11β-HSD1) is widely expressed 
and predominantly functions as an oxoreductase in vivo by converting inactive into 
biologically active glucocorticoids (described in section 1.7.1). 11β-HSD1 
oxoreductase activity critically relies on the presence of NADPH which is generated 
from NADP+ by the enzyme H6PDH. To date, the role of 11β-HSD1 in cardiac 
physiology and disease remains unclear. 
In order to better understand glucocorticoid hormone action in the heart, we 
characterised expression and function of key components of glucocorticoid hormone 
action in isolated adult rat CM, cardiac MyoFb, rodent hearts and human left 
ventricular biopsies. 
3.2 Materials and Methods 
3.2.1 Isolation of rat cardiomyocytes 
Animal studies were performed in accordance with Home Office Guidance (Animals 
Scientific Procedures Act 1986). CM from adult male Sprague-Dawley rats (250-
300g) were isolated as described in section 2.1.1.1. Following isolation, CM were 
incubated in CM culture media. 
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3.2.2 Collection of heart from WT and H6PDH-/- mice 
The H6DPH/KO mice were generated by the replacement of exons 2 and 3 of the 
H6PDH gene with a neomycin resistance cassette as reported (Lavery et al., 2006). 
Homozygous null mice (H6PDH-/-) were generated by heterozygous mating. Mice 
were housed in pathogen-free conditions and had a 12-h light, 12-h dark cycle and 
unlimited access to standard mouse chow and water. 
3.2.3 Cell treatment 
For gene expression studies 200,000 rod shaped CM in suspension were seeded per 
well in 6 well plates in CM culture medium containing 10% FCS to facilitated 
attachment of CM. Following a 1h incubation period, medium and non attached cells 
were discarded and attached CM were gently washed with M199 and incubated in 
CM culture media with no FCS. Cells were then treated with steroid (1-100nM) in the 
presence or absence of corticosteroid receptor antagonists (RU486, RU28318) at a 
concentration of 10µM for 8 hours. 
3.2.4 RNA extraction 
Total RNA from cultured rat CM, cFb or human left ventricular cardiac biopsies was 
extracted employing TriReagent (Applied Biosystems, Warrington, Cheshire, UK). 
For cultured rat CM and cFb 1ml of TriReagent was added to cultured cells; human 
left ventricular cardiac biopsies were homogenised in 1ml of TriReagent using a 
tissue homogeniser. Total RNA was extracted as described in section 2.1.4. 
3.2.5 cDNA synthesis 
Total RNA (0.5 µg) was reversely transcribed in 25 µl total volume using TaqMan 
Reverse Transcription Reagents (Applied Biosystems) as described in section 
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2.1.6.2.1. Following the reverse transcription reaction, the cDNA was diluted to a final 
concentration of 5 ng/µl (human biopsies: 1.25 ng/µl) and stored at −20 °C until 
further use. 
3.2.6 Conventional reverse transcription polymerase chain reaction 
RT-PCR was carried out in a total volume of 20µl using 20ng of cDNA as described 
in section 2.1.6.2.2. Primers used for conventional RT-PCR are listed in Table 3-1. 
For amplification of GR, MR, 11β-HSD1 and 2 in CM and cFb 33 cycles, for 
characterisation of cFb 31 cycles of PCR amplification were carried out. The 
temperate profile for amplification was 1 min at 95°C, 30 sec at 95°C, 1 min at 72°C 
with a final cycle of 7 min at 72°C. 
Table 3-1 Primer pairs used for gene amplification by RT-PCR.  
Gene symbol F/R Sequence Product 
(bp) 
GR F AAGAGCACTGGAAGGACAGC 474 
R TCATTAATAATCAGATCAGGAGCAA 
MR F GTGGACAGTCCTTTCACTACCG 286 
R TGACACCCAGAAGCCTCATCTC 
11β-HSD1 F GGAGCCCATGTGGTATTGAC 577 
R CTGTGCCTTTGATGATCTCC 
11β-HSD2 F TGGCAAGGAGACAGCTAAGAA 679 
R GCAATGCCATTCTGAGTGAA 
PECAM-1 F CTGAGGTGGGCCTCAGTC 449 
R TGTCACCTCCTTTTTGTCCA 
Vimentin F CCAAGTTTGCTGACCTCTCTG 337 
R TCCAGCAGCTTCCTGTAGGT 
ANF F TCTGATGGATTTCAAGAACCTG 366 
R TTCGGTACCGGAAGCTGT 
α-SMA F CGGGAGAAAATGACCCAGAT 548 
R ATAGGTGGTTTCGTGGATGC 
18s F GTTGGTGGAGCGATTTGTCT 397 
R GGCCTCACTAAACCATCCAA 
F: forward, R: reverse, bp: base pairs. 
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3.2.7 Real-time quantitative polymerase chain reaction 
Expression levels of genes of interest were measured using ABI 7500 system 
(Perkin-Elmer, Biosystems). All primers and probes were purchased from Applied 
Biosystems. Primers and probes for 18s rRNA, GR, MR, 11β-HSD1, VEGFa, ACE1 
which were supplied as expression assays (Applied Biosystems, Warrington, 
Cheshire, UK). All reactions were normalised against the house keeping gene 18S 
rRNA. 
3.2.8 Protein extraction and immunoblotting 
Rat heart, liver, kidney and cultured CM were homogenised in RIPA buffer and total 
protein concentration was determined as described in section 2.1.11. Forty 
micrograms of protein sample were resolved on an 8% SDS-PAGE gel and 
transferred onto a nitrocellulose membrane Hybond ECL (GE Healthcare, Chalfont St 
Giles, UK). Primary antibodies raised against the MR and GR (Santa Cruz, UK) were 
used at a dilution of 1:1000. Secondary antibodies were used at a dilution of 1/10000 
(Abcam plc, Cambridge, UK). Membranes were reprobed for ß-actin at a dilution of 
1/5000 (Abcam plc, Cambridge, UK). 
3.2.9 11β-HSD enzyme assays 
For enzymatic assays 200,000 rod shaped CM in suspension per well were cultured 
in 6 well plates in FCS free CM media. Conversion of 11-dehydrocorticosterone to 
corticosterone (oxoreductase) in cultured rat CM and cFb was analysed by incubating 
cells with 100 nM 11-dehydrocorticosterone and tracer amounts of 3H-11-
dehydrocorticosterone (synthesised in-house, described in section 2.1.9) for two 
hours. Dehydrogenase activity (corticosterone to 11-dehydrocorticosterone) was 
assessed using 100 nM unlabelled corticosterone (Sigma-Aldrich Company Ltd, 
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Dorset, UK) diluted in serum-free medium and tracer amounts of 3H-corticosterone 
(specific activity 74·0 Ci/mmol; NEN, Boston, MA, USA) at 37 °C for 8 h. Steroids 
were extracted from the medium with 7ml of dichloromethane, separated by thin-layer 
chromatography with chloroform:ethanol (92:8) as a mobile phase and the fractional 
conversion of steroids was calculated after scanning using a Bioscan 2000 
radioimaging detector (Bioscan, Washington, DC, USA). Enzymatic activities were 
calculated and expressed as pmol/mg protein/hour or pmol/106 cells/h. All assays 
were carried out in triplicate and conversion rates calculated from three individual 
experiments. 
3.2.10 Proliferation assay 
Fibroblast proliferation was assessed by incorporation of 3H-thymidine as described 
in section 2.1.3. Isolated cFb in culture (less than 3 passages) were seeded into 12 
well plates. The following day, cFb were treated with steroids (final concentration) 
DEX, corticosterone, 11-dehydrocorticosterone (1-100nM) in the presence or 
absence of RU486 (1µM). For proliferation assays, MyoFb were treated with 
corticosterone or 11-dehydrocorticosterone (1µM) in the presence or absence of GE 
(10µM). All treatments were performed in triplicate. Each experiment was repeated 3 
times. 
3.2.11 Patients 
Left ventricular (LV) cardiac biopsies were obtained from patients with LV 
hypertrophy (LVH) secondary to aortic valve stenosis undergoing aortic valve 
replacement (AVR) or from transplant donor hearts (courtesy of Mr Domenico 
Pagano and Mr Neil Howell, Department of Cardiothoracic surgery, Queen Elizabeth 
Hospital, Birmingham). 
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Characteristics of aortic stenosis patients (N=17): male/female: 12/5; Age: 68±11; 
BMI: 29±5 kg/m2; IVS: 17±3 mm; aortic gradient: 77±19 mmHg. Four patients had 
coronary artery disease, and all but one patient had a normal LV ejection fraction 
(LVEF). 
Characteristics of heart donor patients (N=15): male/female: 7/8; Age: 51±12 years; 
BMI: 25±3 kg/m2; IVS: 11±2mm; primary cause of death was intracranial bleed (N=8), 
head injury (N=5), infection (N=1) and intracranial tumour (N=1). Donors were part of 
a randomised controlled clinical trial (Venkateswaran et al., 2009). As part of this trial, 
patients were randomised to a 6.3±1.4h treatment with tri-iodothyronine (T3) (N=11) 
or placebo (N=4). Two patients received DEX and one donor received hydrocortisone 
prior to brain stem death. 
Normal human liver (N=4) (Ahmed et al., 2008) and muscle mRNA (N=5) (Morgan et 
al., 2009) was obtained from biopsy material under ethical approval from other 
research programmes within the group evaluating corticosteroid hormone action in 
metabolic tissues (courtesy of Drs Ahmed and Sherlock). All patients or next of kin 
(transplant donors) gave written informed consent. The study protocol was approved 
by the Local Research Ethics Committee. 
3.2.12 Collection of human left ventricular cardiac biopsies 
Full-thickness free wall LV biopsy samples were obtained using Tru-Cut Biopsy 
Needles (Allegiance Healthcare Corp, McGaw Park, Ill) immediately prior to aortic 
cross clamp placement (in both patients undergoing aortic valve replacement and 
donors prior to heart explant). Biopsies were immediately snap frozen in liquid 
nitrogen and stored at -80ºC until further use. 
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3.2.13 Statistical analysis 
Statistical analysis was performed using the software package SPSS for Windows 
Version 16 (SPSS, Inc., Chicago, IL, USA). Data are presented as means±SD. Real-
time PCR analyses were performed following transformation of ∆Cts values into 
arbitrary units through the equation 2−∆Ct. Statistical analyses were performed using a 
t-test/ANOVA for normally distributed data. p values <0.05 were accepted as 
statistically significant. 
3.3 Results 
3.3.1 Characterisation of steroid hormone signalling in 
cardiomyocytes 
We first studied expression of key components involved in corticosteroid hormone 
signalling in rat heart and isolated rat CM in culture by conventional RT-PCR. Both 
the GR and MR were readily expressed in whole rat heart and CM (Figure 3-1). 11β-
HSD1 was also expressed in rat heart and isolated CM. Based on visual comparison 
of band intensities, 11β-HSD1 appeared to be less abundantly expressed compared 
to the GR and MR, whereas 11β-HSD2 was undetectable (Figure 3-1). 
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Figure 3-1 Expression of the glucocorticoid receptor (GR), 
mineralocorticoid receptor (MR), 11β-hydroxysteroid dehydrogenase 
type 1 (11β-HSD1) and type 2 (11β-HSD2) in whole rat heart and 
isolated rat cardiomyocytes by conventional RT-PCR. 
Expression of the GR and MR was confirmed at a protein level by immunostaining. 
Expression levels of GR and MR was higher in extracts from whole rat hearts 
compared to isolated CM (Figure 3-2). 
 
Figure 3-2 Western blot analysis of GR and MR in isolated 
cardiomyocytes (CM) and whole rat heart. 
Relative expression levels of GR, MR, 11β-HSD type 1 and 2 were then compared in 
heart, liver, quadriceps muscle, kidney and gonadal fat of male and female adult 
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C57BL/6 mice by quantitative PCR (Figure 3-3). GR and MR were expressed at 
similar levels in all tissues with highest levels in heart and skeletal muscle. MR 
expression levels were 5-10 fold lower compared to GR in all tissues (Figure 3-3a 
and b). 11β-HSD1 was predominantly expressed in liver, less in kidney and fat and 
lowest in heart and skeletal muscle (Figure 3-3c), whereas 11β-HSD2 was 
exclusively expressed in kidney (Figure 3-3c). With the exception of GR and 11β-
HSD1 which exhibited higher expression levels in the kidney and adipose tissue of 
male compared to female mice, there were no sex differences in expression levels. 
 
Figure 3-3 Relative Expression levels of GR (A), MR (B), 11β-HSD 
type 1 (C) and 2 (D) in male (■, N=3) and female (□, N=3) C57BL/6 
mice in heart, quadriceps muscle, liver, kidney, and gonadal fat 
normalised to 18s by quantitative PCR (data represents mean±SD; 
Gene expression levels between male and female mice were compared 
employing t-test; * p<0.05). 
0.0
0.2
0.4
0.6
0.8
1.0
Heart Muscle Liver Kidney Fat
A
U
0.00
0.05
0.10
0.15
Heart Muscle Liver Kidney Fat
A
U
0.0
0.5
1.0
1.5
2.0
2.5
Heart Muscle Liver Kidney Fat
A
U
0.0
0.1
0.2
0.3
0.4
0.5
Heart Muscle Liver Kidney Fat
A
U
G
R
 /
 1
8
s 
(A
.U
.)
M
R
 /
 1
8
s 
(A
.U
.)
1
1
β
-H
S
D
1
/ 
1
8
s 
(A
.U
.)
1
1
β
-H
S
D
1
/ 
1
8
s 
(A
.U
.)
A B
C D
*
*
* *
Chapter 3 Characterisation of Glucocorticoid Hormone Action in the Mammalian Heart 
  108 
Enzymatic activities of 11β-HSDs in CM were assessed by incubating CM with 11-
dehydrocorticosterone (11-DHB) and corticosterone (B). In CM, 11β-HSD1 
oxoreductase activity (conversion of 11-DHB to B) was readily detectable whereas 
dehydrogenase activity (conversion of B to 11-DHB) was at the lower limit of 
detection (Figure 3-4) consistent with the RT-PCR data which suggesting complete 
absence of 11β-HSD2 in CM (Figure 3-4). 
 
Figure 3-4 11β-HSD oxoreductase and dehydrogenase activity in 
isolated rat cardiomyocytes. Oxoreductase and dehydrogenase activity 
was determined by incubating cardiomyocytes with 11-
dehydrocorticosterone and corticosterone, respectively. Enzymatic 
activities were calculated from the percentage conversion of each 
steroid. (data represents mean of 3 individual experiments ± SEM). 
Kinetic properties of 11β-HSD1 oxoreductase activity were further characterised by 
incubating CM with increasing concentrations of 11-DHB (Figure 3-5a). Following 
Lineweaver-Burk transformation the apparent Km of 11β-HSD1 in CM was calculated 
to be 415nM with a Vmax of 216 pmol/106 cells/h (Figure 3-5b). 
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Figure 3-5 Enzymatic kinetics of oxoreductase activity of 11β-HSD1 
in isolated rat CM. A Concentration dependent conversion of 11-
dehydrocorticosterone (11-DHB) to corticosterone (data represents 
mean of 3 individual experiments). B Lineweaver-Burk graph of 11β-
HSD1 oxoreductase activity in cardiomyocytes normalised to 1x106 
cells. 
Furthermore, we assessed 11β-HSD1 oxoreductase and dehydrogenase activity in 
cardiac explants from C57BL/6 (WT) and H6PDH knock out (H6PDH-/-) mice. While 
WT mice predominantly exhibited oxoreductase and only little dehydrogenase 
activity, enzymatic activities in H6PDH-/- mice were reversed with a loss in 
oxoreductase and gain in dehydrogenase activity (Figure 3-6). 
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Figure 3-6 11β-HSD1 oxoreductase and dehydrogenase activities in 
heart explants from C57BL/6 WT and H6PDH-/- mice. Enzymatic 
activities were calculated from the percentage conversion of each 
steroid. (data represents mean of 3 individual experiments). 
We next assessed the regulation of glucocorticoid target genes in cultured CM. 
Incubation of CM with 100nM DEX for 8h strongly induced expression of the 
angiotensin converting enzyme 1 (ACE1), whereas B and 11-DHB were less potent 
(Figure 3-7a). ACE1 induction by B and 11-DHB was dose dependent (Figure 3-7b 
and c) and was blunted by co-incubation with the GR antagonist RU486 (Figure 
3-7b). ACE1 induction by 11-DHB was dependent on bioactive 11β-HSD1 as co-
incubation with the 11β-HSD1 inhibitor GE blocked the response. 
By contrast, expression of the vascular endothelial growth factor A (VEGFa) was 
repressed following an 8h incubation with 100nM DEX, B, and 11-DHB (Figure 3-8a). 
VEGFa repression by B and 11-DHB was dose dependent (Figure 3-8 b and c) and 
co-incubation of B with RU486 (Figure 3-8b), 11-DHB with GE but not B with GE 
blunted VEGFa repression (Figure 3-8c). 
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Figure 3-7 Induction of ACE1 gene expression by glucocorticoids in 
rat cardiomyocytes. A ACE1 expression is up-regulated by 
dexamethasone (DEX), corticosterone (B) and 11-dehdrocorticosterone 
(A) (100 nM) B ACE1 expression is up-regulated by B in a 
concentration dependent manner (1-100 nM) ± RU486 (10µM) C ACE1 
expression is up-regulated by B and 11-dehydrocorticosterone (A); 
Glycyrrhetinic acid (GE) (10µM) blunts induction bv 11-DHB but not B. 
(The data represents mean±SEM of 3 individual experiments each 
performed in duplicate; Treatment effects vs control (CTRL) were 
compared by one way ANOVA.* p<0.05; ** p<0.01). 
0
1
2
3
4
CTRL GE A -9 A -8 A -7 A/GE
0
1
2
3
4
5
6
CTRL RU486 B -9 B -8 B -7 B/RU486
0
2
4
6
8
10
CTRL DEX -7 B -7 A -7
A
B
C
CTRL   GE 10-5               10-9 A 10-8  10-7  10-7
GE 10-5 
AC
E 
1 
/ 1
8s
 
(fo
ld
 
ch
an
ge
)
*
CTRL     DEX 10-7 B 10-7 A 10-7
AC
E 
1 
/ 1
8s
 
(fo
ld
 
ch
an
ge
) **
*
*
    RU486 10-5  10-9 B 10-8  10-7 B 10-7
RU486 10-5
AC
E 
1 
/ 1
8s
 
(fo
ld
 
ch
an
ge
)
*
**
Chapter 3 Characterisation of Glucocorticoid Hormone Action in the Mammalian Heart 
  112 
 
Figure 3-8 Repression of the VEGFa gene by glucocorticoids in rat 
cardiomyocytes. A VEGFa is suppressed by dexamethasone (DEX), 
corticosterone (B) and 11-dehdrocorticosterone (A) (100nM) B VEGFa 
is repressed by B in a concentration dependent manner (1-100 nM); 
RU486 (10µM) blocked VEGFa induction by B. C VEGFa expression is 
repressed by 11-dehydrocorticosterone (A) and B; glycyrrhetinic acid 
(GE) (10µM) blunted the repression by 11-DHB but not B. (The data 
represents mean±SEM of 3 individual experiments each performed in 
duplicate; Treatment effects vs control (CTRL) were compared by one 
way ANOVA.* p<0.05; ** p<0.01). 
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3.3.2 Characterisation of steroid hormone action in cardiac fibroblasts 
We first assessed purity of primary cultures of rat cFb by assessing expression of cell 
specific markers (Figure 3-9). cFb readily expressed the fibroblast specific marker 
vimentin and α-smooth muscle actin (α-SMA), a marker which is expressed in 
activated fibroblasts suggesting that cFb had transformed into MyoFb. By contrast, 
the endothelial marker platelet/endothelial cell adhesion molecule 1 (PECAM-1) and 
atrial natriuretric factor (ANF) which are only expressed in endothelial cells and CM, 
respectively, were not expressed. These results suggest a pure colony of cardiac 
MyoFb with no evidence of contamination from endothelial cells or myocytes. 
 
Figure 3-9 Characterisation of primary rat cardiac fibroblasts (cFb) 
in culture by conventional RT-PCR. cFb expressed the fibroblast marker 
vimentin and the myofibroblast marker α-smooth muscle actin (α-SMA), 
whereas the endothelial marker platelet/endothelial cell adhesion 
molecule 1 (PECAM-1) and the myocytes marker atrial natriuretric 
factor (ANF) were not expressed in cFb. Whole rat heart was used as a 
positive control. 
We next assessed key components involved in steroid hormone signalling in cFb. We 
found both the GR and 11β-HSD1 to be highly expressed in cFb (Figure 3-10). The 
MR was also readily expressed albeit at lower levels compared to the GR. However, 
similar to CM (Figure 3-1), 11β-HSD2 was not expressed in cFb.  
cFb
rat heart
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Figure 3-10 Expression of the glucocorticoid receptor (GR), 
mineralocorticoid receptor (MR), 11β-hydroxysteroid dehydrogenase 
type 1 (11β-HSD1) and type II (11β-HSD2) in cultured primary rat 
fibroblasts by conventional RT-PCR. Rat kidney served as a positive 
control. 
We next assessed relative expression levels of 11β-HSD1 in CM and cFb in 
comparison to whole rat heart and rat liver by quantitative realtime PCR (qPCR). In 
agreement with the low expression levels of 11β-HSD1 in CM by conventional RT-
PCR, qPCR showed a 10 fold lower expression level of 11β-HSD1 in CM cultures 
and whole heart compared to liver (Figure 3-11).  
 
Figure 3-11 Relative expression levels of 11β-HSD1 in rat 
cardiomyocytes (rCM), cardiac fibroblasts (cFb), whole rat heart and rat 
liver by quantitative realtime PCR. 
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However by contrast, cFb showed high expression levels of 11β-HSD1 which was 
even higher than in liver. 
We next studied functional activities of 11β-HSDs in cFb. Oxoreductase activity was 
high but only very little dehydrogenase activity was detectable (Figure 3-12), 
reflecting the high expression of 11β-HSD1 and absence of 11β-HSD2 observed in 
the conventional RT-PCR (Figure 3-10). 
 
Figure 3-12 11β-HSD oxoreductase and dehydrogenase activities in 
cultured rat cardiac fibroblasts (cFb). Oxoreductase and dehydrogenase 
activities were determined by incubating cFb with 11-
dehydrocorticosterone and corticosterone, respectively. Enzymatic 
activities were calculated from the percentage conversion of each 
steroid (data represents mean of 3 individual experiments). 
Glucocorticoids are a known stimulator of 11β-HSD expression resulting in increased 
oxoreductase activity. Incubation of cFb with DEX resulted in a dose dependent 
induction of 11β-HSD expression (Figure 3-13a) and oxoreductase activity (Figure 
3-13b) which was completely blunted by co-administration of the specific GR 
antagonist RU486. 
Co
n
ve
rs
io
n
(pm
ol
/m
g 
pr
ot
ei
n
/h
)
Chapter 3 Characterisation of Glucocorticoid Hormone Action in the Mammalian Heart 
  116 
 
Figure 3-13 Induction of 11β-HSD by glucocorticoids. 
Dexamethasone (DEX) dose dependently (1-100nM) induces 11β-
HSD1 expression (A) and 11β-HSD oxoreductase activity (B) in cardiac 
fibroblasts. Treatment effects vs control (CTRL) were compared by one 
way ANOVA;* p<0.05. 
We next assessed the effects of glucocorticoids on cFb proliferation. Glucocorticoids 
repressed cFb proliferation (Figure 3-14a). DEX showed the strongest effects on 
proliferation, whereas corticosterone (B) and 11-dehydrocorticosterone (A) showed 
similar but less potent effects. As exemplified by DEX, repression of cardiac 
proliferation by glucocorticoids was dose dependent and was completely blocked by 
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co-administration of RU486 (Figure 3-14b). We next assessed the involvement of 
11β-HSD in mediating the repressive effects of ‘B’ and ‘A’ by co-administration of the 
11β-HSD inhibitor GE (Figure 3-14c). GE by itself had no effect on cFb proliferation 
(Figure 3-14c) whereas GE in the presence of ‘A’ but not ‘B’ blunted the repressive 
effects of glucocorticoids on proliferation suggesting that a functionally active 11β-
HSD1 enzyme is required for repression of cFb proliferation by the biologically 
inactive glucocorticoid 11-dehydrocorticosterone. 
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Figure 3-14 Glucocorticoids repress proliferation of cardiac 
fibroblasts (cFb). Proliferation was measured by incorporation of labeled 
thymidine. A Treatment of cFb for 24h with 100nM dexamethasone 
(DEX), corticosterone (B) and 11-dehydrocorticosterone (A) reduces 
thymidine uptake. B DEX dose dependently (1-100nM) reduces 
thymidine uptake in cFb. C Glycyrrhetinic acid (GE) blunts the effects of 
A but not B. Treatment effects vs control (CTRL) were compared by one 
way ANOVA; * p<0.05; ** p<0.01. 
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3.3.3 Expression studies in human left ventricular biopsies 
We also characterised expression of key components involved in steroid hormone 
signalling in human tissues including skeletal muscle, heart and liver. Expression 
levels of the GR in human left ventricular biopsies from transplant donors was similar 
to liver but about four fold lower compared to skeletal muscle (Figure 3-15a). By 
contrast, MR expression levels were similar in heart and skeletal muscle and 
significantly higher compared to liver (Figure 3-15b). Expression levels of 11β-HSD1 
were found to be 100 fold higher in human liver compared to both heart and skeletal 
muscle (Figure 3-15c). 
 
Figure 3-15 Relative expression levels of the glucocorticoid receptor 
(GR) (A), the mineralocorticoid receptor (MR) (B) and 11β-HSD1 (C) in 
left ventricular biopsies of transplant donor hearts (N=8), human 
quadriceps muscle (N=5) and liver (N=4) biopsies by quantitative 
realtime PCR. Tissue specific expression levels were compared by 
Kruskal-Wallis ANOVA. 
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We next assessed expression of GR, MR and 11β-HSD1 in cardiac hypertrophy. GR 
expression levels were about 50% higher in left ventricular biopsies from patients 
with marked hypertrophy (Figure 3-16a), whereas expression levels for MR were 
similar (Figure 3-16b). 11β-HSD1 showed a trend of decreased expression in 
hypertrophy compared to transplant donors but this was not statistically significant 
(Figure 3-16c).  
 
Figure 3-16 Relative expression levels of the glucocorticoid receptor 
(GR) (A), the mineralocorticoid receptor (MR) (B) and 11β-HSD1 (B) in 
left ventricular biopsies of transplant donor hearts (TD) (N=15) and 
hypertrophied hearts (N=19) by quantitative realtime PCR. Gene 
expression levels between TD and LVH patients were compared by the 
Mann-Whitney-U test. 
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Additionally, we assessed expression levels of collagen 1 and 3 and angiotensin 
converting enzyme 1 in left ventricular biopsies of patients with cardiac hypertrophy 
(LVH) with those non hypertrophied hearts from transplant donors (TD). Expression 
levels for collagen 1 and 3 and ACE-1 were significantly higher in LVH compared to 
TD hearts (Figure 3-17). 
 
Figure 3-17 Relative expression levels of the collagen I (Col1a1) (A), 
collagen IX (Col1a9) (B) and angiotensin converting enzyme 1 (ACE-1) 
(C) in left ventricular biopsies of transplant donor (TD) hearts (8) (N=8) 
and hypertrophied (LVH) hearts (N=7) by quantitative realtime PCR. 
Gene expression levels between TD and LVH patients were compared 
by the Mann-Whitney-U test. 
Given that ACE1 and GR were significantly up-regulated in LVH compared to TD and 
glucocorticoids up-regulated the ACE-1 gene in CM, we analysed if GR expression 
levels were associated with those of the ACE-1 gene. Correlation of ACE-1 and GR 
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in left ventricular biopsies from LVH samples showed a significant positive 
association (Figure 3-18) suggesting that glucocorticoid signalling via GR may 
contribute to cardiac hypertrophy via induction of the ACE-1 gene in humans.  
 
Figure 3-18 Correlations of angiotensin converting enzyme 1 (ACE1) 
and the glucocorticoid receptor (GR) in left ventricular biopsies of 
hypertrophied hearts (N=52) by quantitative realtime PCR. 
3.4 Discussion 
In this chapter we have characterised the expression and function of key components 
involved in glucocorticoid hormone action and glucocorticoid modulation by 11β-
HSD1 in isolated adult rat CM and cardiac MyoFb. 
To date, corticosteroid signalling has only been assessed in neonatal CM which are 
structurally, morphologically and functionally different from mature cells which are 
terminally differentiated cells and no longer have the ability to divide. Our study is the 
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first to address expression of key components involved in corticosteroid signaling and 
enzymatic activities of 11β-HSDs in isolated post-mitotic adult rat CM. In agreement 
with the findings by Sheppard et al from nrCM (Sheppard & Autelitano, 2002), we 
found expression of MR, GR and 11β-HSD type 1 but not type 2 in isolated rat CM. 
The absence of 11β-HSD2 suggests that the MR in CM, in contrast to classic Aldo 
target tissues, is not protected from glucocorticoids and is therefore a target for both 
mineralocorticoids and glucocorticoids given its similar affinities for both steroids. 
Relative expression levels of 11β-HSD1 were considerably lower in rodent hearts 
and isolated rat CM compared to liver tissue. However, despite its relatively low level 
of expression, 11β-HSD1 oxoreductase activity was readily present in isolated CM 
and murine cardiac explants. By contrast and consistent with the absence of 11β-
HSD2 mRNA expression, 11β-HSD dehydrogenase activity was very low. 
In addition to CM, we also assessed corticosteroid hormone action in cFb. 
Characterisation of primary cultures of cFb showed a pure cell population with no 
evidence for contamination with CM or endothelial cells. We found high expression 
levels of the MyoFb marker α-smooth muscle actin (α-SMA) suggesting that cFb had 
spontaneously differentiated into MyoFb in culture. MyoFb are the key cell type 
involved in cardiac remodeling and are the principal cells secreting ECM proteins 
including collagen I and III to stabilise the healing wound and form the infarct scar 
(described in section 1.8.4.2). Transformation of cFb into MyoFb in culture can be 
achieved by treatment with TGF-β1 (Leask, 2007) or, as previously reported by 
seeding fibroblasts at low density which results in spontaneous differentiation into 
MyoFb (Masur et al., 1996). Although activated MyoFb as opposed to resting cFb are 
key in the formation of the ECM in heart disease (Porter & Turner, 2009), so far 
steroid hormone action in MyoFb has not been characterised. 
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Cultured MyoFb readily expressed the GR and MR albeit at lower levels compared to 
the GR. Furthermore, MyoFb showed high expression levels of 11β-HSD1 whereas 
11β-HSD2 was absent. Comparison of 11β-HSD1 expression showed that its levels 
in MyoFb were much higher than in CM and even exceeded those of liver tissue 
which is known to highly express 11β-HSD1 (Tannin et al., 1991). Enzymatic studies 
reflected expression data and showed high oxoreductase but negligible 
dehydrogenase activity in keeping with previous reports investigating fibroblasts from 
other sources (Hardy et al., 2006; Onyimba et al., 2006). 
In human left ventricular biopsies, the relative expression patterns of the GR in 
relation to skeletal muscle and liver was different in man compared to mice. GR 
expression in human hearts was similar to liver tissue but skeletal muscle showed a 4 
fold higher expression level, whereas GR expression in mice was similar in the heart 
and skeletal muscle and approximately 3 fold higher compared to liver. With regard to 
MR, we found a similar pattern of expression in mice and man, while the relative 
abundance of 11β-HSD1 in heart compared to liver was much less in man (1-2%) 
compared to mice (10%). These expression studies suggest and confirm that there 
are no fundamental but relative differences in the expression level of GR, MR and 
11β-HSD1 between mice and man. 
11β-HSD1 is a bidirectional enzyme and its oxoreductase activity critically depends 
on the presence of the co-factor NADPH. H6PDH is an enzyme expressed in the 
endoplasmic reticulum which regenerates NADPH from NADP+ by converting 
glucose 6-phosphate to 6-phosphogluconolactonate. We have recently shown that 
the enzymatic activity of 11β-HSD1 in mice with a targeted deletion of the H6PDH 
changes from an oxoreductase to a dehydrogenase in liver microsomes (Lavery et 
al., 2006). Here we show that cardiac explants from H6PDH-/- mice exhibit a similar 
change, namely reversal of oxoreductase to dehydrogenase activity. Interestingly and 
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similar to mice with a deletion of the HSD11B1 gene (Kotelevtsev et al., 1997), 
H6PDH-/- mice do not exhibit any obvious structural or functional cardiac changes at 
rest (Lavery et al., 2006) but the role of 11β-HSD1 in the pathogenesis and 
modulation of heart disease so far has not been fully elucidated. A previous report 
suggests that 11β-HSD1 may play a modulatory role in ischaemic heart disease. In 
this animal model of MI, mice with a targeted deletion of the 11β-HSD1 gene (11β-
HSD1-/- mice) exhibited increased neovascularisation and improved cardiac function 
compared to WT mice (McSweeney et al., 2010; Small et al., 2005). Similarly, 
administration of the GR antagonist RU486 in this model also augmented 
angiogenesis following MI suggesting that not loss of 11β-HSD1 per se but reduced 
glucocorticoid levels, caused increased angiogenesis in this model (Small et al., 
2005). 
A number of studies have linked glucocorticoid hormone action with cardiac 
hypertrophy. In Cushing’s syndrome, a condition characterised by glucocorticoid 
excess, a high percentage of patients show left ventricular hypertrophy which 
however, in part may be secondary to concomitant high blood pressure (Muiesan et 
al., 2003; Muiesan et al., 2008). In neonatal rats (de Vries et al., 2002; La Mear et al., 
1997) and fetal sheep (Lumbers et al., 2005) glucocorticoids have been shown to 
induce cardiac hypertrophy. These findings are supported by in vitro studies, which 
show that DEX treatment of isolated nrCM increases markers of CM hypertrophy 
including protein content per cell and cell size (Whitehurst et al., 1999). This 
response is dependent on L-type Ca2+ channels as co-administration of the L-type 
specific antagonist nifedipine was able to block the effect. Lister and colleagues 
investigated expression and function of components involved in corticosteroid 
signalling in a model of pharmacologically induced hypertrophy in nrCM in vitro 
(Lister et al., 2006). Both phenylephrine and the protein kinase C activator PMA 
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induced expression of the atrial natriuretic peptide (ANP), a marker gene of 
hypertrophy. Similarly, expression levels of GR and MR increased by 2 fold following 
both treatments, whereas expression and activity of 11β-HSD1 was only induced 
following PMA but not phenylephrine treatment of CM (Lister et al., 2006). Ang II 
which is generated by ACE from Ang I, is critically involved in various aspects of 
cardiac remodelling in heart disease (Sun, 2009). In keeping with a modulatory role 
of local ACE1 expression in cardiac hypertrophy, ACE1 expression has been shown 
to be increased in experimental cardiac hypertrophy (Schunkert et al., 1990). 
Furthermore, overexpression of ACE1 in CM augments hypertrophy induced by 
pressure overload suggesting that up-regulation of ACE1 plays a causative rather 
than consequential role in the pathogenesis of cardiac hypertrophy (Tian et al., 
2004). Expression of ACE1 so far has not been assessed in cardiac hypertrophy in 
humans. For the first time, we found the ACE1 gene to be up-regulated in left 
ventricular biopsies from patients with cardiac hypertrophy secondary to aortic 
stenosis compared to normal hearts from transplant donors in keeping with the 
experimental data. 
ACE1 expression is modulated by corticosteroids. In nrCM it was previously shown 
that Aldo up-regulates ACE1 expression (Harada et al., 2001) and that 
glucocorticoids augment ACE activity (Barreto-Chaves et al., 2000). Our data confirm 
these previous findings and show dose dependent up-regulation of the ACE1 gene 
via GR in CM. 
Local glucocorticoid generation in CM can be modulated by 11β-HSD1 by activating 
11-dehydrocorticosterone to corticosterone thereby facilitating glucocorticoid 
hormone action. Mazancova et al have addressed 11β-HSD1 expression and activity 
in hearts from various rat strains including spontaneous hypertensive rats (SHR), 
WKY, Dahl salt-sensitive (DS) and Dahl salt-resistant (DR) rats (Mazancova et al., 
Chapter 3 Characterisation of Glucocorticoid Hormone Action in the Mammalian Heart 
  127 
2005). The main finding of their study was that expression levels and activity of 11β-
HSD1 considerably varied in different rat strains but did not change when DS rats 
were fed a high salt diet which induced high blood pressure, and as a consequence 
cardiac hypertrophy, suggesting that local glucocorticoid generation by 11β-HSD1 
does not contribute to cardiac hypertrophy. This notion is supported by our findings in 
human hearts which did not show a significant change in 11β-HSD1 expression in 
hypertrophied compared to transplant donor hearts. Therefore similar to rodents, 
11β-HSD1 does not seem to play a major role in cardiac hypertrophy in humans. 
However, a pathophysiological role for glucocorticoid hormone action in the 
regulation of the ACE1 gene in cardiac hypertrophy is endorsed by our findings in 
human left ventricular heart biopsies. Compared to transplant donors, patients with 
left ventricular hypertrophy showed increased GR and ACE1 expression underlining 
the implication of glucocorticoid hormone action and local Ang II production, 
respectively, in the pathophysiology of cardiac hypertrophy. The potential regulatory 
role of glucocorticoid action in the regulation of ACE1 is further underlined by the 
positive correlation of GR and ACE1 expression in hypertrophied hearts. However, a 
definitive answer to the involvement of GR mediated glucocorticoid hormone action in 
cardiac hypertrophy can only be expected from CM specific GR knock out mice which 
at the present time have not been reported. 
In addition we assessed the effects of glucocorticoids on the expression of VEGFa 
which has previously been shown to be down-regulated by glucocorticoids (Iwai et 
al., 2004; Machein et al., 1999). In CM, glucocorticoids repressed VEGFa expression 
via the GR which in case of 11-dehydrocorticosterone was dependent on 11β-HSD1 
bioactivity. It is therefore tempting to speculate that augmented angiogenesis in 11β-
HSD1-/- mice following MI (Small et al., 2005) might at least in part be explained by 
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an increased expression of the VEGFa gene as a result of reduced local 
glucocorticoid levels. 
11β-HSD1 expression and activity has previously been found to be up-regulated by 
glucocorticoids suggesting a potential feed-forward mechanism of action (Sai et al., 
2008; Sun & Myatt, 2003; Yang et al., 2009). In agreement with these studies we 
found a dose dependent up-regulation of 11β-HSD1 expression and activity mediated 
via the GR in MyoFb. Moreover, we assessed the effects of glucocorticoids and 11β-
HSD1 on MyoFb proliferation. Previous reports suggested that glucocorticoids and 
mineralocorticoids have opposing roles on fibroblast proliferation. While the effects of 
Aldo on fibroblast proliferation have been conflicting (Rombouts et al., 2001; 
Stockand & Meszaros, 2003), glucocorticoids have been shown to be potent 
inhibitors of fibroblasts proliferation (Durant et al., 1986) but so far this has not been 
assessed in cardiac MyoFb. We here show that glucocorticoids suppress MyoFb 
proliferation in a dose dependant manner. This effect is mediated via the GR and in 
the case of 11-dehydrocorticosterone is dependent on biologically active 11β-HSD1. 
Given the high expression levels of 11β-HSD1 in MyoFb we conclude that 11β-HSD1 
may be an important autocrine mechanism to facilitate and modulate glucocorticoid 
hormone action in MyoFb and thereby repress MyoFb proliferation. McSweeney and 
colleagues recently reported that 11β-HSD1 knock out mice following MI had thicker 
infarct scars and improved cardiac function compared to WT animals (McSweeney et 
al., 2010), which may be explained by increased proliferation of MyoFb in 11β-HSD1-
/-
 mice resulting from reduced cellular glucocorticoid levels. By contrast, systemic 
administration of glucocorticoids appears to delay healing in animal models of MI (El-
Helou et al., 2008; Shizukuda et al., 1991). In keeping with these findings, 
glucocorticoid treatment of patients with MI in the early post infarct period has been 
associated with an increased risk of rupture of the left ventricular free wall and thus, 
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systemic glucocorticoid treatment following MI should be avoided (Bulkley & Roberts, 
1974; Sholter & Armstrong, 2000). Given the high activity of 11β-HSD1 in MyoFb 
treatment with specific 11β-HSD1 inhibitors may provide a novel therapeutic way to 
improve cardiac remodelling following MI. These drugs are currently tested in 
patients with diabetes (Ge et al.) and the metabolic syndrome (Stewart & Tomlinson, 
2009) but may also prove beneficial in cardiovascular disease such as ischaemic 
heart disease (Hadoke et al., 2009). 
In summary, adult rat CM and MyoFb readily express corticosteroid hormone 
receptors and 11β-HSD type 1, whereas 11β-HSD type 2 is not expressed. 
Consistent with this expression pattern, CM and MyoFb almost exclusively exhibit 
11β-HSD oxoreductase but not dehydrogenase activity. Similar to other tissues, we 
found that 11β-HSD type 1 can facilitate glucocorticoid hormone action and thereby 
modulate target gene expression in CM and MyoFb and impact on proliferation of 
cFb. However, to date the modulatory role of 11β-HSD1 in the pathophysiology of 
heart disease and the potential therapeutic implications of 11β-HSD1 inhibitors in 
cardiovascular disease remain unclear. Importantly, complete absence of 11β-HSD 
type 2 in CM and fibroblasts leaves the MR unprotected from glucocorticoid binding 
and action raising the question of specificity. In an attempt to identify differentially 
regulated genes which may give further insights into corticosteroid hormone action in 
these cells we have performed a microarray screening experiment in CM (see 
Chapter 4). 
 
  
 
 
 
 
 
 
 
 
 
Chapter 4  - Identification of Differentially Regulated 
Genes by Gluco- and Mineralocorticoids in 
Cardiomyocytes 
 
Chapter 4  Differential Gene Regulation by Corticosteroids in Cardiomyocytes 
131 
4.1 Introduction 
Both glucocorticoid and mineralocorticoid excess confers cardiovascular injury but 
the differential effects of corticosteroids via their cognate receptors and the 
downstream effects on target gene regulation remain largely unknown. It is clear from 
experimental and clinical studies that only blockade of the MR (Brilla et al., 1993; Pitt 
et al., 2003a; Pitt et al., 1999) but not GR (Rickard et al., 2006; Rickard et al., 2007) 
is cardioprotective, suggesting that the MR plays a pivotal role in mediating adverse 
steroid effects. The MR exhibits similar affinities for Aldo and corticosterone 
(Edwards et al., 1988; Funder et al., 1988), which is explained by the high homology 
of the receptors (described in section 1.4.1) and structural similarities of 
corticosteroids (described in section 1.3.2). In classical mineralocorticoid target 
tissues, MR specificity for Aldo is ensured at a pre-receptor level by the enzyme 11β-
HSD2 which selectively inactivates corticosterone to 11-dehydrocorticosterone 
(described in section 1.7.2.2) leaving Aldo the principal MR ligand in classical MR 
target tissues. In non-classical tissues which do not express 11β-HSD2, however, 
both Aldo and corticosterone must be considered MR ligands which raises the 
question of ligand specificity. The ability of Aldo to induce cardiac fibrosis in animal 
models (described in section 1.9.2.1) and cardiac hypertrophy in primary 
hyperaldosteronism (described in section 1.9.1.1.1) independently of blood pressure, 
suggests that Aldo has direct cardiac effects, whereas the role for glucocorticoids is 
less clear. In an animal model of cardiac fibrosis, Young and colleagues recently 
reported overlapping effects of mineralocorticoids and glucocorticoids via MR (Young 
et al.). Molnar and colleagues studied the downstream effects of corticosterone via 
MR in vascular smooth muscle cells (VSMCs) which in contrast to CM express 11β-
HSD2. Nevertheless, corticosterone even at very low concentrations induced rapid 
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MR signalling involving the mitogen-activated protein kinase kinase/extracellular 
signal-regulated kinase-dependent pathway (Molnar et al., 2008). Mihailidou and 
colleagues recently studied the effects of corticosteroids in an ex vivo model of MI 
and found that cardiac damage is similarly aggravated by Aldo and cortisol via 
activation of MR (Mihailidou et al., 2009). Although these studies provide evidence 
that glucocorticoids may indeed induce similar effects via MR, the significance of 
these findings in the pathophysiology of heart diseases remains unclear. In contrast 
to these findings, a transgenic mouse model over-expressing 11β-HSD2 which 
results in artificial glucocorticoid inactivation at the pre-receptor level suggests that 
glucocorticoids may be cardioprotective (Qin et al., 2003). These mice develop 
severe heart failure and cardiac fibrosis and as a consequence die at a young age 
suggesting that loss of tonic MR blockade by glucocorticoids facilitates MR activation 
by Aldo which in turn triggers the detrimental phenotype observed in these mice. On 
aggregate, these data suggest, that signalling via MR is detrimental because 
blockade of the MR attenuates these effects whereas signalling via GR appears to be 
of minor importance. However, the role of glucocorticoid binding to the MR remains 
unclear. 
In an attempt to discover selective Aldo target genes, three studies employing whole 
genome microarrays and one study using a serial analysis of gene expression 
(SAGE) library have been conducted. Turchin et al, injected mice with a bolus of Aldo 
and gene expression in the heart was investigated at various time points (0.5, 1, 2, 3, 
4, 5 and 12h) to study temporal expression patterns of Aldo regulated target genes 
(Turchin et al., 2006). As expected, the authors observed a rapid rise of plasma Aldo 
levels following the injection but plasma levels of corticosterone exhibited a similar 
stress induced pattern as the animals were not adrenalectomised prior to Aldo 
injection, questioning the specificity of their findings. Fejes-Toth et al, chose a 
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different approach and investigated early changes in the transcriptome of H9C2 cells, 
which is a myoblast cell line derived from embryonic rat heart, after 2h in response to 
a physiological concentration of Aldo (1nM) (Fejes-Toth & Naray-Fejes-Toth, 2007). 
In this study 12 known genes and three expressed sequence tags (ESTs) were 
identified by microarray analysis to be regulated by Aldo of which 8 (tenascin-X, 
ADAMTS1, PAI-1, UPAR, hyaluronic acid synthase-2, RGS2, adrenomedullin and 
orosomucoid) were confirmed by subsequent RT-PCR studies. However, the 
physiological relevance of these findings must be questioned; H9C2 cells may be an 
artificial model as they have lost expression of the MR which had to be stably 
expressed in these cells prior to these studies. Finally, Muller et al studied the effects 
of high doses of Aldo (1µM) on the transcriptome nrCM employing a SAGE library 
(Muller et al., 2007). In this study, 101 genes were found to be regulated by Aldo 
after 4h. In their subsequent analysis, they focused on only one Aldo regulated gene, 
ecto-ADPribosyltransferase-3 (Art3), and showed by using neonatal CM isolated from 
MR and GR knock out mice that Art3 was solely regulated by Aldo via the GR but not 
the MR. The fact that the authors identified Art3 as an Aldo target gene being 
regulated via GR is not surprising as Aldo at very high concentrations is known to 
also bind and activate the GR. Therefore the implications of this study with regard to 
identification of Aldo target genes induced via the MR appear to be flawed by the 
experimental design. Thus, these approaches to elucidate novel Aldo regulated 
genes appear to be limited by methodological problems and hence, the relevance of 
these results must be questioned. Yoshikawa and colleagues studied differential 
gene regulation in nrCM following a three hour treatment of the highly selective GR 
agonist, cortivazol, as well as corticosterone and Aldo to define specificity of 
glucocorticoid hormone action via GR in CM (Yoshikawa et al., 2009). A high degree 
of overlap of the three steroids in gene regulation was found for up-regulated, but not 
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for down-regulated genes. Perhaps, not surprisingly, the authors found that 
glucocorticoids in comparison to Aldo were the major determinants of GR-mediated 
gene expression in this study. Unfortunately, subsequent analysis of microarray 
results focused on the specific effects of glucocorticoids via GR whereas regulation of 
Aldo target genes via MR was not further explored. 
In summary, these studies have not provided conclusive answers regarding 
differential downstream signalling of glucocorticoids as opposed to mineralocorticoids 
in CM. In an attempt to do so, we studied gene regulation in adult rat CM using the 
steroids Aldo, corticosterone and DEX and studied differential gene regulation in CM 
in the presence or absence of the selective GR and MR antagonists RU486 and 
RU28318, respectively. 
4.2 Materials and Methods 
4.2.1 Experimental set up 
The experimental set up to study differentially regulated genes is shown in Figure 
4-1. Untreated cells (panel A) and the specific GR (panel B) and MR (panel C) 
antagonist served as controls. To study genes that are regulated via GR the GR 
agonist DEX was chosen (panel D) and GR specificity was ensured by co-treatment 
of DEX with the GR antagonist RU486 (panel E). To study gene regulation via MR, 
the MR agonist Aldo was chosen (panel F) and specificity was ensured by co-
treatment of Aldo with the MR antagonist RU28318 (panel G). In order to study 
differential effects of corticosterone (B) via GR and MR, CM were treated with 
corticosterone only (panel H), with corticosterone in the presence RU486 to identify 
genes regulated by corticosterone via MR (panel I) or corticosterone in the presence 
of RU28318 to identify genes regulated by corticosterone via GR (panel J). 
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Figure 4-1 Schematic overview of treatments to study differential 
gene regulation in cardiomyocytes employing microarray technology. 
Panels A-C: Controls; panels D-G: gene regulation by dexamethasone 
(DEX) ± RU486 and aldosterone (Aldo) ± RU28318; panels H-J: 
differential signalling of corticosterone (B) via MR and GR. 
Isolated CM from one rat heart were split and subjected to the 10 different treatments 
(Figure 4-1). The experiment was repeated three times (biological replicates). 
4.2.2 Isolation and culture of cardiomyocytes 
For CM isolation male Sprague-Daley with a body weight of 250 to 300g were used. 
Rats were fed regular chow with no restrictions to food or water intake. CM were 
freshly isolated from rat hearts as described in section 2.1.1.1. CM were counted in a 
haemocytometer and approximately 200,000 rod shaped CM per well were incubated 
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in CM culture media in the presence of 10% FCS in 6-well plates for 1h to let CM 
attach and adhere to the culture plate (Corning, Surrey, UK). Non-adherent CM were 
aspirated and the adherent CM were washed once with M199 media and 
subsequently incubated in 1.5 ml / well CM culture media. 
4.2.3 Treatment of rat cardiomyocytes 
Before treatment of rat CM, steroids and antagonists were diluted from 10mM stock 
solutions. Steroids (DEX, Aldo and corticosterone (B)) were first diluted in CM culture 
media 1:1000 to yield a concentration of 10µM of which 15µl were added per well to 
yield a final concentration of 100nM. Antagonists (RU486, RU28318) were initially 
diluted 1:10 to yield a concentration of 1µM of which 15µl were added per well to 
yield a final concentration of 10µM. Ethanol traces from stock solutions were 
compensated by addition of 15µl of 1:10 diluted ethanol to all treatments with no 
antagonists. 
4.2.4 RNA isolation, labelling and hybridisation 
RNA of CM in culture was performed as described in section 2.1.5. Quality and purity 
of RNA was assessed on a Bioanalyser-2100 (Agilent, Birkshire, UK) and a 
Nanodrop (ND-1000) spectrophotometer (Thermo Scientific, Cheshire, UK). RNA 
integrity numbers (RIN) were above 8 for all samples, the OD260/280 indicating protein 
contamination was above 1.8 and the OD260/230 indicating solvent contamination was 
found to be between 1.5 and 2.5 suggesting intact and pure RNA. 
4.2.4.1 Preparation of one-color Spike mix 
In order to compare microarray results from different slides an internal standard was 
added to the RNA sample prior to the reverse transcription and labeling reaction. The 
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stock solution of the one-color Spike-Mix was diluted 1:5000 with the supplied dilution 
buffer and 3µl were added to 7.3µl of the RNA sample and 1.2µl T7 promoter, 
incubated at 65ºC for 10 min and then placed on ice for 5 min. 
4.2.4.2 cDNA synthesis 
For cDNA synthesis 4µl [5x] first strand buffer, 2µl [0.1M] dithiothreitol (DTT), 1µl 
[10mM] dNTP, 1µl MMLV-RT and 0.5µl RNase inhibitor were added to each RNA 
sample from step 4.2.4.1 and incubated at 40ºC for 2h. Subsequently the samples 
were incubated at 65ºC for 15min to inactivate the reverse transcriptase. 
4.2.4.3 cRNA synthesis 
For synthesis of labeled cRNA 15.3µl nuclease free water, 20µl [4x] transcription 
buffer, 6µl [0.1M] DTT, 8µl NTP mix, 6.4µl [50%] polyethylenglycol (PEG), 0.5µl 
RNase inhibitor, 0.6µl inorganic pyrophosphate, 0.8µl T7 RNA polymerase and 2.4µl 
Cyanine 3-CTP were added to the cDNA from step 4.2.4.2 and incubated at 40ºC for 
2h 
4.2.4.4 cRNA purification 
The labeled cRNA was purified using the Qiagen RNeasy Mini kit according the 
manufacturer’s manual. In brief, 20µl of ddH20, 350µl RLT buffer, 250µl 70% ethanol 
were added to the cRNA, transferred to a Qiagen RNA column and centrifuged for 30 
seconds at 13,000 rpm in order to bind the RNA to the matrix of the column. The 
cRNA was then washed twice with 500µl RPE buffer and eluted with 30µl ddH20 at 
13,000 rpm for 1 minute. 
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4.2.4.5 Quantification of cRNA concentration and specific activity 
The concentration of the purified cRNA and incorporation of Cyanine 3 (Cy3) was 
measured using a NanoDrop ND-1000 UV-VIS spectrophotometer. The total amount 
of labeled cRNA and the specific activity of the cRNA probe were calculated 
according to the following formulas: 
 
cRNA yield = cRNA [µg/µl] * total volume [µl] 
Specific activity [pmol/µg] = Cy3 concentration [pmol/µl] / concentration of cRNA 
[µg/µl] 
 
The labeling reaction resulted in sufficient amounts of cRNA (total amount > 1.65µg) 
required for microarray hybridisation. The specific labeling activities indicating 
incorporation of Cy3 into the cRNA ranged between 12 and 18 pmol/µg for all 30 
samples, well above the minimum activity recommended by the manufacturer (9 pmol 
Cy3/µg cRNA). 
4.2.4.6 Hybridisation of labeled cRNA with microarrays 
Prior to hybridisation of the cRNA probes to the microarrays, 1.65µg of cRNA was 
fragmented by adding 11µl [10x] blocking agent and 2.2 µl [25x] fragmentation buffer 
in a total volume of 55µl at 60ºC for exactly 30min. The fragmentation reaction was 
stopped by adding 55µl [2x] GE hybridisation buffer. The samples were centrifuged 
for 1 min at 13,000 rpm and kept on ice until loading. Following fragmentation 55µl of 
ddH20 was added to the cRNA. 
For hybridisation of microarrays, 100µl of the cRNA containing hybridisation solution 
was applied onto gasket slides. Microarray slides were then carefully laid on top of 
the gasket slides so that the hybridisation solution was held within the rubber wall of 
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the gasket slide. The sandwich-pairs were then fitted into hybridisation chambers and 
incubated in a hybridisation oven for 17h at 65ºC rotating at 10 rpm. 
The following day the hybridisation chamber was disassembled, the slides removed 
and the microarray slides were dismantled from the gasket slides submerged in wash 
buffer #1. Subsequently the microarray slides were washed for 60 seconds in wash 
buffer #1 at RT and then transferred and incubated for 60 seconds in wash buffer #2 
at RT and another 60 seconds in the same buffer pre-warmed to 37ºC. Following the 
second wash, the microarray slides were dried at RT and scanned. 
4.2.4.7 Scanning of microarrays and feature extraction 
The microarray slides were placed in a slide holder and fitted into the carousel of an 
Agilent High-Resolution Microarray Scanner (Thermo Scientific, Cheshire, UK) and 
scanned at a resolution of 5µm. The scanned image was then processed using the 
Agilent feature extraction (FE) software (Version 9.5.3). The FE software translates 
the intensity of fluorescence of every individual gene spot into a number representing 
the expression level and allocates this intensity to the corresponding probe name. 
4.2.5 Normalisation of expression data and quality assessment 
Assessment and analysis of microarray data was done employing the software “R: A 
language and environment for statistical computing” (http://www.r-project.org/) using 
packages from Bioconductor, open source software for bioinformatics. 
(http://www.bioconductor.org/). Of all 30 microarrays, 29 showed a very similar 
density spectrum (Figure 4-2a). For unknown reasons, one array (treatment: 
Aldo+RU28318) showed a very different density spectrum from all other 29 arrays 
and was therefore excluded from all subsequent analysis. The remaining 29 arrays 
were then normalised using quantile normalisation which is based on the magnitude 
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(quantiles) of measures in order to achieve the highest degree of comparability 
between microarrays. Density plots following quantile normalisation are depicted in 
Figure 4-2b which shows a perfect fit of all 29 individual density plots. 
 
Figure 4-2 Density plots of scanned microarrays before A and after 
B quantile normalisation. Each line represents the distribution of 
features (x-axis: expression strength, y-axis: relative quantity) of one 
microarray. One array showed a considerably different density 
spectrum and was excluded from all subsequent analysis. 
In a typical microarray experiment, it becomes impossible to make a visual inspection 
of the relationship between genes or conditions in such a multi-dimensional matrix. 
Therefore the expression states are defined by a core set of independent features 
that allow direct comparison. Principal components analysis (PCA) is a statistical 
technique for determining the key variables in a multidimensional data set that 
explains the differences in the observations. To achieve a graphical visualisation, 
PCA reduces data dimensionality by performing a covariance analysis between 
factors. The variance accounted for by each of the components is its associated 
eigenvalue which is the variance of a component over all genes. Consequently, the 
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eigenvectors with large eigenvalues are the ones that contain most of the information 
whereas eigenvectors with small eigenvalues are uninformative. The principal 
component 1 (PC1) individuates the direction along the greatest variation. PC2 the 
direction with maximum variation left in data orthogonal to the direction (i.e. vector) of 
PC1, PC3 the direction with maximum variation left in data orthogonal to the plane of 
PC1 and PC3 (rarely used), and so on to the component PCn.  
Figure 4-3a shows PCA eigenvalues of the present study. The first component 
exhibits the largest eigenvalue that indentifies the main direction of the data variance. 
Other eigenvalues are modest (the second one) or negligible. Figure 4-3b shows the 
data set of all microarrays, each represented by a box, projected onto the plane 
individuated by the axis of PC1 (horizontal) and PC2 (vertical). Microarray distribution 
did not appear widespread or clustered indicating similar global features among 
microarray hybridisations. 
 
Figure 4-3 Principal component analysis of the study dataset. A plot 
of the eigenvalues; iteratively, the direction with largest variance is 
selected as the ith principal component (orthogonality constraint). B 
Projection of microarray samples 
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Associations of treatment effects were visualised using the correspondence analysis 
(CA). Like PCA, CA reveals the principal axes of this high-dimensional space, 
enabling projection into a subspace of low dimensionality that accounts for the main 
variance in the data. Unlike PCA, CA is able to account for the genes in a 
hybridisation-dimensional space and the hybridisations in a gene-dimensional space 
at the same time (biplots). CA attempts to separate dissimilar objects (genes or 
sample hybridisations) from each other; similar objects are clustered together 
resulting in small distances. In contrast, the distance between a gene and a sample 
hybridisation cannot be directly interpreted. 
In CA, points are depicted such that the sum of the distances of the points to their 
centroid (called ‘‘total inertia’’) is proportional to the value of the χ2 statistic of the 
microarray data. For a positive association like up-regulation of a gene in a particular 
condition, the two points will lie on the same side of the centroid, with the larger the 
distance to the centroid, the stronger the association. A negative association like 
down-regulation will cause the sample-point and the gene-point to lie on opposite 
sides of the centroid. Figure 4-4 shows a projection of microarray samples. Along the 
y-axis clustering of the three CM preparations can be observed, whereas clustering 
of treatments are observed along the x-axis. 
Analysis of microarray data by CA shows some details masked in PCA. The 
moderately widespread clusters of DEX and B shows the highest distances from the 
origin of the centroid, indicating relative strong associations and low affinity with the 
others samples. On the contrary the other samples show affinities independently from 
the treatment resulting in three main grouped sets in which they are relatively close to 
each other (Figure 4-4). 
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Statistical analysis to select differentially expressed genes was performed using the 
“limma“ (Linear Models for Microarray Analysis) package. The core of the limma 
package is an implementation of the empirical Bayes linear modeling approach of 
Smyth (Smyth, 2004) and can be used for stable analysis even for smaller sample 
sizes. 
 
Figure 4-4 Correspondence analysis of microarrays. Microarray 
samples are projected into a 2 dimensional space and show clustering 
along the x-axis according to treatment and along the y-axis according 
to cardiac preparations. 
4.2.6 Visual analysis of treatment effects by MA plots 
Following normalisation and quality assessment mean gene expression strength for 
each feature was calculated from the three biological replicates. Treatment effects in 
comparison to untreated cells (control) were assessed graphically by MA plots using 
R software (Figure 4-5 and Figure 4-6). Each dot represents one feature. The 
distance from the X-axis reflects the logarithm of the fold change of the respective 
feature in comparison to untreated cells (control) and the distance from the y-axis 
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reflects its expression strength. The dot colour indicates significance (red and green 
dots represent significantly up- and down-regulated features; blue colour indicates 
non significant regulation). Figure 4-5 shows DEX and Aldo effects on gene 
regulation in the presence or absence of specific antagonists. Visual analysis of MA 
plots suggest that both DEX and Aldo treatment results in many significantly up- and 
down-regulated genes which is greatly diminished in the presence of the respective 
steroid hormone receptor antagonist suggesting by and large specific up-regulation 
of DEX genes via GR and Aldo genes via MR. 
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Figure 4-5 MA plots of dexamethasone (DEX) and aldosterone 
(Aldo) regulated genes. A DEX regulated genes. B DEX regulated 
genes in the presence of RU486. C Aldo regulated genes. D Aldo 
regulated genes in the presence of RU28318. Average expression 
strength (mean of three microarray experiments) is depicted on the x-
axis and Log (fold change) in comparison to control (CTRL) on the y-
axis. Significantly up-regulated genes are depicted in red, significantly 
down-regulated genes in green and non-significantly regulated genes in 
blue colour. 
A similar analysis was down for corticosterone treatments in the presence or absence 
of the GR antagonist RU486 and MR antagonist RU28318 (Figure 4-6). Visual 
analysis suggests that blockade of steroid hormone receptors greatly diminishes the 
magnitude of gene regulation suggesting that GR and MR are not redundant and 
both required for a full biological effect of corticosterone. 
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Figure 4-6 MA plots of corticosterone (B) regulated genes. A B 
regulated genes in the absence of antagonists. B B-regulated genes in 
the presence of RU28318. C B-regulated genes in the presence of 
RU486. 
4.3 Results 
For simplification purposes, the term gene instead of features will be used although 
strictly speaking this is incorrect because some genes are represented by multiple 
features on every microarray. Gene regulation (up or down) was defined if gene 
expression in response to treatment was significantly (p<0.05) increased or 
decreased by at least 2 fold compared to control. These genes are referred to as 
‘regulated genes’. Venn diagrams were chosen to depict differential expression 
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patterns of genes. Non overlapping parts of circles indicate the number of genes that 
were exclusively regulated by one but not any other treatment and are referred to as 
‘selective genes’. Because some of these selective genes were also significantly 
regulated (p<0.05) yet to a lesser degree (2.0 < FC < 1.5) by one or both of the other 
treatments and hence did not fulfil the criteria of a selectively regulated gene, we 
subtracted these genes from the number of selective genes and thereby calculated 
the number of ‘highly selective genes’ which may be a better reflection of true 
differential regulation. The total number of these highly selective genes is shown in 
brackets behind the total number of selective genes in the Venn diagrams. 
4.3.1 Differential gene regulation by corticosterone via the 
glucocorticoid and mineralocorticoid receptor 
We first studied if gene regulation was receptor dependent by analysing the 
transcriptomes induced by corticosterone via GR (B/GR), MR (B/MR) or both 
receptors (B/GR+MR) employing the specific steroid hormone receptor antagonists 
RU28318, RU486 (Figure 4-7). Comparison of corticosterone regulated genes in the 
absence of antagonists with regulated genes after blocking the GR or MR with 
RU486 or RU28318, respectively, showed a great reduction of the total number of 
up-regulated genes (B only: 328; B+RU486: 75; B+RU28318: 115) and down-
regulated genes (B only: 215; B+RU486: 53; B+RU28318: 86), suggesting that both 
receptors are required for a maximal effect on transcriptional regulation. Moreover, 
we found only a small subset of genes to be selectively up- or down-regulated in the 
presence of RU486 (up: 15; down: 10) or RU28318 (up: 2; down: 12). When applying 
the criteria of highly selective genes only 3 and 2 genes were up-regulated and 0 and 
4 genes were down-regulated in the presence of RU486 reflecting B/MR signalling or 
in the presence of RU28318 reflecting B/GR signalling, respectively. These data 
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suggest that signalling of corticosterone via GR or MR does not result in a differential 
transcriptome. 
 
Figure 4-7 Venn diagram of corticosterone (B), B+RU486 and 
B+RU28318 regulated genes (fold change (FC)>2, p<0.05) 
(concentration: B 100nM; RU486, RU28318 10µM). A Up-regulated 
genes: B: 328, B+RU486: 75 and B+RU28318: 115; selectively up-
regulated genes by B: 210, B+RU486: 15 and B+RU28318: 2 (in 
brackets: number of highly selective genes (see text)). B Down-
regulated genes: B: 215, B+RU486: 53 and B+RU28318: 86; selectively 
up-regulated genes by B: 134, B+RU486: 10 and B+RU28318: 12. 
4.3.2 Differential gene regulation by aldosterone compared to 
corticosterone via the mineralocorticoid receptor 
We next assessed ligand specificity at the MR by comparing the transcriptomes 
induced by Aldo via MR (Aldo/MR) with that of corticosterone via MR (B/MR), which 
was  achieved by blocking corticosterone signalling via GR employing RU486 (Figure 
4-8). Both treatments resulted in a significant overlap of regulated genes which was 
more pronounced for down-regulated genes (21 of 37 Aldo and 53 B+RU486 
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regulated genes) than for up-regulated genes (30 of 124 Aldo and 76 B+RU486 
regulated genes). Nevertheless, 94 and 46 genes were selectively up-regulated and 
16 and 31 were selectively down-regulated by Aldo/MR and B/MR, respectively. 
These results suggest that signalling of Aldo and corticosterone via MR results in a 
common as well as a differential transcriptome suggesting that interaction of Aldo 
and corticosterone with the MR induces a ligand specific transcriptome via the MR. 
 
Figure 4-8 Venn diagram of aldosterone (Aldo) and 
corticosterone+RU486 (B+RU486) regulated genes (fold change 
(FC)>2, p<0.05). (concentration: A, B 100nM; RU486 10µM). A Up-
regulated genes: Aldo: 124, B+RU486: 76; selectively up-regulated 
genes by Aldo: 94, B+RU486: 46 (in brackets: number of highly 
selective genes (see text)). B Down-regulated genes: Aldo: 37, 
B+RU486: 53; selectively up-regulated genes by Aldo: 16, B+RU486: 
53. 
4.3.3 Differential gene expression by DEX, Aldo and B 
To address receptor specific gene regulation via GR, MR or both receptors we 
treated CM with the GR agonist DEX, the MR agonist Aldo or corticosterone, 
respectively (Figure 4-9). The total number of up- and down- regulated genes was 
highest for DEX (up: N=503; down: N=554), followed by B (up: N=328; down: N=215) 
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(124)
B+RU486
(76)
Up-regulated genes [FC>2; p<0.05] Down-regulated genes [FC>2; p<0.05]
Aldo
(37)
B+RU486
(53)
16 (10) 21 31 (11)94 (58) 30 46 (32)
A B
Chapter 4  Differential Gene Regulation by Corticosteroids in Cardiomyocytes 
150 
whereas Aldo showed the smallest response (up: N=124; down: N=37), suggesting, 
firstly, that DEX is a more potent GR agonist than B and, secondly, that GR activation 
by DEX induces a stronger response than MR activation by Aldo. There was a high 
degree of genes regulated by all three treatments (up: 97; down: 27) suggesting a 
high degree of redundancy for the different ligands interacting with GR and/or MR. In 
addition, all three treatments also induced a subset of genes that were not regulated 
by any of the other treatments. However, the number of highly selectively regulated 
genes was considerably smaller compared to the number of selective genes (DEX: 
up: 235 vs 61; down: 356 vs 90; B: up: 66 vs 37; down: 20 vs 9; Aldo: up: 17 vs 12; 
down: 1 vs 1) suggesting that only a subset from these genes were truly differentially 
regulated. In contrast to DEX and B, the total number of highly selective Aldo genes 
was similar to that of selective Aldo genes (up: 17 vs 12; down: 1 vs 1). Treatment 
with DEX and B resulted in a huge overlap of regulated genes (up: N=260 (163+97); 
down: N=192 (165+27)). With regard to Aldo, a high percentage of genes was also 
regulated by either DEX and/or B, hence, the number of selectively regulated genes 
(up: 17, down: 1) by Aldo in relation to the total number of Aldo regulated genes (up: 
N=124, down: 37) was small. 
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Figure 4-9 Venn diagram of dexamethasone (DEX), aldosterone 
(Aldo) and corticosterone (B) regulated genes (fold change (FC>2, 
p<0.05) (DEX, Aldo, B concentration: 100nM). A Up-regulated genes (in 
brackets total number of features): DEX: 503, Aldo: 124, B: 328; 
selective up-regulated genes by DEX: 235, Aldo: 17 and B: 66 (in 
brackets are shown the number of highly selective regulated genes 
(see text)). B Number of down-regulated genes: DEX: 554, Aldo: 37 
and B: 215 and selectively down-regulated genes: DEX: 356, Aldo: 1 
and B: 20. 
Table 4-1 shows a list of genes selectively up- and down-regulated by Aldo but not 
corticosterone using the fold change cut-off of 2. Regulation by DEX was not an 
exclusion criteria because these genes may be relevant to physiology given the 
synthetic nature of DEX. Out of the total 25 (17 Aldo, 8 DEX+Aldo genes) up- and 7 
(1 Aldo, 6 Aldo+DEX genes) down-regulated genes by Aldo (Figure 4-9), 6 (up) and 1 
(down) probes bound to intronic gene regions, 7 (up) probes bound to sequences in 
the rat genome that did not belong to genes, 1 (down) probe did not match any 
sequence in the rat genome and 2 (up) and 2 (down) probes were not blocked by 
RU28318 and are not shown in Table 4-1. 
DEX
(503)
B
(328)
Aldo
(124)
Up-regulated genes [FC>2; p<0.05]
DEX
(554)
B
(215)
Aldo
(37)
356 (90)
27
165 3
20 (9)
6 1 (1)
Down-regulated genes [FC>2; p<0.05]
A B
235 (61)
97
163 2
66 (37)
8 17 (12)
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Table 4-1 List of up- and down-regulated genes by aldosterone (FC≥2). 
Aldo Aldo/ RU28318 B Expr Gene Symbol Gene Name FC P FC P FC p 
10.4 0.029 -1.2 0.902 -1.0 0.996 5.0 LPAR4 Lysophosphatidic acid receptor 4 
9.6 0.027 -1.0 0.969 -1.0 0.980 4.8 Fbxo48 F-box protein 48  
7.9 0.047 -1.3 0.825 -1.2 0.868 5.4 OLR760 Olfactory receptor 760 
5.6 0.002 2.5 0.117 2.6 0.068 7.3 Rps26 ribosomal protein S26 
3.1 0.021 1.0 0.951 1.0 0.974 4.9 DUSP8 Dual specificity phosphatase 8 
2.6 0.027 1.1 0.866 1.0 0.923 10.5 VPS4A 
Vacular protein sorting 4, yeast, 
homolog of, A 
2.5 0.029 1.0 0.986 1.0 0.941 9.2 PURA Purine-rich element-binding protein A 
2.3 0.000 1.0 0.863 -1.2 0.234 8.1 Usp25 Ubiquitin specific peptidase 25 
2.2 0.000 1.3 0.083 1.2 0.119 7.3 Pnn Pinin 
2.1 0.041 1.8 0.138 1.7 0.132 7.4 Unknown Hypothetical LOC503134  
-2.0 0.000 1.0 0.806 -1.4 0.000 10.6 Fst Follistatin 
FC=fold change, p=level of significance. Expr: expression strength. 
To allow detection of less strongly regulated yet potentially more pathophysiologicaly 
relevant genes we lowered the fold change cut-off for regulated genes from 2 to 1.4 
fold. The lower and less stringent cut-off of 1.4 fold was chosen arbitrarily and was 
based on the assumption that a change in gene expression in response to treatment 
of 1.4 fold may still be of biological relevance. Table 4-2 shows a selection of genes 
that were significantly up- or down-regulated by Aldo (FC≥1.4) but not corticosterone 
(p>0.05), blocked by co-administration of the MR antagonist RU28318 and are likely 
to be of biological relevance after careful review of the literature. 
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Table 4-2 List of up- and down-regulated genes by aldosterone (FC≥1.4). 
Aldo Aldo/ RU28318 B Expr Gene Symbol Gene Name FC P FC P FC p 
1.5 0.014 1.0 0.895 1.0 0.966 4.7 AQP4 Aquaporin 4 
1.4 0.001 -1.1 0.204 1.0 0.754 9.6 STIM1 Stromal interaction molecule 1 
1.4 0.001 -1.0 0.835 1.1 0.333 11.4 SIK1 Salt-inducible kinase 1 
1.4 0.005 1.1 0.269 1.2 0.120 10.9 RAB1 RAB1, member RAS oncogene family 
1.4 0.016 -1.0 0.845 1.1 0.319 11.0 SPEC1 Small protein effector of Cdc42 
-1.4 0.014 1.1 0.340 1.1 0.631 8.8 CDKN1C Cyclin-dependent kinase inhibitor 1C 
-1.4 0.000 -1.1 0.433 -1.2 0.078 13.8 PHB Prohibitin 
-1.4 0.050 -1.0 0.879 -1.1 0.709 9.3 ZFHX3 Zinc finger homeobox 3 
-1.5 0.004 1.2 0.208 1.1 0.343 7.6 SPEG The striated preferentially 
expressed gene 
-1.8 0.009 -1.0 0.930 -1.2 0.313 8.9 TBC1D20 TBC1 domain family, member 20 
FC=fold change, p=level of significance. Expr: expression strength; AU: arbitrary 
units. 
4.4 Discussion 
Here we studied differential gene regulation by corticosteroids in primary cultures of 
isolated adult rat CM employing microarray technology in an attempt to shed light on 
differential effects of corticosterone and Aldo signalling via GR and MR and thereby 
identified several genes selectively regulated by Aldo via the MR. 
DEX, Aldo and corticosterone revealed a great overlap in their gene expression 
patterns consistent with a high degree of redundancy in corticosteroid hormone 
action. DEX exhibited the greatest effect on gene regulation indicated by the number 
of up- and down-regulated genes, followed by corticosterone and Aldo. This finding is 
consistent with the findings by Yoshikawa and colleagues who found in a similar 
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experimental set up that overall gene regulation via GR compared to MR was 
stronger (Yoshikawa et al., 2009). 
Our results indicate that corticosteroid hormone signalling is ligand rather than 
receptor dependent. We found that gene regulation by corticosterone via GR or MR 
does not induce a differential transcriptome, indicating receptor redundancy in the 
context of corticosterone signalling. Presence of GR and MR resulted in the greatest 
transcriptional response (number of regulated genes), whereas the blockade of either 
receptor greatly reduced the total number of regulated genes, suggesting that GR 
and MR act synergistically and are both required for a maximal effect on gene 
regulation. This observation is likely to be attributable to formation of GR-MR 
heterodimers following binding of corticosterone. Previous studies have shown that 
interaction of GR and MR does occur both in vitro and in vivo (Liu et al., 1995; Savory 
et al., 2001; Trapp et al., 1994). Our findings are in good agreement with the study by 
Trapp et al who found an augmented transcriptional response of glucocorticoid target 
genes by GR-MR heterodimers compared to GR homodimers (Trapp et al., 1994). 
However by contrast, Liu et al reported attenuation of gene regulation by GR-MR 
heterodimers compared to GR homodimers (Liu et al., 1995). The conflicting results 
of these two studies are most likely related to the different gene context. Our results 
indicate firstly, that gene regulation by corticosterone via GR or MR is not 
fundamentally different and secondly suggest, that formation of GR-MR heterodimers 
occurs in CM and is required for a maximal effect. The biological meaning of these 
findings remains unclear at the present time. But CM specific GR and MR knock out 
mice may provide models to clarify this question in the future. 
We next addressed if gene regulation via MR was ligand-dependent by comparing 
the transcriptomes induced by Aldo via MR (Aldo/MR) with that of corticosterone via 
MR (B/MR). As expected, there was a considerable overlap in the transcriptomes 
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induced by both ligands. However, we also identified a subset of genes that were 
only regulated by one or the other ligand, indicating that gene regulation of 
corticosteroids in CM, at least in part is ligand-dependent. The differential 
transcriptome induced by Aldo and corticosterone via MR raises the question of the 
underlying molecular mechanisms. In contrast to the kidney, CM do not express 11β-
HSD2 (see Chapter 3) thus pre-receptor metabolism cannot be accounted for the 
effects observed in our study. At the receptor level, ligand binding to the MR may 
induce differential conformational changes of the receptor that may be different for 
Aldo and corticosterone. Aldo dissociates more slowly from the MR and induces 
greater transactivation than cortisol (Farman & Rafestin-Oblin, 2001; Lombes et al., 
1994). Moreover, the interaction between the MR N-terminal domain and the C-
terminal hinge and ligand binding domain (or the N/C–interaction), which stabilises 
the ligand-receptor complex (Centenera et al., 2008; Li et al., 2006) is much stronger 
in the presence of Aldo than cortisol, offering another mechanism of ligand specificity 
(Rogerson & Fuller, 2003). Furthermore, at the post-receptor level, an expanding 
library of nuclear receptor co-regulators has been identified (Lonard & O'Malley B, 
2007). These co-regulators play a central role in modulating gene expression and are 
thought to confer ligand- and tissue-specificity due to their structural and functional 
diversity and tissue specific expression patterns, respectively (described in section 
1.4.2). To date, interaction with the MR has only been demonstrated for 11 co-
activator and 5 co-repressor proteins (Yang & Young, 2009). From these co-
regulators only one, the subunit C of the nuclear transcription factor Y (NF-YC), has 
been shown to repress MR dependent gene transcription in an Aldo-specific fashion 
as co-repression by cortisol was not detected (Murai-Takeda et al.). In conclusion, 
ligand specificity in the absence of 11β-HSD2 can be explained by molecular 
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mechanisms at the receptor and post-receptor level which to date remain 
incompletely understood. 
We next analysed the Aldo specific transcriptome with the aim to identify selective 
Aldo target genes that may provide molecular insights into the adverse effects of Aldo 
in cardiac remodelling. Applying the fold change cut-off of 2 for regulated genes we 
detected a small number of genes to be specifically regulated by Aldo. However, after 
careful review of the literature only the purine rich element binding protein α (PURA) 
and the lipoprotein a receptor type 4 (LPAR4) appeared to be candidate genes of 
pathophysiological relevance with regard to Aldo action. 
We found PURA to be selectively up-regulated by Aldo. PURA has previously been 
reported to bind to the purine-rich negative regulatory (PNR) element located in the 
first intron of the α-myosin heavy chain (α-MHC) gene (Gupta et al., 1998) and 
thereby represses α-MHC transcription and translation (Gupta et al., 2003). Down-
regulation of α-MHC and concomitant up-regulation of the β-MHC gene is a key 
feature of heart failure pathology, which may be modulated by Aldo via up-regulation 
of PURA in failing hearts. 
We also found the lysophosphatidic acid receptor 4 (LPAR4) to be selectively up-
regulated by Aldo. Lysophosphatidic acid (LPA) is a natural lipid with a broad range 
of cellular actions (Choi et al.). In the CVS LPA is involved in angiogenesis and in the 
pathogenesis of atherosclerosis. Treatment of CM with LPA has been shown to 
induce a hypertrophic response in vitro (Hilal-Dandan et al., 2004). Therefore, 
augmented LPA signalling induced by up-regulation of LPAR4 by Aldo may 
participate in cardiac hypertrophy and remodelling. 
In an attempt to identify Aldo target genes which may be less strongly regulated yet 
potentially more relevant to Aldo pathophysiology we lowered the fold change cut-off 
for regulated genes from 2 to 1.4 and thereby identified candidate genes which are 
Chapter 4  Differential Gene Regulation by Corticosteroids in Cardiomyocytes 
157 
likely to play a role in Aldo pathophysiology. Aldo induces cardiac hypertrophy in vitro 
and in vivo (described in section 1.9.3.5.2). In our microarray study, we found several 
genes that have previously been linked to cardiac hypertrophy to be selectively 
regulated by Aldo but not corticosterone including RAB1, the stromal interaction 
molecule 1 (STIM1), the small protein effector of Cdc42 (SPEC1) and the striated 
preferentially expressed gene (SPEG). 
RABs are guanosine triphosphatases (GTPases) that belong to the Ras-related small 
GTPases super-family. Rab1 is localised in the ER and the Golgi apparatus and 
regulates export and transport of newly synthesised proteins from the endoplasmic 
reticulum (ER) to the Golgi. Overexpression of RAB1 in nrCM has been shown to 
induce hypertrophic growth with an increase in total protein synthesis, cell size and 
sarcomeric organisation (Filipeanu et al., 2004). Consistent with these findings, 
overexpression of RAB1 in a transgenic mouse model results in cardiac hypertrophy 
and heart failure (Wu et al., 2001). In addition, TBC1D20 has recently been identified 
as a RAB GTPase-activating protein (GAP) (Sklan et al., 2007). We identified both 
RAB1 and TBC1D20 to be selectively up-regulated by Aldo suggesting that 
increased RAB1 expression and TBC1D20 dependent activation may provide a 
molecular mechanism by which Aldo induces cardiac hypertrophy independent of 
blood pressure. 
Cardiac hypertrophy depends on sustained Ca2+ entry into CM. Ca2+ homeostasis is 
regulated by the transient receptor potential canonical channel 1 (TRPC1) via store-
operated Ca2+ (SOC) channels and thereby plays a pivotal role in cardiac 
hypertrophy by subsequent activation of the nuclear factor of activated T-cells 
(NFAT). It was recently shown that knock down of the stromal interaction molecule 1 
(STIM1) inhibits up-regulation of TRPC1 and thereby attenuates the hypertrophic 
response induced by endothelin-1, Ang II and phenylephrine (Ohba et al., 2009). We 
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identified STIM1 to be selectively down-regulated by Aldo which provides another 
molecular mechanism by which Aldo may induce cardiac hypertrophy. 
Cell division control protein 42 (Cdc42) is member of the Rho family of small 
GTPases which is involved in cell cycle regulation. Overexpression of Cdc42 in 
cardiomyocytes enhances myocyte growth, while overexpression of a dominant 
negative Cdc42 mutant has the opposite effect by modulating sarcomere assembly in 
vitro (Nagai et al., 2003). In agreement with these findings, CM specific deletion of 
Cdc42 in vivo renders the mouse heart more capable of hypertrophic growth 
following pressure overload, neuroendocrine agonist infusion, and exercise, 
suggesting that activation of Cdc42 antagonises cardiac growth (Maillet et al., 2009). 
Cdc42 activation is inhibited by the small protein effector of Cdc42 (SPEC1) through 
direct interaction with Cdc42 (Pirone et al., 2000) which we identified to be selectively 
up-regulated by Aldo. 
Furthermore, the striated preferentially expressed gene (SPEG) is a member of a 
family of myosin light-chain kinases (MLCKs) that are required for cytoskeletal 
remodelling. SPEG knock out mice are characterised by CM hypertrophy, myofibril 
degeneration, and a marked decrease in cardiac function resulting in dilated 
cardiomyopathy (Liu et al., 2009a). We found SPEG to be down-regulated by Aldo 
which thereby may play a role in myocyte dysfunction and the development of heart 
failure. On aggregate, our microarray experiment has identified several novel 
selective Aldo target genes that may explain the direct, blood pressure independent 
effects of Aldo on cardiac hypertrophy. 
Aldo excess in primary hyperaldosteronism has been associated with an increased 
risk of atrial fibrillation (Milliez et al., 2005). Moreover, drugs interfering with the 
RAAS such as ACEi and ARBs reduce the incidence and recurrence of atrial 
fibrillation (Iravanian & Dudley, 2008). A genome wide association study has recently 
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identified an intronic single nuclear polymorphism (SNP) in the zinc finger homeobox 
3 (ZFHX3) gene to increase the risk of atrial fibrillation (Benjamin et al., 2009). 
ZFHX3 regulates myogenic and neuronal differentiation and has been reported to be 
a tumour suppressor gene in several cancers whereas its function in cardiac tissue is 
largely unknown. We identified ZFHX3 to be selectively down-regulated by Aldo 
which may provide a mechanism by which Aldo exerts proarrhythmic effects. 
Prohibitins (PHB) are ubiquitous, evolutionarily conserved proteins involved in 
mitochondrial structure and function. Overexpression of prohibitin 1 (PHB1) in CM 
protects mitochondria from oxidative stress or hypoxia induced injury and thereby 
attenuates CM apoptosis in vitro (Liu et al., 2009b; Muraguchi et al.). We identified 
PHB1 to be selectively down-regulated by Aldo which may confer susceptibility to 
oxidative stress resulting in CM apoptosis. 
Aquaporins are water channels that play a pivotal role in water flux across 
membranes. Ischemia of the myocardium is characterised by swelling of CM resulting 
in cardiac dysfunction. In an animal model of MI, AQP4 expression was increased in 
ischaemic CM and correlated with infarct size (Warth et al., 2007). We found AQP4 to 
be selectively up-regulated by Aldo which may augment cell swelling following MI. 
Furthermore, attenuation of AQP4 expression may be a one mechanism by which 
MR antagonists provide cardio protection post MI. 
Furthermore, we identified two genes, the salt-inducible kinase 1 (SIK1) and the 
cyclin-dependent kinase inhibitor 1C (CDKN1C, also known as p57Kip2), to be 
selectively regulated by Aldo in our microarray screen. SIK1 is a serine/threonine 
kinase which is a member of the adenosine monophosphate kinase (AMPK) family of 
kinases. It participates in the regulation of Na+/K+-ATPase activity under sodium 
stress conditions in a calcium dependent manner (Sjostrom et al., 2007). P57Kip2 is a 
member of the cyclin-dependent kinase inhibitor family which is involved in the 
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control of cell proliferation and differentiation. SIK1 and p57Kip2 have recently been 
shown to play an important role during cardiac development (Romito et al.). Using a 
model of embryonic stem cell-derived embryonic bodies, absence of SIK1 resulted in 
a lack of p57Kip2 up-regulation and a delay of terminal cardiac differentiation which 
could be rescued by constitutive overexpression of p57Kip2. These findings suggest 
that SIK1 is one of the key regulators in the cascade of events leading to 
cardiomyogenesis through the modulation of p57Kip2 expression. The biological role 
of SIK1 and p57Kip2 in adult cardiomyocytes is less clear. Overexpression of p57Kip2C 
in CM in a transgenic mouse model has recently been shown to result in resistance 
to myocardial ischemia/reperfusion injury and improve recovery of cardiac function in 
adult mice (Haley et al., 2008) whereas the role of SIK1 in CM beyond development 
remains unknown. 
In summary, our microarray experiment identified several genes which are selectively 
regulated by Aldo. These genes may provide novel molecular mechanisms through 
which Aldo exerts its detrimental effects on the heart. 
Several caveats related to the experimental set up need to be kept in mind when 
interpreting the differential corticosteroid hormone effects in this study. Despite the 
preferential affinity of DEX for GR and Aldo for MR both steroids show some cross 
reactivity with the respective other corticosteroid hormone receptor (Coirini et al., 
1985) and hence, cannot be regarded as selective agonists. Cross reactivity may 
particularly be of relevance with regard to Aldo given the supra-physiological 
concentration of 100nM that was used in this study. The reason for choosing such a 
high Aldo concentration was because preliminary studies showed no or only very little 
effect on target gene regulation when Aldo was used at high (1-10nM) physiological 
concentrations. This finding is consistent with many other reports in the literature 
which only observed significant transcriptional responses by Aldo at a minimum 
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concentration of 10nM or above (Boixel et al., 2006; Doi et al., 2008; Harada et al., 
2001; Lalevee et al., 2005; Lee et al., 2004; Lopez-Andres et al., 2008; Okoshi et al., 
2004). However reassuringly, gene regulation by cross reactivity of Aldo with GR 
appeared to be of minor significance in our study because only 5 of the 25 Aldo 
selective genes remained significantly (p<0.05) up-regulated in the presence of the 
MR antagonist RU28318 suggesting that the remainder of genes were regulated via 
MR. 
We chose an incubation period of 8h in this study although transcriptional regulation 
of steroid target genes has been observed as early as 30 minutes following treatment 
and then may return to baseline levels within hours (Kellner et al., 2003). The 
identified genes in this study must therefore not be regarded as direct corticosteroid 
target genes because they firstly, are likely to represent secondary or maybe even 
tertiary gene regulatory events and secondly, may result from an initial non-genomic 
steroid effect (described in section 1.4.3) which subsequently triggers downstream 
transcriptional events. However, given our overall aim of discovering differentially 
regulated genes by corticosteroids relevant to cardiovascular disease, discrimination 
of direct vs indirect regulatory effects by Aldo on these genes was not important and 
should be addressed in future studies. 
In conclusion, our study shows that Aldo and corticosterone induce a common as 
well as a differential transcriptome through their cognate steroid hormone receptors 
in CM which provides novel insights into the molecular mechanisms of corticosteroid 
action in the heart. 
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5.1 Introduction 
Hypertension is a prevalent condition affecting more than 25% of the adult population 
world wide (Kearney et al., 2005). The RAAS plays a central role in the regulation of 
blood pressure and primary hyperaldosteronism, a condition characterised by Aldo 
excess (described in section 1.6.3), has now undoubtedly emerged as the most 
frequent form of secondary hypertension but its true prevalence among 
hypertensives and patients with resistant hypertension remains controversial 
(Calhoun et al., 2002; Douma et al., 2008; Mosso et al., 2003; Rossi et al., 2006). 
Further support for the pivotal role of the RAAS in the pathogenesis of essential 
hypertension comes from the Framingham offspring study which suggests that prior 
to clinical manifestation of hypertension, patients with high-normal Aldo levels are the 
ones at increased risk to develop hypertension in the future (Vasan et al., 2004). 
There is biochemical and genetic evidence that a subgroup of patients with essential 
hypertension have a mild inefficiency of the enzyme 11β-hydroxylase, which 
catalyses the final enzyme in cortisol synthesis (described in section 1.3.2), which is 
thought to lead to compensatory HPA activation via ACTH resulting in normal cortisol 
yet mildly but inappropriately increased Aldo production (Davies et al., 2009). 
Similar to mineralocorticoid excess, glucocorticoid excess in Cushing’s syndrome 
results in hypertension (described in section 1.5.3). Several mechanisms may be 
involved to drive blood pressure In Cushing’s syndrome. Besides increased Aldo 
secretion secondary to ACTH drive in Cushing’s disease and forms of ectopic ACTH 
secretion, 11β-HSD2 may be swamped by the high circulating cortisol levels resulting 
in illicit activation of the MR, which exhibits similar affinities for Aldo and cortisol in 
vitro (Arriza et al., 1987), in the kidney by glucocorticoids (Stewart et al., 1996; Ulick 
et al., 1992). Glucocorticoid driven MR activation is also found in patients with the 
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syndrome of apparent mineralocorticoid excess (AME), which is characterised by a 
functionally inactive 11β-HSD2 enzyme secondary to mutations in the HSD11B2 
gene (described in section 1.7.2.3). Lessons learned from these extreme but very 
rare forms of hypertension suggest that more subtle changes in 11β-HSD2 activity 
caused by polymorphism in the HSD11B2 gene may be implicated in the 
pathogenesis of essential hypertension, particularly in patients who are susceptible to 
salt (described in section 1.7.2.5). Nevertheless, the exact contribution of 
glucocorticoid and mineralocorticoid secretion and metabolism to drive blood 
pressure in essential hypertension remains unclear (Hammer & Stewart, 2006). 
We here studied steroid hormone secretion and metabolism by measuring circulating 
steroid hormones and urinary steroid hormone metabolites in patients with essential 
hypertension with the aim, firstly, to define the prevalence of primary 
hyperaldosteronism in unselected patients with essential hypertension and, secondly, 
to gain more insight into the role of corticosteroid hormones in the pathogenesis of 
essential hypertension. 
5.2 Materials and Methods 
5.2.1 Patients 
Patients were recruited from GP practices in south Birmingham. Inclusion criteria 
were white caucasian background, age>18 years, uncomplicated hypertension (blood 
pressure >150/90 on 3 occasions or on antihypertensive treatment) and current blood 
pressure <180/110 (if already on treatment). Exclusion criteria comprised a history of 
diabetes, heart disease, peripheral vascular or cerebrovascular disease and renal or 
liver disease. 
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5.2.2 Study protocol 
At baseline, patients were assessed by means of taking a clinical history and physical 
examination; office blood pressure was measured using a validated oscillometric 
sphygmomanometer (Dinamap® Procare, GE). In addition, a random blood sample 
was taken for electrolytes, creatinine and urea, random PRA and Aldo. In all patients 
on antihypertensive medication, antihypertensive agents were stopped sequentially 
(one drug per week) and blood pressure was monitored weekly. In case of 
uncontrolled hypertension (office blood pressure > 180/100), patients were excluded 
from the study and restarted on antihypertensive medication. 3 weeks after cessation 
of the last antihypertensive drug, patients underwent a 24h ambulatory blood 
pressure measurement (Meditech® ABPM-04) and collected a 24h urine for analysis 
of steroid hormone metabolites. Venous blood samples were taken for analysis of 
electrolytes, creatinine and urea. In addition, PRA and Aldo were measured after 30 
min supine rest. After completion of the study, patients were restarted on their 
antihypertensive medication unless 24h ABP revealed a normal blood pressure 
(<125/80 mmHg). The protocol was approved by the South Birmingham Local 
Research Ethics Committee and all patients gave written informed consent prior to 
enrolment.  
5.2.3 Biochemical assays 
Plasma Aldo and PRA were measured as described in section 2.2.1.2.1. 
5.2.4 Urinary steroid metabolites 
Mineralocorticoids and glucocorticoids are metabolised by various enzymes and are 
excreted as metabolites in the urine. The main urinary metabolites of mineralo- and 
glucocorticoids including their precursors were measured by GC/MS and global 
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enzymatic activities were inferred from the ratio of urinary substrate metabolites 
divided by product metabolites as described in section 2.2.1.1. 
5.2.5 Statistical Analysis 
Normally distributed data were expressed as means ± SD (unless stated). Non 
parametric data were expressed as median (interquartile range) and were log-
transformed before statistical analysis. For comparisons of two independent variables 
Student’s t-test was used. Correlations were expressed by Pearson’s correlation 
coefficient. Statistical significance was assumed at p<0.05. 
5.3 Results 
Of the 117 patients who fulfilled the inclusion criteria, 4 patients were excluded for 
developing dangerous hypertension, 5 patients were excluded because of newly 
developed symptoms (ie shortness of breath or headache), 2 were excluded because 
of poor comprehension and 2 were lost to follow up, therefore results from 104 
patients were analysed. Patient characteristics are given in Table 5-1. 41% of 
patients were newly diagnosed and on no antihypertensive medication whereas the 
remaining patients were on one to three antihypertensive agents. 
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Table 5-1 Patient characteristics at baseline 
  Reference Range 
Male gender (%) 59 (57)  
Age (years) 56 ± 11  
BMI (kg/m2) 28.6 ± 4.9  
Na+ (mmol/l) 139 ± 2.5 (134-145) 
K+ (mmol/l) 4.1 ± 0.35 (3.5 – 5.0) 
Creatinine (µmol/l) 81 ± 13 (50 -110) 
Urea (mmol/l) 5.6 ± 1.7 (2.5 – 10.7) 
eGFR (ml/min/1.73m2) 73 ± 11 (> 90) 
PRA (ng/ml/h) 2.2 (1.2,5.0) (0.51 – 2.64) 
Aldo (pmol/l) 222 (152, 294) (28 – 445) 
ARR (pmol/l/ng/ml/h) 105 (40, 189) (< 450) 
Number of antihypertensive drugs (%)   
 nil 
 #1 
 #2 
 #3 
43 (41%) 
26 (25%) 
29 (28%) 
6 (6%) 
 
Antihypertensive class (%)   
 ACEi/ARB 
 Diuretic 
 Beta blocker 
 Calcium channel blocker 
40 (38%) 
32 (30%) 
13 (13%) 
16 (15%) 
 
Values are mean ± SD; in brackets: SI units and normal reference range where 
applicable; ACEi: angiotensin converting enzyme inhibitor; eGFR: estimated 
glomerular filtration rat; PRA: plasma renin activity; Aldo: aldosterone; ARR: 
aldosterone renin ratio; ARB: angiotensin receptor blocker. 
Three patients (4%) exhibited an increased Aldo / PRA ratio (ARR) > 750 with an 
absolute Aldo concentration > 400pmol/l suggesting primary hyperaldosteronism 
(PHA) as the underlying cause. After withdrawal of antihypertensive medication, both 
systolic and diastolic office blood pressure significantly increased (Table 5-2). 
Antihypertensives had no effect on sodium or the estimated glomerular filtration rate 
(eGFR) but potassium levels were significantly lower off medication. Antihypertensive 
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medication had no significant effect on Aldo levels but PRA was significantly lower 
and the Aldo renin ratio (ARR) significantly higher after withdrawal of 
antihypertensive medication (Table 5-2). Stratification of Aldo and PRA by 
antihypertensive agents revealed that only patients taking ACEi or ARBs had a 
significantly higher PRA, whereas PRA in patients on other antihypertensive agents 
including calcium channel blockers (CCB), beta blockers (BB) and diuretics were 
comparable to treatment naive patients (Figure 5-1a). By contrast, Aldo levels were 
no different among treatment groups (Figure 5-1b). 
Table 5-2 Effect of antihypertensive medication 
 on treatment off treatment 
Office blood pressure (mmHg)   
 Systolic 145 ± 19.1 154 ± 18.3 (p=0.005) 
 Diastolic 84 ± 11.0 88 ± 11.0 (p=0.008) 
Mean 24h ambulatory blood pressure (mmHg)   
 Systolic  144 ± 12.3 
 Diastolic  88 ± 9.0 
Electrolytes & creatinine   
 Na+ (nmol/l) 139 ± 2.6 139 ± 2.3 
 K+ (nmol/l) 4.1 ± 0.4 4.0 ± 0.3 (p=0.05) 
 eGFR (ml/min) 72 ± 10.2  69 ± 14.4 
RAAS   
 PRA (ng/ml/h) 3.3 (1.3,6.8) 0.95 (0.56,1.71) (p<0.001) 
 Aldo (pmol/l) 223 (151,315) 244 (138,313) 
 ARR 62 (32,180) 222 (108,484) (p<0.001) 
Values are mean ± SD or median (interquartile range). eGFR: estimated glomerular 
filtration rat; PRA: plasma renin activity; Aldo: aldosterone; ARR: aldosterone renin 
ratio. Treatment effects were analysed by t-test for parametric and Mann-Whitney-U 
test for non-parametric data. 
 
 
 
Chapter 5  Steroid Hormone Secretion and Metabolism in Essential Hypertension 
169 
 
Figure 5-1 Plasma renin activity (PRA) (A) and aldosterone (B) in 
patients with essential hypertension (N=68) stratified by classes of 
antihypertensive agents (no Tx: no antihypertensive medication (N=17); 
CCB/BB/diuretics: calcium channel blockers and/or beta-blockers 
and/or diuretics (N=17); ACEi: angiotensin converting enzyme inhibitor; 
ARB angiotensin receptor blocker (N=34)). (Treatment groups were 
compared by Kruskal-Wallis ANOVA). 
Following withdrawal of antihypertensive medication, 24h ABP confirmed 
hypertension in 96 patients, whereas 8 patients (8%) had a normal mean 24h blood 
pressure (<125/80 mmHg) suggesting white coat hypertension. Age and kidney 
function were both negatively correlated with mean 24h diastolic blood pressure 
(Table 5-3). Plasma Aldo was correlated with 24h urinary excretion of TH-Aldo 
(r=0.423, p<0.001), the main urinary Aldo metabolite. PRA showed an inverse 
association with mean 24h blood pressure, whereas plasma Aldo, the aldosterone-
renin ratio (ARR) and 24h urinary TH-Aldo excretion were positively correlated with 
24h blood pressure (Table 5-3). By contrast, neither 24h urinary total cortisol 
metabolite (total F metabolites) excretion nor circulating cortisol was associated with 
blood pressure (Table 5-3). 
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Table 5-3 Correlations with blood pressure 
 
24h ambulatory blood pressure 
 Systolic Diastolic 
Patient characteristics 
  
 Age (years) 0.017 (p=0.864) -0.254 (p=0.010) 
 Body weight (kg) 0.071 (p=0.480) 0.084 (p=0.405) 
 BMI (kg/m2) 0.095 (p=0.344) 0.034 (p=0.738) 
 eGFR (ml/min) 0.018 (p=0.868) -0.307 (p=0.003) 
Blood parameters 
  
 Na+ (mmol/l) -0.025 (p=0.811) 0.009 (p=0.930) 
 K+ (mmol/l) -0.189 (p=0.073) -0.221 (p=0.036) 
 PRA (ng/ml/h) -0.264 (p=0.012) -0.261 (p=0.013) 
 Aldo (pmol/l) 0.095 (p=0.371) 0.275 (p=0.009) 
 ARR 0.304 (p=0.005) 0.397 (p<0.001) 
 Cortisol (nmol/l) 0.128 (p=0.286) 0.105 (p=0.383) 
Urinary steroid hormone metabolites 
  
 TH-Aldo (µg/24h) 0.212 (p=0.038) 0.275 (p=0.007) 
 Total F metabolites (µg/24h) 0.149 (p=0.145) 0.107 (p=0.298) 
 DHEA (µg/24h) 0.053 (p=0.613) 0.128 (p=0.218) 
Enzymatic activities 
  
 11β-HSD1 (THF+5αTHF / THE) 0.076 (p=0.460) 0.055 (p=0.595) 
 11β-HSD2 (UFF / UFE) -0.258 (p=0.011) -0.247 (p=0.015) 
 11β-hydroxylase (THS / total F metabolites) -0.106 (p=0.300) -0.205 (p=0.044) 
 5α-reductase (THF / 5αTHF) -0.075 (p=0.469) -0.157 (p=0.128) 
Values are Pearson correlation coefficients. PRA: plasma renin activity; Aldo: 
aldosterone; ARR: aldosterone renin ratio; TH-Aldo: tetrahydro-aldosterone; THF: 
tetrahydro-cortisol; THE: tetrahydro-cortisone; UFF: urinary free cortisol; UFE: urinary 
free cortisone; THS: tetrahydro-desoxycortisol. 
Using ratios of urinary steroid hormone metabolites as a surrogate for global activities 
of steroidogenic enzymes, there was no indication of an association of 5α-reductase 
(THF/5α-THF) or 11β-HSD1 activity (THF+5α-THF/THE) with blood pressure. 
However, 11β-HSD2 activity reflected by the excretion of urinary free cortisol / 
cortisone (UFF/UFE) and 11β-hydroxylase activity reflected by excretion of (THS / 
total cortisol metabolites were negatively associated with blood pressure, indicating 
reduced enzymatic activities with increasing blood pressure (Table 5-3). 
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5.4 Discussion 
In this study we assessed the role of corticosteroid hormone secretion and 
metabolism in patients with essential hypertension. 
Primary hyperaldosteronism is now accepted as the most common form of secondary 
hypertension, but its true prevalence in hypertensive patients remains unclear. In the 
largest study to date, the primary hyperaldosteronism prevalence (PAPY) study, 
11.2% of patients with hypertension were found to have underlying primary 
hyperaldosteronism (Rossi et al., 2006). However, this might be an overestimate of 
the true prevalence among hypertensives as patients were referred from primary care 
to specialised centers for evaluation of secondary hypertension. Previously, Mosso 
and colleagues reported a lower primary hyperaldosteronism prevalence of 6.1% in 
609 hypertensives recruited from primary care which may be a more precise 
reflection of its prevalence in unselected hypertensives (Mosso et al., 2003). Here we 
found 4% of our patients to have a positive ARR of >750 with an Aldo level greater 
than 400pmol/l suggesting PHA, although confirmatory testing was not done. A likely 
explanation for the lower prevalence in our study is the fact that about half of our 
patients (45%) had only mildly elevated blood pressure (JNC-7 grade 1 hypertension: 
140-159 / 90-99 mmHg), for which the prevalence of primary hyperaldosteronism in 
the PAPY study was merely found to be 6.6% (Rossi et al., 2006). In patients with 
resistant hypertension, who are believed to have the highest percentage of primary 
hyperaldosteronism, a recent report only found a prevalence of 11.3% although 
previous reports suggested a much higher prevalence of 20% (Calhoun et al., 2002). 
Our results are in good agreement with the findings by Mosso and colleagues (Mosso 
et al., 2003) and suggest that the overall prevalence of primary hyperaldosteronism 
among unselected hypertensive patients may be in fact closer to 5% than 10%. 
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After stopping antihypertensive medication, we found that 9% of patients who had 
high office blood pressure had a normal mean 24h ABP suggesting white coat 
hypertension. Although, excess cardiovascular risk of these patients remains 
controversial, a recent meta-analysis did not find an increased risk in patients with 
white-coat hypertension compared to normotensives (Fagard & Cornelissen, 2007). 
Guidelines suggest that in the absence of organ damage antihypertensive treatment 
is not recommended (2003). Given that 9% of patients in our cohort were falsely 
labeled as hypertensive, 24h ABP measurement which is inexpensive and can 
conveniently be performed at home, should probably be used more often, particularly 
in patients with only mildly elevated office blood pressure or if the diagnosis is in 
doubt in order to prevent unnecessary treatment – a burden for both patients and 
health care budgets. 
We found a significantly up-regulated PRA in patients on ACEi and ARBs compared 
to patients on calcium channel blockers (CCB), diuretics and or beta blockers (BB), 
while circulating Aldo was similar suggesting a compensatory activation of the RAAS. 
Another mechanism that is likely to contribute to the finding that Aldo levels were 
similar among the different patient groups is the phenomenon of ‘aldosterone escape’ 
which describes the normalisation of Aldo levels in patients on long term ACEi or 
ARB treatment despite an initial suppression when treatment is initiated (Bomback & 
Klemmer, 2007). 
There is no doubt about the pivotal role of Aldo in the pathogenesis and maintenance 
of hypertension in primary hyperaldosteronism whereas its role in essential 
hypertension is far less clear. Historic studies in patients with essential hypertension 
have found conflicting results with some studies reporting higher Aldo levels in 
patients with essential hypertension (Genest et al., 1975; Ljungman et al., 1982), 
whereas others have found similar (Wisenbaugh et al., 1972) or even lower levels 
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(Walker et al., 1979) compared to normotensive controls and as a consequence, 
plasma Aldo levels have been associated with blood pressure both in a positive 
(Ljungman et al., 1982) and negative (Walker et al., 1979) fashion. In our cohort 
plasma Aldo and urinary TH-Aldo excretion were positively correlated with blood 
pressure suggesting that circulating Aldo levels contribute to elevated blood pressure 
in patients with essential hypertension. Furthermore, increased 24h urinary excretion 
of TH-Aldo with blood pressure suggests that relative Aldo excess is secondary to 
hyperactivity of adrenal mineralocorticoid production. However by contrast, PRA 
showed a negative association with blood pressure suggesting a salt and volume 
replete state with increasing blood pressure. 
The ARR, the most sensitive marker of mineralocorticoid excess for salt/volume 
status, is an established screening test for primary hyperaldosteronism and when 
above a certain cut-off primary hyperaldosteronism is likely but warrants confirmatory 
testing (Funder et al., 2008). Besides the associations of Aldo and PRA with blood 
pressure we found the ARR to be most strongly associated with blood pressure 
suggesting an increasing relative mineralocorticoid excess state (RME) with higher 
blood pressure levels. In line with this notion we found a negative correlation of blood 
pressure with circulating potassium levels, a reflection of mineralocorticoid action in 
epithelial cells of the distal nephron of the kidney. Further support for the gradual 
mineralocorticoid excess state with increasing blood pressure comes from an 
interventional study which found the ARR to be highly predictive of the reduction in 
blood pressure achieved when initiating treatment with the mineralocorticoid receptor 
antagonist Spiro (Mahmud et al., 2005). 
Our findings suggest that the ARR, besides its established role as screening test for 
the presence of absolute mineralocorticoid excess in primary hyperaldosteronism, is 
a useful marker of relative mineralocorticoid excess. This finding is supported by two 
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recent reports (Alvarez-Madrazo et al., 2009; Tomaschitz et al.) which show that the 
ARR is continuously distributed and over its whole spectrum associated with blood 
pressure even well below the cut-off used for screening for PHA. This illustrates the 
importance of ARR on blood pressure modulation not only in hypertensive but also 
normotensive subjects. On aggregate, the findings of others and us suggest that the 
role of ARR with regard to blood pressure needs to be expanded from simply being a 
measure of “absolute” mineralocorticoid excess when screening for PHA, to a more 
gradual measure of “relative” mineralocorticoid excess (RME). As suggested by the 
study of Mahmud and colleagues, determination of the relative mineralocorticoid 
excess of a patient may be highly relevant when deciding on which antihypertensive 
agent to use (Mahmud et al., 2005).  
Given that renin via Ang II is believed the principal regulator of Aldo, the fact that 
Aldo and PRA correlate divergently with increasing blood pressure raises the 
question of Aldo regulation. In this respect, a number of reports have suggested that 
ACTH, which is known to stimulate steroid hormone secretion from of all three layers 
of the adrenal cortex, might contribute to Aldo secretion in hypertensives. Evidence 
for this theory comes from the observation that a polymorphism (-344T) in the 
aldosterone synthase gene (CYP11B2), which has previously been found to be 
associated with mineralocorticoid production (Davies et al., 1999; Paillard et al., 
1999) and blood pressure (Lim et al., 2002), is also associated with a reduced 11β-
hydroxylase activity (encoded by the CYP11B1 gene) catalysing the conversion of 
11-deoxycortisol  to cortisol, the final step in cortisol synthesis (see section 1.3.2). In 
order to overcome inefficient cortisol synthesis, HPA drive via ACTH is induced 
resulting in normal cortisol yet mildly but inappropriately elevated Aldo levels (Freel et 
al., 2008). However, in our study HPA drive (using total cortisol metabolites as a 
surrogate) was not associated with blood pressure. We therefore conclude that 
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neither renin nor HPA drive explains Aldo levels in our cohort suggesting that Aldo is 
regulated by a novel factor which is neither renin nor HPA drive or alternatively, by an 
intra-adrenal mechanism. Moreover, we did not find evidence for impaired 11β-
hydroxylase activity (using the urinary THS/total cortisol metabolites ratio) with higher 
blood pressure but conversely, found 11β-hydroxylase activity to be increased with 
higher blood pressure. Similarly, global 11β-HSD2 activity as assessed by the urinary 
free cortisol / cortisone ratio was also increased rather than reduced suggesting that 
inefficient cortisol inactivation did not contribute to higher blood pressure in our 
cohort. Previous studies have given conflicting results with some studies reporting a 
reduced 11β-HSD2 activity while others did not find such an association suggesting 
that impaired 11β-HSD2 activity might  play a role in a subset of patients but certainly 
does not appear to be a universal mechanism driving blood pressure in essential 
hypertension (Ferrari, 2009). 
Limitations of this study are its observational nature which does not allow any 
causative conclusions, the relatively small size of the cohort and a the lack of a 
matched normotensive control cohort, whereas its strengths are the fact that patient 
were on no antihypertensive medication and recruited rather than referred from 
primary care ruling out selection bias. 
In summary, we found a low prevalence of suspected primary hyperaldosteronism of 
4% in our cohort of unselected patients with high blood pressure. Our results suggest 
that Aldo plays an important contributory role to high blood pressure defining 
essential hypertension as a state of relative mineralocorticoid excess. 
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6.1 Introduction 
In chronic kidney disease (CKD) the RAAS becomes progressively activated with 
decreasing kidney function (Hillege et al., 2000) and Ang II and Aldo have emerged 
as important drivers of both kidney disease progression and increased cardiovascular 
mortality (Go et al., 2004; Mann et al., 2002; Tonelli et al., 2006). Consequently, 
RAAS inhibition by ACEi and ARB remains the mainstay of treatment. However, 
RAAS inhibition by ACEi or ARBs is only partial and a recent study suggests that 
addition of the MR antagonist Spiro in CKD patients already treated with an ACEi and 
ARB, further reduces markers of renal disease progression (Tylicki et al., 2008). 
Similarly, the use of MR antagonists in heart failure patients in addition to established 
treatment regimens including ACEi and ARBs has been shown to dramatically 
improve survival (Pitt et al., 2003b; Pitt et al., 1999). 
One important mode of action of MR antagonists in CKD patients is blood pressure 
reduction through blockade of renal MR in epithelial cells of the distal nephron. The 
MR has similar affinities for mineralocorticoids and glucocorticoids in vitro (Arriza et 
al., 1987) and is only protected from glucocorticoid activation by the enzyme 11β-
HSD2 which inactivates cortisol to cortisone. Reduced activity of 11β-HSD2 results in 
glucocorticoid mediated MR activation and has been described in selected patients 
with salt sensitive essential hypertension (Agarwal et al., 2000; Lovati et al., 1999). In 
CKD patients 11β-HSD2 activity (N'Gankam et al., 2002; Whitworth et al., 1989) and 
expression (Quinkler et al., 2005) declines with progressively impaired renal function 
suggesting that in these patients blood pressure and renal damage may be partly 
driven by glucocorticoid induced MR activation. Therefore this mechanism provides a 
rationale for the incremental benefit of MR antagonists on lowering blood pressure in 
CKD patients. 
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Besides MR blockade, animal and in vitro studies also suggest that Spiro and its 
active metabolites can also inhibit steroidogenic enzymes including 11β-hydroxylase 
and thereby may impact on corticosteroid hormone synthesis (Cheng et al., 1976; 
Greiner et al., 1976). However, so far this has never been investigated in humans. In 
addition, studies in healthy subjects suggest that hippocampal MR may play a role in 
the modulation of HPA drive (Heuser et al., 2000; Young et al., 1998) but so far this 
has never been demonstrated in patients on long-term low-dose Spiro treatment. 
Here we studied corticosteroid hormone secretion and metabolism in CKD patients 
with mild-moderate renal impairment at baseline and following treatment with low 
dose Spiro. We hypothesised that some of the beneficial effects of Spiro may relate 
to changes in cortisol secretion and/or metabolism. 
6.2 Materials and Methods 
6.2.1 Study design 
In collaboration with Prof Townsend and Dr Edwards (Department of Cardiology, 
Queen Elizabeth Hospital, UHB Trust, Birmingham) who conducted a clinical trial 
evaluating the effects of Spiro on left ventricular mass and aortic stiffness in CKD we 
analysed urinary steroid hormone metabolites by GC/MS from participating patients 
(Edwards et al., 2009). A sample size of 90 patients assigned equally to the 2 
treatment groups was calculated to provide 95% power to detect a change in LV 
mass of 10 g (SD 12 g) on CMR and 80% power to detect a change in PWV of 0.6 
m/s (SD 1.0 m/s) with an alpha error of 0.05 in each case. No power calculations 
were performed for analysis of steroid hormone secretion and metabolism. This was 
a single centre, prospective, double-blind, placebo controlled, randomised 
intervention trial in patients with early stage CKD of diverse aetiologies including 
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glomerulonephritis (IgA nephropathy, nephrotic disease, focal segmental glomerular 
sclerosis) (53%), quiescent vasculitis (19%), adult polycystic kidney disease (8%), 
reflux (8%), calculi (4%) and others (8%) (Henoch-Schoenlein purpura, sickle cell 
disease, sarcoidosis, nephrectomy). Patients had stage 2 (GFR 60-89 
ml/min/1.73m2) (GFR was calculated using the 4 variable MDRD equation) or stage 3 
CKD (GFR 30-59 ml/min/1.73m2) and evidence of kidney damage for ≥3 months) 
(Sarnak et al., 2003). All patients were treated with an ACE inhibitor and / or ARB for 
at least 6 months to maximally tolerated dose and had controlled blood pressure 
(mean daytime 24 hour ambulatory blood pressure monitoring <130/85 mmHg). 24 
patients with CKD secondary to vasculitis were on a stable immunosuppressive 
treatment with glucocorticoids which was not altered during the study period. Patients 
were excluded if they had a history of diabetes, or symptomatic ischaemic or non-
ischaemic heart disease, peripheral vascular or cerebrovascular disease, 
renovascular disease, anaemia (<12g/dL) or previous documented hyperkalaemia 
(>5.5mmol/L). 
A Spiro dose of 25mg was chosen in this study as previously low dose Spiro has 
been shown to be safe and clinical effective in patients with heart failure (Pitt et al., 
1999). All patients received a 4 week open label run-in phase of 25mg of Spiro once 
daily (or alternate days if potassium levels were between 5.5 and 5.9mMol/l), after 
which patients were randomised to continue treatment with 25 mg Spiro or to placebo 
for a further 36 weeks. Patients were assessed at baseline (before the run in phase) 
and at the end of the study (week 40) with a clinical history and examination, 24 hour 
ambulatory blood pressure monitoring, and collection of a 24h urine sample. Venous 
blood samples were also collected after 30 minutes supine rest for routine 
hematology and biochemistry and measurement of PRA, Aldo and Ang II. 
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During the open-label run-in phase, 1 patient developed serious hyperkalaemia 
(potassium 6.5mMol/l) and was withdrawn, 6 (5%) patients had potassium levels 
between 5.5 and 5.9mMol/l and were switched to Spiro on alternate days as per 
protocol. On blinded treatment, 4 patients had potassium levels between 5.5 and 
5.9mMol/l that required a dose reduction to alternate day treatment. After unblinding, 
two of these 4 patients were found to have received placebo. After randomisation, no 
patients were withdrawn because of hyperkalemia, and there were no reported side 
effects, including gynecomastia or menstrual disturbances. The protocol was 
approved by South Birmingham Local Research Ethics Committee and all patients 
gave written informed consent. 
6.2.2 Blood Pressure 
Office brachial blood pressure was recorded with the subject lying supine after 10, 20 
and 30 minutes in the non-dominant arm using a validated oscillometric 
sphygmomanometer (Dinamap® Procare, GE). In addition, all subjects underwent 24 
hour ambulatory blood pressure monitoring (Meditech® ABPM-04) at baseline and at 
week 40.  
6.2.3 Biochemical assays 
PRA, plasma Ang II and plasma Aldo was measured was measured as described in 
section 2.2.1.2.2. 
6.2.4 Urinary steroid metabolites 
Mineralocorticoids and glucocorticoids are metabolised by various enzymes and are 
excreted as metabolites in the urine. The main urinary metabolites of mineralo- and 
glucocorticoids including their precursors were measured by GC/MS and global 
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enzymatic activities were inferred from the ratio of urinary substrate metabolites 
divided by product metabolites as described in section 2.2.1.1. 
6.2.5 Statistical Analysis 
Normally distributed data were expressed as means ± SD (unless stated). Non 
parametric data were expressed as median (interquartile range) and were log-
transformed where applicable. Treatment groups were compared using t tests or chi-
square tests (at baseline) and repeated measures analysis of variance (for changes 
over time). Correlations of non-parametric data were assessed by the Spearman’s 
correlation coefficient. 
6.3 Results 
All 112 patients enrolled in this study had stage 2 or 3 CKD, were all on either ACEi 
or ARB treatment for more than 6 months and had normal office blood pressure 
levels (Table 6-1). There were no differences in blood pressure or gender distribution 
between the two groups. However, body weight and BMI was higher in the Spiro 
compared to the placebo group and in the Spiro group significantly more patients 
were treated with beta-blockers and statins compared to the placebo group (Table 
6-1). As expected, at baseline patients on beta blockers had a significantly lower 
PRA (median (interquartile range): 23 mU/l (8, 85) vs 82 mU/l (49, 185), p<0.001) 
and Ang II levels (4.9 pmol/l (3.1, 8.3) vs 9.9 pmol/l (5.0, 23.1), p<0.05) compared to 
patients not taking beta-blockers. However by contrast, the plasma aldosterone 
concentration (PAC) was slightly but significantly higher in patients on beta-blocker 
treatment (222 pmol/l (152, 300) vs 166 pmol/l (108, 222), p<0.05) suggesting an 
alternative mechanism of Aldo release in addition to Ang II. Analysis of urinary 
glucocorticoid and mineralocorticoid steroid hormone metabolites between patients 
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on and off beta-blockers did not reveal significant differences suggesting that beta-
blockers do not have a major influence on steroid hormone production or metabolism. 
Comparison of patients on ACEi vs ARB at baseline did not reveal any differences in 
PRA (64 mU/l (37, 133) vs 81 mU/l (25, 151), p=0.676), PAC (169 pmol/l (114, 247) 
vs 172 pmol/l (97, 238), p=0.627) or 24h urinary excretion of TH-Aldo (18.1 µg/24h 
(10.5, 26.8) vs 17.5 µg/24h (13.4, 25.4), p=0.984). However as expected, circulating 
Ang II levels were significantly lower in the ACEi compared to the ARB group (5.3 
pmol/l (3.8, 10.5) vs 31.6 pmol/l (12.6, 72.7), p<0.001). No significant differences 
were found between males and females with regard to PRA, Ang II, PAC or urinary 
TH-Aldo. 
Total body weight and BMI were correlated with 24h total glucocorticoid excretion 
(r=0.407, p<0.001; r=0.296, p=0.003) but not with 5α-reductase activity as assessed 
by urinary metabolite ratios (5α-THF/THF). PAC levels were significantly correlated 
with 24h urinary TH-Aldo excretion (r=-0.214; p=0.036) and furthermore showed a 
significant negative association with the estimated glomerular filtration rate (eGFR) 
(r= -0.331, p<0.001). However, 24h urinary TH-Aldo excretion was not associated 
with eGFR. 
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Table 6-1 Patient characteristics at baseline. 
 
Placebo 
(n=56) 
Spironolactone 
(n=56) 
Male (%) 33 (59) 32 (57) 
Age (years) 53 ± 12 54 ± 12 
Body weight (kg) 74 ± 14 81 ± 14†  
BMI (kg/m2) 25.9 ± 3.8 28.0 ± 4.4†  
Office blood pressure (mmHg) 
 Systolic 
 Diastolic 
 
130 ± 19 
77 ± 10 
 
130 ± 16 
77 ± 10 
Creatinine (µmol/l) 123 ± 35 132 ± 29 
eGFR (ml/min/1.73m2) 53 ± 12 49 ± 12 
 
 
Medication 
ACE Inhibitors (%) 39 (70) 38 (68) 
Angiotensin receptor blockers (ARBs) (%) 19 (34) 19 (34) 
Beta blockers (%) 8 (14) 15 (27) 
Calcium channel blockers (%) 17 (30) 13 (23) 
Diuretics (%) 13 (23) 18 (32) 
Statins (%) 17 (30) 27 (48) 
Values are Mean ± SD; †: p<0.01 spironolactone vs. placebo. Treatment groups 
were compared by the use of t-tests or chi-square. 
Mean diastolic 24h ABP showed a significant correlation with 24h urinary TH-Aldo 
excretion (Figure 6-1) but not with PAC.  
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Figure 6-1 Correlation of 24h urinary TH-Aldo excretion with 
diastolic 24h ABP. 
 
Figure 6-2 Correlation of 24h urinary total cortisol (F) metabolite 
excretion with systolic 24h ABP. 
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Moreover, after adjusting for age, BMI and eGFR, systolic 24h ABP was significantly 
associated with 24h urinary total cortisol metabolite excretion at baseline (Figure 
6-2). 
Table 6-2 Changes following placebo / spironolactone treatment. 
 
Placebo  Spironolactone  
Week 0  Week 40    Week 0    Week 40    
24 ABP (mmHg) 
Systolic 
Diastolic 
 
125 ± 12 
77 ± 9 
 
124 ± 11 
76 ± 7 
 
124 ± 11 
76 ± 8 
 
119 ± 11† 
73 ± 8† 
Na+ (mmol/l) 139 (138,141) 140 (139,142) 140 (139,142) 140 (138,141) 
K+ (mmol/l) 4.3 (4.1,4.6) 4.3 (4.2,4.5) 4.4 (4.1,4.7) 4.5 (4.3,5.0) 
Creatinine (mmol/l) 123 ± 35 126 ± 35 132 ± 29 140 ± 32†† 
eGFR (mmol/min/1.73m2) 53 ± 12.3 52 ± 12.1 49 ± 12 46 ± 15.9 
ACR (mg/mmol) 8.2 ± 48.4 9.5 ± 34.9 17.8 ± 48.6 5.4 ± 34.9† 
 
Renin Angiotensin Aldosterone System 
PRA (mU/l) 83 (34,138) 68 (42,148) 75 (36,146) 130 (72,260)†† 
Angiotensin II (pmol/l) 9.0 (4.6,17.0) 7.9 (4.5,20.1) 7.5 (4.5,18.2) 13.6 (6.2, 22.4)†† 
PAC (pmol/l) 186 (114,252) 166 (114,219) 133 (83,230) 360 (233, 557)†† 
 
24h urinary steroid hormone metabolite excretion 
Total F (µg/24h)  5218 (2510,7370) 4938 (2992,7327) 6108 (3928,8663) 6024 (4040,8218) 
5β-TH-DOC (µg/24h) 10.1 (7.0, 18.0) 12.0 (7.1,19.9) 14.4 (8.2,20.8) 10.4 (6.8,16.6)†† 
5α-TH-DOC (µg/24h) 3.1 (1.7,4.4) 3.1 (1.5,5.3) 2.8 (2.1,5.7) 2.7 (1.6,5.5) 
TH-Aldo (µg/24h) 16.8 (13.3,26.5) 18.3 (12.8, 23.3) 18.9 (10.6, 26.3) 27.3 (17.4, 42.3)†† 
 
Steroid hormone metabolite ratios 
5α-reductase              
(THF/5α-THF) 1.12 (0.82,2.13) 1.16 (0.83, 2.06) 1.26 (0.91,1.74) 1.10 (0.80,1.76)†† 
11β-HSD1  
(5αTHF+THF/THE) 1.1 (0.8,1.3) 1.1 (0.83,1.37) 1.0 (0.7, 1.4) 1.1 (0.8, 1.5) 
11β-HSD2                      
(F/E) 0.69 (0.59,0.87) 0.68 (0.55,0.94) 0.62 (0.51,0.84) 0.69 (0.54,0.83) 
11β-hydroxylase              
(total F metabolites/THS) 98 (66, 137) 86 (50, 121) 105 (80, 151) 110 (79, 145) 
Values are median (interquartile range). ACR: albumin creatinine ratio; TH-DOC: 
tetrahydro-DOC. Normally distributed values are presented as mean ± SD otherwise 
as mean (inter quartile range). To compare changes in the two groups repeated 
measures analysis of variance with the time point (week 0, week 40) as the ‘within 
subjects’ factor and the group (spironolactone and placebo) as the ‘between subjects’ 
factor were used. † p<0.01, †† p<0.01 spironolactone vs. placebo at week 40 
(changes over time were analysed by repeated measures analysis of variance). 
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No correlation was found for systolic (r=0.156, p=0.1) or diastolic blood pressure 
(r=0.105, p=0.271), TH-Aldo (r=-0.112, p=0.284), eGFR (r=-0.097, p=0.313) and the 
ARR. Moreover, neither urinary (THF + 5α-THF / THE) ratio) reflecting global 11β-
HSD1 activity, nor urinary free cortisol / cortisone (UFF/UFE) reflecting 11β-HSD type 
2 activity were associated with blood pressure or eGFR (Table 6-2). However, PRA 
was positively associated with the urinary THF+5αTHF/THE ratio (Figure 6-3). 
 
Figure 6-3 Correlation of PRA with the urinary THF+5αTHF/THE 
ratio reflecting global 11β-HSD1 activity. 
24 patients were on stable glucocorticoid treatment for their underlying kidney 
disease throughout the study period. However, inclusion or exclusion of 
glucocorticoid treated patients did not have a significant effect on the analysis of 
steroid hormone metabolites (total glucocorticoid excretion, TH-Aldo, enzymatic 
activities) between the placebo and Spiro group. Treatment with Spiro compared to 
PRA (mU/l)
(T
HF
+
5α
-
TH
F/
TH
E)
R= 0.35; p<0.001
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placebo significantly reduced both systolic and diastolic 24h ABP despite a significant 
increase in circulating PRA, Ang II and Aldo levels (Table 6-2). Induction of the RAAS 
was reflected by a significant increase in 24h urinary TH-Aldo excretion, consistent 
with an increased aldosterone synthase activity (Table 6-2). By contrast, Spiro had 
no effect on global 11β-hydroxylase, 11β-HSD type 1 and 2 activity or total cortisol 
metabolite excretion as assessed by 24h urinary steroid hormone excretion. 
6.4 Discussion 
In this study we assessed corticosteroid hormone secretion and metabolism in CKD 
patients on stable treatment with ACEi or ARB before and after addition of Spiro by 
means of urinary steroid hormone metabolite analysis which allows assessment of 
cumulative 24h steroid hormone production and, secondly, an estimation of steroid 
hormone enzyme activities. 
As expected, 24h urinary TH-Aldo excretion correlated with PAC although this 
association was weak. A possible explanation for this weak association could be that 
the 24h urine collection for TH-Aldo was performed on a different day than blood 
sampling for circulating Aldo was done. Additionally, Aldo levels are stimulated by 
ACTH during stress such as a venous puncture which is likely to vary between 
individuals. Circulating Aldo concentrations have previously been shown to correlate 
with blood pressure in black hypertensive (Kidambi et al., 2007) and the polycystic 
ovarian syndrome (Cascella et al., 2006) patients. However, we did not find a 
correlation of PAC with systolic or diastolic 24h ABP. In this study lack of association 
might be explained by the interfering effects of ACEi and ARB on the RAAS and 
variable stress induced PAC fluctuations during blood sampling. Nevertheless, 
cumulative 24h urinary TH-Aldo excretion reflecting 24h Aldo production was indeed 
positively correlated with 24h blood pressure as well as PAC. It was recently reported 
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that Aldo levels in CKD patients treated with an ACEi are lower compared to ARB 
treated patients (Haddad et al., 2007). However, in our study we did not find any 
significant differences in PAC or urinary TH-Aldo excretion, suggesting that ACEi and 
ARBs have a similar effect on Aldo secretion. 
Total urinary 24h cortisol metabolite excretion is a well established measure to 
assess daily cortisol production rate and thus reflects activity of the HPA axis. In 
agreement with previous studies, we found total glucocorticoid metabolite excretion 
to be correlated with total body weight and BMI (Andrew et al., 2002). Furthermore, 
24h glucocorticoid secretion rate was positively correlated with 24h systolic blood 
pressure after correction of potential confounders such as age, BMI, and eGFR, 
suggesting that increased total glucocorticoid production as a result of increased 
HPA activity is implicated in blood pressure regulation in CKD patients. Although the 
vast majority of patients with Cushing’s syndrome exhibit hypertension (Hammer & 
Stewart, 2006), increased 24h cortisol production within the physiologic range has to 
our knowledge not been associated with blood pressure so far. Increased HPA-drive 
may therefore be a novel risk factor in CKD patients by driving blood pressure levels. 
These findings are in line with a recent report in which high yet within the normal 
range serum cortisol levels were found to be associated with an adverse outcome in 
heart failure patients (Guder et al., 2007). Further clinical studies are urgently needed 
to better define and understand the mechanisms of high-normal as opposed to low-
normal cortisol levels on blood pressure and ultimately cardiovascular risk in these 
patients. 
Previous studies on glucocorticoid metabolism in CKD patients suggest that 11β-
HSD2 activity (N'Gankam et al., 2002; Whitworth et al., 1989) and expression 
(Quinkler et al., 2005) declines with reduced GFR which in turn may lead to 
increased MR activation by glucocorticoids leading to increased sodium retention and 
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blood pressure. In our study we did not find a correlation between renal function and 
the UFF / UFE ratio reflecting renal 11β-HSD2 activity. This is most likely explained 
by the relatively mild impairment in renal function in our cohort, whereas cohorts in 
previous studies included patients with more severe renal impairment as well as 
patients on haemodialysis.  
Following Spiro treatment all components of the RAAS were significantly up-
regulated including PRA, Ang II and PAC levels. Consistent with a RAAS activating 
effect, total 24h urinary TH-Aldo excretion was also significantly increased in the 
Spiro but not the placebo group. Our findings are in good agreement with a recent 
report on the neurohormonal effects of Spiro in patients with CHF and on stable ACEi 
treatment, which showed increased Ang II and Aldo levels following Spiro treatment 
(Rousseau et al., 2002). These findings suggest that MR blockade by Spiro results in 
a compensatory stimulation of the RAAS despite tonic inhibition by ACEi and ARBs. 
However, the degree of compensation inflicted by Spiro is not complete as both 
diastolic and systolic 24h ABP were reduced compared to baseline. 
Previous reports suggested that Spiro and its metabolites exert direct inhibitory 
effects on steroidogenic enzymes (Cheng et al., 1976; Greiner et al., 1976). Here, 
using urinary steroid hormone metabolites as a surrogate, Spiro did not exert an 
obvious direct inhibitory effect on 11β-hydroxylase. The most likely explanation for 
this finding may be that the Spiro dose used in this study was too low to exert a 
measurable effect on 11β-hydroxylase compared to previous studies. 
However, by contrast, we found an increased aldosterone synthase activity following 
Spiro treatment. AS is the final enzyme involved in Aldo production by converting 
DOC to Aldo in the zona glomerulosa and is regulated by circulating Ang II which was 
also significantly increased following Spiro. This finding is consistent with in vitro 
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studies which show increased expression of AS following Ang II treatment (Bird et al., 
1993). 
Compared to baseline, Spiro treatment did not alter total urinary 24h cortisol 
metabolite excretion in this study. The main conclusion that can be drawn from this 
observation is that MR blockade does not seem to interfere with the negative 
feedback mechanism of cortisol on the HPA axis. Although the hypothalamus mainly 
expresses the GR but not the MR (Pryce, 2008), the hippocampus readily expresses 
both receptors and is implicated in HPA axis modulation (de Kloet et al., 1998; 
Jacobson & Sapolsky, 1991). It is therefore conceivable that the negative feedback of 
cortisol is not solely mediated through the GR, particularly as the MR in vitro shows a 
10 fold higher affinity for cortisol than the GR (Rupprecht et al., 1993). A number of 
studies have addressed the role of the MR in mediating negative cortisol feedback. 
Most studies have shown a short term stimulatory effect on the HPA axis following 
canrenoate infusion (Arvat et al., 2001; Dodt et al., 1993; Grottoli et al., 2002) or 
Spiro treatment (Heuser et al., 2000; Young et al., 1998). However, a recent study 
assessing the effects of the GR antagonist RU486 and Spiro alone or in combination 
on the HPA axis (Mattsson et al., 2009) showed that RU28486 and Spiro by 
themselves had no effect but in combination showed a significant compensatory 
activation of the HPA axis. It is difficult to compare the findings of these studies with 
our own results for a number of reasons. First of all we assessed HPA axis activity 
indirectly by means of urinary steroid metabolite excretion. Moreover, treatment 
duration and doses of MR antagonists were considerably different. Our study does 
not support a major effect of low dose Spiro on HPA axis modulation but equally does 
not rule out more subtle changes. 
Indirect analysis of global 11β-HSD type 1 and 2 activity by means of urinary steroid 
hormone metabolite ratios did not reveal any significant differences following Spiro 
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treatment. It has been suggested that the UFF/UFE ratio more precisely reflects renal 
11β-HSD2 activity than the (THF + 5α-THF) / THE ratio which is a better surrogate 
marker for global 11β-HSD1 activity (Palermo et al., 1996; Stewart et al., 1988). In 
the kidney the enzyme 11β-HSD2 protects the MR from illicit cortisol binding and 
thereby ensures Aldo specificity. Loss of function mutations are the underlying cause 
of severe hypertension and hypokalaemia in AME patients, whereas polymorphisms 
in HSD11B2 encoding for 11β-HSD2 have been associated with salt-sensitive 
essential hypertension (Hammer & Stewart, 2006). Spiro did not result in 
downregulation of 11β-HSD type 2 activity, which would allow cortisol to activate the 
MR and thereby lead to sodium and fluid retention, suggesting that only RAAS 
activation but not modulation of 11β-HSD2 in the kidney is involved in compensating 
MR antagonism. 
Interestingly, global 11β-HSD1 activity was correlated with PRA in this study. We are 
not aware of a direct interaction of 11β-HSD1 activity and PRA but one could 
speculate that 11β-HSD1 activity and PRA are regulated by a common factor. 
In summary, total 24h production of Aldo and cortisol are positively associated with 
blood pressure in CKD patients suggesting that adrenal hyperactivity may contribute 
to the hypertension and increased cardiovascular risk. Addition of Spiro resulted in 
compensatory RAAS activation but did not affect glucocorticoid production or 
metabolism. 
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The rationale for our interest to characterise and study corticosteroid hormone action 
in the CVS is based upon the adverse effects of corticosteroid hormones on cardiac 
structure and function which is highlighted in states of hormone excess such as 
Cushing’s syndrome (Baykan et al., 2008; Muiesan et al., 2003) and primary 
hyperaldosteronism (Matsumura et al., 2006; Muiesan et al., 2008; Rossi et al., 
1996). Furthermore, even in the absence of overt steroid excess corticosteroid 
hormones appear to play an adverse modulatory role in heart disease (Beygui et al., 
2006; Guder et al., 2007; Palmer et al., 2008; Swedberg et al., 1990; Vantrimpont et 
al., 1998) and pharmacological blockade of the MR provides cardio protection 
(Fraccarollo et al., 2003; Fraccarollo et al., 2005; Rocha et al., 2000)  and thereby 
reduces morbidity and mortality in heart failure patients (Pitt et al., 1996; Pitt et al., 
2003a). 
7.1 Experimental studies 
We have characterised relative expression levels of key components involved in 
corticosteroid hormone signalling including GR, MR, 11β-HSD1 and 2 in isolated 
adult rat CM and cardiac MyoFb in culture. All components involved in corticosteroid 
signalling were readily expressed in adult CM and cardiac MyoFb with the exception 
of 11β-HSD2. Compared to liver, expression of 11β-HSD1 in CM was low whereas its 
abundance in cardiac MyoFb was high. These findings were underlined by enzymatic 
studies, which predominantly showed 11β-HSD oxoreductase as opposed to 
dehydrogenase activity. Moreover, in the heart 11β-HSD oxoreductase activity was 
dependent on the presence of H6PDH. Functional studies of 11β-HSD1 showed 
facilitated transcription of glucocorticoid target genes and an inhibitory effect on 
cardiac MyoFb proliferation. 
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It was recently shown that global 11β-HSD1 knock out mice exhibit increased 
neovascularisation and improved cardiac function following MI (McSweeney et al., 
2010; Small et al., 2005) suggesting that glucocorticoids play a modulatory role in 
cardiac remodelling following MI. However, these studies do not provide an answer 
as to which cell type is responsible for the observed effects. Our results indicate that 
11β-HSD1 is highly expressed and functionally active in MyoFb and thereby impacts 
on proliferation. McSweeney et al reported thicker infarct scars following MI in 11β-
HSD1 knock out compared to WT mice. It is therefore intriguing to speculate that 
reduced cellular glucocorticoid levels in 11β-HSD1 knock out mice results in 
increased MyoFb proliferation and formation of thicker scars. Furthermore, it will be 
interesting to investigate if pharmacological inhibition 11β-HSD1 has similar effects 
which may provide a novel therapeutic strategy to improve outcome in MI patients. 
Besides MI, glucocorticoids may play a role in CHF as circulating glucocorticoid 
levels in these patients predict mortality (Guder et al., 2007). It will therefore be 
interesting to address if a reduction in local glucocorticoid regeneration by 11β-HSD1 
will also impact on the course of CHF. 
Our results in human cardiac biopsies suggest that cardiac hypertrophy is associated 
with increased glucocorticoid hormone signalling as we found increased expression 
levels of GR in cardiac biopsies from hypertrophied hearts. Future studies in CM 
specific GR knock out mice will clarify if increased GR expression plays a causative 
role or rather is a consequence of hypertrophy. In case of the former, it will be 
interesting to see if a reduction of local glucocorticoid hormone levels by 
pharmacological inhibition or inactivation of the 11β-HSD1 gene will result in 
amelioration of hypertrophy. Finally, animal models of CM specific GR and MR knock 
will be key to dissect the contribution of GR and MR not only in hypertrophy but also 
ischaemic heart disease and CHF. 
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To better understand differential effects on gene transcription by corticosteroid 
hormones we performed a microarray screening experiment. Our results show that 
transcriptional events were rather ligand than receptor dependent and that presence 
of GR and MR are required for a maximal biologic effect of corticosterone suggesting 
formation of GR-MR heterodimers. Moreover, we found a high degree of overlap in 
corticosterone and Aldo signalling via the GR and MR, respectively, but at the same 
time discovered several genes that were selectively regulated by Aldo and have 
previously been shown to play a role in cardiac disease. These genes may provide 
novel insights into the molecular mechanisms by which Aldo exerts its adverse 
effects on cardiac remodelling. Although these genes provide promising novel Aldo 
targets, future studies are required to validate and further characterise regulation of 
these genes and their downstream effects by Aldo. 
7.2 Clinical studies 
We studied the role of corticosteroid hormone action in patients with essential 
hypertension and the effects of Spiro upon corticosteroid hormone secretion and 
metabolism in patients with CKD. Our results suggest that mineralocorticoids but not 
glucocorticoids play a role in blood pressure modulation in essential hypertension as 
we found an increasing relative mineralocorticoid excess state with increasing blood 
pressure. However, the lack of a well matched control cohort did not allow us to 
compare our findings in hypertensives with those of healthy, normotensive controls 
which would substantiate our findings. Mahumud et al have shown that the ARR 
predicts the fall in blood pressure in patients with long standing, uncontrolled 
hypertension in response to treatment with Spiro (Mahmud et al., 2005). It would be 
interesting to see in future studies if these findings also apply to unselected patients 
with essential hypertension. If the findings by Mahmud et al hold true in such a 
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cohort, MR antagonists may become first line antihypertensive agents for all patients 
with essential hypertension who have an elevated ARR. It is conceivable that this will 
lead to better blood pressure control and as a consequence a lower cardiovascular 
risk in these patients. Moreover, our clinical study addressing the effects of Spiro in 
CKD patients shows that MR blockade results in reduced blood pressure levels 
despite compensatory up-regulation of the RAAS but did not affect glucocorticoid 
secretion or metabolism. These findings are reassuring as an increased in the HPA 
drive secondary to treatment with MR antagonists may have adverse metabolic 
effects. 
The future studies described in this chapter will help to further determine the 
modulatory role and the underlying molecular mechanisms of corticosteroid hormone 
action in the CVS with the overall aim to improve outcome of cardiovascular disease 
in the future. 
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